var title_f33_24_34176="Cyclosporine: Pediatric drug information";
var content_f33_24_34176=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclosporine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/42/23202?source=see_link\">",
"       Cyclosporine (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/55/36729?source=see_link\">",
"       Cyclosporine (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13193 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34176=[""].join("\n");
var outline_f33_24_34176=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/42/23202?source=related_link\">",
"      Cyclosporine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/55/36729?source=related_link\">",
"      Cyclosporine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_24_34177="Port wine stain - leg";
var content_f33_24_34177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Port wine stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A port wine stain, manifesting as an erythematous patch with multiple small, vascular papules, is present on the leg of this adult.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34177=[""].join("\n");
var outline_f33_24_34177=null;
var title_f33_24_34178="Patient information: Skull and facial fractures (The Basics)";
var content_f33_24_34178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16962\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/49/31507\">",
"         Skull bones",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/47/8947\">",
"         Patient information: Closed head injury (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/12/22722\">",
"         Patient information: Concussion (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/16/34050\">",
"         Patient information: Going home from the hospital (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/45/40658\">",
"         Patient information: Head injury in children and adolescents (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/43/3763\">",
"         Patient information: Meningitis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/4/41026\">",
"         Patient information: Nose fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/59/41905\">",
"         Patient information: Vertigo (a type of dizziness) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Skull and facial fractures (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/skull-and-facial-fractures-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9538869\">",
"      <span class=\"h1\">",
"       What are skull and facial fractures?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A fracture is another word for a broken bone. When people have a skull or facial fracture, they have broken 1 or more bones of their skull (head) or face (",
"      <a class=\"graphic graphic_figure graphicRef62443 \" href=\"mobipreview.htm?30/49/31507\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Skull and facial fractures can happen when people are hit hard on their head or face. Common causes of skull and facial fractures are falls, car accidents, and sports injuries.",
"     </p>",
"     <p>",
"      There are different kinds of fractures, depending on how the bone breaks. Some fractures are more serious than others. If the bone is only cracked, the fracture is usually not as serious. But if part of the bone is pushed in toward the brain, the fracture is more serious.",
"     </p>",
"     <p>",
"      Skull and facial fractures sometimes lead to serious problems, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Brain damage",
"       </li>",
"       <li>",
"        Bleeding in or on top of the brain",
"       </li>",
"       <li>",
"        An infection of the tissues around the brain and spinal cord",
"       </li>",
"       <li>",
"        Seizures &ndash; Seizures are waves of abnormal electrical activity in the brain. They can make people pass out, or move or behave strangely.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9538884\">",
"      <span class=\"h1\">",
"       What are the symptoms of a skull or facial fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can be mild or severe, depending on where the fracture is and how serious it is. Possible symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain, swelling, or bleeding &ndash; Sometimes, it takes a day for the swelling to start.",
"       </li>",
"       <li>",
"        A headache",
"       </li>",
"       <li>",
"        Feeling very tired, confused, or dizzy",
"       </li>",
"       <li>",
"        Bruising around the eyes, or behind the ear",
"       </li>",
"       <li>",
"        Bleeding from the nose or ear",
"       </li>",
"       <li>",
"        Clear fluid draining from the nose or ear &ndash; This is spinal fluid, the fluid that surrounds the brain and spinal cord.",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Trouble smelling, hearing, or seeing",
"       </li>",
"       <li>",
"        Weakness or numbness of the face",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9538899\">",
"      <span class=\"h1\">",
"       Is there a test for a skull or facial fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor will ask about the symptoms and injury, and do an exam. To look for a fracture, he or she can do a CT scan of the head. This is an imaging test that creates pictures of the skull and brain.",
"     </p>",
"     <p>",
"      The doctor might also do skull X-rays or other imaging tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9538914\">",
"      <span class=\"h1\">",
"       How are skull and facial fractures treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of fracture and where it is.",
"     </p>",
"     <p>",
"      Many people will not need any treatment. If the skull bone only cracks but doesn&rsquo;t move out of place, people usually don&rsquo;t need treatment. But their doctor will watch them to follow their symptoms.",
"     </p>",
"     <p>",
"      People whose symptoms go away after a short time can usually leave the hospital after a few hours. But the doctor will probably recommend that someone watch them at home for 24 hours to make sure their symptoms don&rsquo;t get worse. &nbsp;",
"     </p>",
"     <p>",
"      People who have a serious fracture, or symptoms that get worse or don&rsquo;t go away, will need to stay in the hospital for a longer time. Depending on their fracture, people might be treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotic medicines to prevent infections",
"       </li>",
"       <li>",
"        Anti-seizure medicines to prevent seizures",
"       </li>",
"       <li>",
"        Vaccines &ndash; Vaccines are treatments that can prevent certain serious infections.",
"       </li>",
"       <li>",
"        Surgery",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9538929\">",
"      <span class=\"h1\">",
"       When should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After the person with the fracture leaves the hospital, call the doctor or nurse if he or she has:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Nausea",
"       </li>",
"       <li>",
"        A headache that won&rsquo;t go away",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should bring the person back to the hospital immediately if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Starts vomiting",
"       </li>",
"       <li>",
"        Has a severe headache",
"       </li>",
"       <li>",
"        Has a seizure",
"       </li>",
"       <li>",
"        Has trouble walking, talking, or seeing",
"       </li>",
"       <li>",
"        Has weakness or numbness in his or her body",
"       </li>",
"       <li>",
"        Isn&rsquo;t acting like him- or herself",
"       </li>",
"       <li>",
"        Has blood or fluid leaking from the nose or ear",
"       </li>",
"       <li>",
"        Passes out",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9538944\">",
"      <span class=\"h1\">",
"       What can people do to help prevent skull and facial fractures?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help prevent skull and facial fractures, people can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wear a helmet when they ride a bike or motorcycle, or play certain sports.",
"       </li>",
"       <li>",
"        Wear a seat belt every time they drive or ride in a car.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9538959\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/45/40658?source=see_link\">",
"       Patient information: Head injury in children and adolescents (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22722?source=see_link\">",
"       Patient information: Concussion (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/16/34050?source=see_link\">",
"       Patient information: Going home from the hospital (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/43/3763?source=see_link\">",
"       Patient information: Meningitis in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41905?source=see_link\">",
"       Patient information: Vertigo (a type of dizziness) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=see_link\">",
"       Patient information: Closed head injury (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/4/41026?source=see_link\">",
"       Patient information: Nose fracture (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/24/34178?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16962 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-DA858D2583-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34178=[""].join("\n");
var outline_f33_24_34178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9538869\">",
"      What are skull and facial fractures?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9538884\">",
"      What are the symptoms of a skull or facial fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9538899\">",
"      Is there a test for a skull or facial fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9538914\">",
"      How are skull and facial fractures treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9538929\">",
"      When should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9538944\">",
"      What can people do to help prevent skull and facial fractures?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9538959\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16962\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/49/31507\">",
"      Skull bones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=related_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22722?source=related_link\">",
"      Patient information: Concussion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/16/34050?source=related_link\">",
"      Patient information: Going home from the hospital (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/45/40658?source=related_link\">",
"      Patient information: Head injury in children and adolescents (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/43/3763?source=related_link\">",
"      Patient information: Meningitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/4/41026?source=related_link\">",
"      Patient information: Nose fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41905?source=related_link\">",
"      Patient information: Vertigo (a type of dizziness) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_24_34179="Pancuronium: Patient drug information";
var content_f33_24_34179=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pancuronium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=see_link\">",
"     see \"Pancuronium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/0/34821?source=see_link\">",
"     see \"Pancuronium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2980447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pancuronium Bromide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be watched closely by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles during surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles while on a breathing machine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pancuronium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzyl alcohol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10925 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-430C2FE721-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34179=[""].join("\n");
var outline_f33_24_34179=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980447\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020595\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020597\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020596\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020600\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020601\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020603\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020599\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020605\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19990?source=related_link\">",
"      Pancuronium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/0/34821?source=related_link\">",
"      Pancuronium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_24_34180="Nose lat wall nasopharynx";
var content_f33_24_34180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Anatomy of the lateral wall of the nasal cavity and the nasopharynx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34180=[""].join("\n");
var outline_f33_24_34180=null;
var title_f33_24_34181="Anal fissure: Clinical manifestations, diagnosis, prevention";
var content_f33_24_34181=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anal fissure: Clinical manifestations, diagnosis, prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/24/34181/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/24/34181/contributors\">",
"     Elizabeth Breen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/24/34181/contributors\">",
"     Ronald Bleday, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/24/34181/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/24/34181/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/24/34181/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/24/34181/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/24/34181/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/24/34181/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anal fissure is one of the most common benign anorectal conditions that may result from high anal pressure. Anal fissures may be acute or chronic. Acute fissures may result from local trauma or may be secondary to an underlying",
"    <span class=\"nowrap\">",
"     medical/surgical",
"    </span>",
"    condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51847610\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anal fissure is a tear in the anoderm distal to the dentate line (",
"    <a class=\"graphic graphic_figure graphicRef62539 \" href=\"mobipreview.htm?14/30/14819\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/1\">",
"     1",
"    </a>",
"    ]. By definition, an acute anal fissure typically heals within six weeks with conservative local management, while a chronic anal fissure fails conservative management and requires a more aggressive, surgical approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The etiology of the fissure determines if it is primary (eg, local trauma) or secondary (eg, inflammatory bowel disease, malignancy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51847618\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anal fissure is the result of the stretching of the anal mucosa beyond its normal capacity. Once the tear occurs, it begins a cycle leading to repeated injury. The exposed internal sphincter muscle beneath the tear goes into spasm. In addition to causing severe pain, the spasm pulls the edges of the fissure apart, which impairs healing of the wound. The spasm also leads to further tearing of the mucosa with the passage of subsequent bowel movements. This cycle leads to the development of a chronic anal fissure in approximately 40 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that ischemia may contribute to the development of an anal fissure. Blood flow in the anoderm at the posterior midline, the site of most fissures, is less than one-half that in other quadrants in the anal canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Furthermore, the rate of perfusion is inversely related to anal pressure and, in one study, patients with chronic anal fissure had higher anal pressures than those with fecal incontinence, hemorrhoids, or other colorectal disorders, or controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/5\">",
"     5",
"    </a>",
"    ]. The demonstration of reduced blood flow provided the rationale for the use of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    in the treatment of this disorder (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15384?source=see_link&amp;anchor=H72479779#H72479779\">",
"     \"Anal fissure: Medical and surgical management\", section on 'Topical nitroglycerin'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The elevation in anal pressure in patients with chronic anal fissure may result from increased tone of the internal anal sphincter, which can be demonstrated manometrically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In one study, for example, manometry was performed in 12 patients with chronic anal fissure and in 12 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/7\">",
"     7",
"    </a>",
"    ]. The mean average resting pressure of the internal sphincter was significantly higher in patients with a chronic anal fissure (120 versus 83 mmHg).",
"   </p>",
"   <p>",
"    The most common location for a primary anal fissure is the posterior anal midline; only 10 percent of females and 1 percent of males have a primary anal fissure located in the anterior midline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with an anterior fissure are more likely to have occult external sphincter injury and impaired external sphincter function compared with patients with a posterior fissure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/1\">",
"     1",
"    </a>",
"    ]. Factors other than reduced blood flow also may contribute to the posterior predilection for anal fissures. Elevated internal sphincter pressures are not confined to the site of the fissure; in one study, they were highest on the distal anterior surface, which may favor posterior mucosal tearing during defecation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/7\">",
"     7",
"    </a>",
"    ]. Another hypothesis is the elliptical arrangement of anal sphincter fibers, which lends less support to the posterior aspect of the anal canal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51847626\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal fissures most often affect infants and middle-age individuals. The true prevalence of anal fistulas in adults is unknown, as anorectal discomfort is often attributed to symptomatic hemorrhoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/10\">",
"     10",
"    </a>",
"    ]. It is estimated that approximately 235,000 new cases of anal fissure occur every year in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20606158\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of anal fissures are primary and caused by local trauma, such as passage of hard stool, prolonged diarrhea, vaginal delivery, or anal sex. Secondary anal fissures can be found in patients with previous anal surgical procedures; inflammatory bowel disease (eg, Crohn's disease); granulomatous diseases (eg, extrapulmonary tuberculosis, sarcoidosis); malignancy (eg, squamous cell anal cancer, leukemia); and communicable diseases (eg, HIV infection, syphilis, chlamydia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. These conditions are discussed as separate topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51847546\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51847554\">",
"    <span class=\"h2\">",
"     Patient presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an acute anal fissure present with tearing pain accompanying the passage of bowel movements. Patients may also describe bright rectal bleeding, usually limited to a small amount on the toilet paper or on the surface of stool. Some patients complain of perianal pruritus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin irritation. Patients with a chronic fissure typically have less intense pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51848230\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common location for a primary anal fissure is the posterior anal midline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/2\">",
"     2",
"    </a>",
"    ]. The fissure is typically identified as a laceration ranging in depth from a superficial, shallow laceration to a deep wound extending into the external sphincter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An acute fissure appears as a fresh laceration, much like a paper cut; a chronic fissure has raised edges exposing the white, horizontally oriented fibers of the internal anal sphincter muscle fibers at the base of the fissure (",
"    <a class=\"graphic graphic_picture graphicRef51583 \" href=\"mobipreview.htm?34/14/35040\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Chronic anal fissures are often accompanied by external skin tags (sentinel pile) at the distal end of the fissure, and hypertrophied anal papillae at the proximal end. The features of a chronic fissure are attributed to chronic infection and the development of fibrotic connective tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51847578\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of anal fissure is based on the history of painful defecation and the physical examination finding of a superficial tear in the anoderm. A primary fissure typically occurs posteriorly; secondary fissures occur laterally as well as posteriorly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The pathognomonic feature of an acute fissure is a superficial tear, while a chronic fissure appears hypertrophied with skin tags",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    papillae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5351461\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best approach to diagnose an anal fissure during physical examination is to spread the buttocks apart gently, looking carefully in the posterior midline. Patients are often too uncomfortable to tolerate a digital rectal examination or anoscopy. The second most frequent location is the anterior midline, which should also be inspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/12\">",
"     12",
"    </a>",
"    ]. Eccentrically located (lateral) fissures occur, but are most often associated with atypical etiologies (eg, inflammatory bowel disease, granulomatous diseases).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51847594\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5350533\">",
"    <span class=\"h2\">",
"     Perianal ulcers or sores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal ulcers can be caused by inflammatory bowel diseases and granulomatous diseases (eg, Crohn&rsquo;s, tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]), and sexually transmitted diseases (eg, syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/15\">",
"     15",
"    </a>",
"    ]). A primary fissure, while technically an ulcer, is thinner than ulcers caused by underlying conditions (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/34/21034?source=see_link&amp;anchor=H22503404#H22503404\">",
"     \"Cutaneous manifestations of tuberculosis\", section on 'Metastatic tuberculous abscesses (tuberculous gummas)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5351512\">",
"    <span class=\"h2\">",
"     Anorectal fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anorectal fistula typically presents as a painful, purulent draining perirectal skin lesion. If probed, a track can be identified extending from the perianal skin to the anus or rectum. A fissure does not have a track. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12694?source=see_link\">",
"     \"Anorectal fistula: Clinical manifestations, diagnosis, and management principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5351726\">",
"    <span class=\"h2\">",
"     Solitary rectal ulcer syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solitary rectal ulcer syndrome is an uncommon rectal disorder that can present with bleeding, passage of mucus, straining during defecation, and a sense of incomplete evacuation. The name of the syndrome is misleading, since patients can often present with lesions that are neither solitary nor ulcerated. Findings vary and can include mucosal ulcerations, polypoid and mass lesions (mimicking rectal cancer) or simply erythema. The lesions are located in the anterior rectal wall within 10 cm of the anal verge in the majority of patients. Symptoms are variable (eg, rectal bleeding, pelvic fullness, straining, tenesmus, pain) or may be absent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21125?source=see_link\">",
"     \"Solitary rectal ulcer syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51847586\">",
"    <span class=\"h1\">",
"     POSTDIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rectal bleeding should undergo endoscopy. A sigmoidoscopy may be reasonable in patients younger than 50 who have no family history of colon cancer; in other patients, a full colonoscopy should be performed. Patients who have atypical fissures (eg, lateral, anterior) or other clinical features raising suspicion for underlying Crohn's disease should have a full colonoscopy and imaging of the small bowel. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20490?source=see_link&amp;anchor=H12689183#H12689183\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Small bowel disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51848260\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal fissures can be prevented by using proper anal hygiene, including keeping the anal area dry, and wiping with a soft cotton or moistened cloth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34181/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. Other measures that may be helpful include preventing constipation by consuming a high fiber diet and adequate fluids, avoiding straining during defecation, avoiding trauma to the anus, and prompt treatment of diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2710?source=see_link\">",
"     \"Prevention and treatment of acute constipation in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35048?source=see_link\">",
"     \"Constipation in the older adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5350710\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most primary anal fissures respond to conservative management (eg, local wound care, relief of constipation). Chronic and secondary fissures require more extensive management",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    management of the underlying condition. The medical and surgical management of anal fissures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15384?source=see_link\">",
"     \"Anal fissure: Medical and surgical management\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/7/28786?source=see_link\">",
"       \"Patient information: Anal pruritus (anal itching) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331247745\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An anal fissure is a tear in the lining of the anal canal distal to the dentate line. A fissure may be primary, resulting from local trauma, or secondary from an underlying medical condition (eg, malignancy, infection). (See",
"      <a class=\"local\" href=\"#H51847610\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common location for a primary anal fissure is the posterior anal midline; only 10 percent of females and 1 percent of males have a primary anal fissure located in the anterior midline. (See",
"      <a class=\"local\" href=\"#H51847618\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common etiology of a primary anal fissure is trauma. Secondary anal fissures can be the manifestation of an underlying medical condition, such as granulomatous diseases (eg, extrapulmonary tuberculosis), malignancy (eg, squamous cell anal carcinoma), inflammatory bowel disease (eg, Crohn&rsquo;s disease), or infections (eg, HIV). (See",
"      <a class=\"local\" href=\"#H20606158\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An anal fissure is diagnosed from the history of anal pain with defecation and the physical examination finding of a superficial tear in the anoderm, distal to the dentate line. (See",
"      <a class=\"local\" href=\"#H51847546\">",
"       'Clinical manifestations'",
"      </a>",
"      above.) The pathognomonic feature of an acute fissure is a superficial tear, while a chronic fissure appears hypertrophied with skin tags",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      papillae. (See",
"      <a class=\"local\" href=\"#H51847578\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anal fissures can be prevented by using proper anal hygiene and avoiding anal trauma, constipation, and straining during bowel movements. (See",
"      <a class=\"local\" href=\"#H51848260\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/1\">",
"      Zaghiyan KN, Fleshner P. Anal fissure. Clin Colon Rectal Surg 2011; 24:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/2\">",
"      Madalinski MH. Identifying the best therapy for chronic anal fissure. World J Gastrointest Pharmacol Ther 2011; 2:9.",
"     </a>",
"    </li>",
"    <li>",
"     Dykes SL, Madoff RD. Benign Anorectal: Anal Fissure. In: Wolff BG, Fleshman JW, Beck DE, Pemberton JH, Wexner SD, et al., editors. The ASCRS textbook of colon and rectal surgery. New York: Springer Science and Business Media LLC; 2007. pp. 178&ndash;191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/4\">",
"      Perry WB, Dykes SL, Buie WD, et al. Practice parameters for the management of anal fissures (3rd revision). Dis Colon Rectum 2010; 53:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/5\">",
"      Schouten WR, Briel JW, Auwerda JJ. Relationship between anal pressure and anodermal blood flow. The vascular pathogenesis of anal fissures. Dis Colon Rectum 1994; 37:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/6\">",
"      Klosterhalfen B, Vogel P, Rixen H, Mittermayer C. Topography of the inferior rectal artery: a possible cause of chronic, primary anal fissure. Dis Colon Rectum 1989; 32:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/7\">",
"      Keck JO, Staniunas RJ, Coller JA, et al. Computer-generated profiles of the anal canal in patients with anal fissure. Dis Colon Rectum 1995; 38:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/8\">",
"      Farouk R, Duthie GS, MacGregor AB, Bartolo DC. Sustained internal sphincter hypertonia in patients with chronic anal fissure. Dis Colon Rectum 1994; 37:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/9\">",
"      Horvath KD, Whelan RL, Golub RW, et al. Effect of catheter diameter on resting pressures in anal fissure patients. Dis Colon Rectum 1995; 38:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/10\">",
"      Nelson RL, Abcarian H, Davis FG, Persky V. Prevalence of benign anorectal disease in a randomly selected population. Dis Colon Rectum 1995; 38:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/11\">",
"      Oh C, Divino CM, Steinhagen RM. Anal fissure. 20-year experience. Dis Colon Rectum 1995; 38:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/12\">",
"      Lund JN, Scholefield JH. Aetiology and treatment of anal fissure. Br J Surg 1996; 83:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/13\">",
"      Gupta PJ. Ano-perianal tuberculosis--solving a clinical dilemma. Afr Health Sci 2005; 5:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34181/abstract/14\">",
"      Mathew S. Anal tuberculosis: report of a case and review of literature. Int J Surg 2008; 6:e36.",
"     </a>",
"    </li>",
"    <li>",
"     Diseases characterized by genital, anal, pr perianal ulcers. Sexually Transmitted Diseases treatment Guidelines. 2012 cdc.gov/std/treatment/2010/genital-ulcers.htm.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2543 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5CA193EFE4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34181=[""].join("\n");
var outline_f33_24_34181=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H331247745\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51847610\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51847618\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51847626\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20606158\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51847546\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51847554\">",
"      Patient presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51848230\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51847578\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5351461\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51847594\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5350533\">",
"      Perianal ulcers or sores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5351512\">",
"      Anorectal fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5351726\">",
"      Solitary rectal ulcer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51847586\">",
"      POSTDIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51848260\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5350710\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H331247745\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2543|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/30/14819\" title=\"figure 1\">",
"      Anatomy of the anus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2543|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/14/35040\" title=\"picture 1\">",
"      Chronic anal fissure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15384?source=related_link\">",
"      Anal fissure: Medical and surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12694?source=related_link\">",
"      Anorectal fistula: Clinical manifestations, diagnosis, and management principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35048?source=related_link\">",
"      Constipation in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/34/21034?source=related_link\">",
"      Cutaneous manifestations of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/7/28786?source=related_link\">",
"      Patient information: Anal pruritus (anal itching) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2710?source=related_link\">",
"      Prevention and treatment of acute constipation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21125?source=related_link\">",
"      Solitary rectal ulcer syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_24_34182="Phytophotodermatitis 2";
var content_f33_24_34182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phytophotodermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 371px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFzAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0O2UqzbyrMUzkHAPPT/61O1DcEjXJJzyA3IxUsYco4YBs/e/H9e1VtVZkMDhkb5WwucAnj/PWvYbOGJraYoa1jkYsSx3SEjg8nqK0YvkkjbPysGIBJ461X06Ly7WCNi2CvJI61diVrmdREVLdkPPA/wA/rxWTla9zax5j8fdQuToOnaFaRNLJeTtcXAQks0Uf3R2G0sckkgjyx17eD3n2xpJA7bL+CPahFs8LTRjknk43DnI2nOe5Ir0Hxr4li8QeMdSvba4RbKNvsttIcDdGvG4N0ZS2SPXg8EZrnNUWRIWeKVbYBt+6Gf5g2cbgT0PPPY5IJNfO1q3PUcj2cPT5KaXU4G902KeSQPdQmd2BjaMlI3HJyuV7dCDg8g89syWwvtPkRf3Mm75tow5GD3B6dOnfFdrdXc8ilLhbOZpMM6eUSlx23AcjqeSCME9DkGsW/mMakQI4VeNs2Dj057ccYOSOlONVlSpKRyss3nTtvAXecnZ8gJ9cdB9OKt+TdWyxsonXzhlQJQCygkdAc9QfyrQktZUWXz7fzMDnZjA5689B+HHrTLfTm8y3xbCCVjkEOd3J4IA6gc4xW3tEzH2LQ+Sz1ATRi4ieONiowx3kZ6DGevbjHWrtvasH1Se9kxcRvh1XbGAc4K7B0Gc56AbT61DqFklpFFLPe3jzODIr7wcMpwBnr2Izjk+wqxBp8Ftp14QlxNgM2XO1P97Hf5ht5qHLQ0UHcg12+WbVAkUq3AWVpzImSpDEZwDjpwe3TJ9Kt67Bc3F9eTagXM00aMgSQsN7v092IYnPA5OBWjoenj7bazuYy8t1HaPEwWMJCYpN0hyR0UHJI4xzmqN/KBPp/wBpjNybaQQvvQIpTgR42ng4wcZPHPqBDe1i4xSbudF4wDPPbWtvDII570/IDwwjVYsZzwFJZcnodtQ2Mr316tna/aZhK8UdoFbJw7I8jeuQnJ/3mPSrFvYnVbO4uL4yR2zJO0hT5ZN5JkfGRx8zRjOecD1qHwdOV1H7a8qwwRQBSuMMf3HljB68Pkce9YN2R0pHpNu63d9eBBIQZjGVUAYVUyAPzUfWrOnxlpDJcz4EW5fL3kEFeCWPoOF9cn61X8ORFL6/MoCqpKqMH73IHTvgL9KtpD8jRIoZfMAy3zFuOp7DnLc5rlba1R0w00Lgl+2XUzwuA7tiZwo2xouTtPcnI59wBTWR4owEG1ncySSOcvtGedo6HJ/nUthZxwRxRFwGR/MdXJwn3sFgP4uc47064MjMGSFQCv3VzgLnGCBk5J561m22rlLexW81VbdE6ySzRszTPkBMHCKMDk4IHtx6mqF46xkxymaeReCVP33xyS2eMD0H+NaSRTQLGpm85/MbaQgADA4weOmeck//AFmLADbN51yA7AEMFyCDzgjuenTgjntUO7LTSKqqbny5UciNkyFc7FVc/d9+gJ9TUoZoolCmMZwpfqIgT6f0xn2qw1uvzozOpBASNiAVPJJJ7nPp0zmkK+TNIyIUgYKuJF2EjPUsM8nJ9cAClqirliBfJt/tLL8rDd5siksxx/COpbnqePx5qq8c8s63ETNE6qdiopAVB1+pIHvU7Qwm5Blja4lfB2SkleMFRgHtgEjP5Z4szJLJG+LuRFeTbNJINpkIOcBRyFGc/j9KtaoW2pVgtbqMtIkokumJLZAfbjrgkHJ7exqTYwjVppVkJG1UWUEL68HODUs9ku0RFnzJ8wt4s5KYyGkOflHXjPPXjrSXkdxa2JMiQwR7TvkUAnjA2queexLY7jnBotYV0yu8YZ2WSZ7iNScRQkAD2HFRKomyu6TYhywdyqgdNvHQ9eRVi0aS4tiFEdvbKp/eyNsZ89mI4z9Kkt5EiiXcW8vaT5gQDb9QQfz69OlIt6FSUwW7PF5TQ8YAA+f0z0HAqOGQxztCIwnyZKufmK+xzxV66hma2d4gGgznlfMLkd8nk8enFRSWiInkM6JKQMZb5sf7Pr9OaVtRaWKciuzrIVCW8RztD/xfXuBx+JqBihmMgZgEO3bIffgn168fSrBjVZn2x5hKfNIfmPsQvb8ajs083bJcOwYjZAWXJ2gEHJ7YNO4W6jLqGQzYVEyg5QPhQfVv51UmjaXeWw+0ckHCt6HNa4REbynt2XB3OynOR6jufpVeW3cBpGiD5HHlnnGfSqWpLVzLlt0eMRyfLIw5LHqO2Pp2rOvrEyREt8yrjdn39u9bZi23LrEpYKN2f7vNR3drKZI/3a7pF5w3y5HPB7//AF60Rm1bQ4qSKfT7stbyBULDMRY/MPYdqvMbe9fdDIG83qpOCMDOD+NWNTtVdA3lFeSvTI3f5xWCd9nNHI6eWwO0kDHPYk+lWm9iHHqPuLeR5ywndLhFwSB95QOua57UCwldzvYjnOTwPSuknliuoc7v3ozlc/dx6Vjak6vjfgkr1P3W/H1+tbxZzyWpytyhhVVLOQp4PfFaNtKzDEZ3jB/LPaob2INIRuD4AAPYHHT2x0zUsEJMY8vbtxxjsa1k9DFLUswuynzI225PQckGtKC+ljeQhEeQ8Bc9/p1rPSJzEcuC3QMG6fUetWIkMZQSxu7Fv9ZtI4/D/PFYy1NUdDbahJJMI54sgc4LEFfwNTyXysrEbTjAIbG4Z65HBx71iwMgPySEjaCFbhW46ZPStC3nid2V9hb7o5zk+gzWT0ZdrjLnNxCyhSADtyF4YdhzXG32iA3UjAMATkBSeB6dK7tU/d7cuqY5JGQB6YpLeFmTcE3gnIO01rTqOGxlUpKWjR9BoFVFdSpUN/CpBA+nX86r6mivGI4yqjcuP9nnrVuCJQpKhlIGMZ/rUc8aNcQRh2CmVWIY9QK+rkfNRWhseY6wf6ohmGNqsPy5/Q+wrB+Iuur4b+H+rXHnmG/ulNlasp+Yu4PIwRgqoZsg8da3lUvdBOEIGMHgqO5P+e1eT/Ge7XWvFFjpkY/0XTIssh5VpJMF++G2oEUHqMuK4MZVVOk/M7MPT9pNI8/0S2ENnAJIwGCA/N1PHXHrV+6ljgi86VSNpyoC5Zh7e5rRjtSpVAC0pGViGOPdvQfXmpI9NiiZpplEkoI3SPk+Vx0A6DrXgyZ7KscjJZT6lPIvlneGAD79qxYGTtOM56HIA6YyKz30yTz1Ezx3e18F3/d7umQrYO3nPUc8c9cdvMvl3CSuqjcRHhj8q/3fwySOKrz24YFVUPgAEFc7s+vYe4Pp0pKTNLXPNr6zElwLKG0MLSmOFUUj96SeSSPwPPr7VHbx2/2tp1t5m3osUKbmVSzHbtJY/dGQOpz7jr1d1ok8UySWDpHM7lsHBRCFbnJz3Prgk/lzOrtLHbrcQ+XIvnu2ETGI1ZVDBckjJIHrwMHINdEJX0M6kS5exWzXyGSKOH7FZtL5fdW3BUDtgbj1JPqfwNKw8ye40+BptjSRqkZcMVwAGdiAOeQecdzVu30+Z/Ept75fOkERTbuCLI5m2oT1znIPIPr2zUE09umszNDE4jt7WTyw2WaPB6qMfKSXPXgfgKryM46M0bVGm0RiZoiIb5bZJHjAMMW3yzx6DLcHGcZPXBypo2vPPvBbySPKjRKGGxkLYRHOM/Md2QO2T1OK6TVbNIkW0U+YEs54nBJbMqt5nGOrhQcnjHas/RbfdpM00U8YEipcSMg+VCwKI2SCd6sz8DHODxjNTe2ppGPQ6W0udlp9nvJ40WBVupV8vlihVZew4aQHnvjPes3w1Gkmi6ikyiZ7G7itVCLjgyscZPGMpnrwTT9Gkt54kKQHy7q2mSe4ADMDGqhhz1Y/K+0eoHarnguFLm+tYpncrdiS4lBJCs4CybsEcfKcLnv0rCRvBHolmRZQSPGPMbC7GYcyNtA3H8sYH9aUxlEeO4kyEUfMGDbiuWJHqTwKsRyNLaGSPMcz7UAjOSDggAe2acFiECbPKdUQRR+WeTliCwP/AH1+HHauV6msSOFkKyiSJ1lciSR2blicYHqTwcnvj0pba9kltmmMkAcr5Ue1euD1Gc4A569c9aWQhHZE3O0G1CygYkk4Un8AcfgaekYl80y/Z1CkFUKkrjrhF785Jx9ajY16ClBDD5Moj3BC7pJks3XA44xnHGe/Ps97YHM8oAk6htxUAc8bRyc9B9KmZgVjUjLOokZsje3t7Zz/AJ6U26YrcnKbJQyowQbm2rjITrz0G4+9J9wV+hVcfZVKqskcj8u+MsvJ4Hv706Q4KxSl4ZpI8yKx+YRYGAFH3c5Ge/NWFOCGZWaWQkqAejZ4ZiRnru4HFRT2z+Zvfcvmy7pppH3CQZznJ5xn046Ui1qyWG08xPk32sC4JkbCswxyB6D0GPqatwwfaI2SyjOEGfNmOFTk4KrxjkDv2PTrVG20xpLqOW/u5hbSShIULbiyjtxjjjqe59sVdeUSLE83EaOQsFsM7iQQBnGCMZG7thsVdrET7JjBb2EcLNNcRFLg/MFGFduc7Rjleg5+8OO9V7u0s3HmxRbcAkSzZYZB7D+7/tNj+VaEyu08RmQTXGwtAr/IidBgt1Ix1wOfWmymG7Xz43n2xMGdFi2ozey+nYZ7c455aS6CjJ73Fj06Mopu78M5XfGjIMhQPQDhe/TJprWDvazYmXofJiQAO59Pm7e/b8Ku7XgCHC4mOxZ3JZ0Yc4wOG/l+gqYRIHZxmOdv9Xkb12Afxt2HXoa0suxPM1szn0s3gM6zRzZh+9Orc8/wkY4J9fX60xbS0RtuHSJkJQ+USSR6ntWvNIyupN5EdQC7iqYZGXAbOenf3qoJ93lrYzPM7ZkaORdoQk87vUemKzaSZqm3qZFyFhuEcorBVG4RN8rZ6Z7g0XEDlVMzt5UnOUYZHsf5nHetNoYZN2xdyyEiY7sfMeev16Hj0+kEywCIvtaMK2G2uBkggfj+VTYq5UXfBGMt+5jO1CoO5QfU1X+yW9tLJPGSplYYcZLbh1Hp+eKlkaJfNlLSlhtUKmMMvX5fzzzS24ZSyCUSQkKyxu2CRn19e9C1HYrRsXlSRB84kwWRt2ef4h6VXvIvMnDRs37tjIVY5UjpkehqzEgjuIigKmRSskaP8r/X0bkYP+NVrxmSKVRGSyEo8S5yD6r221pEhrXQoXqMs7BT5eQGKM/Q5xmsjUoIbiSZZEO1sBljODn+laiy/aI4mvEMcrJtJKgjjoc+mOPwrLmhXzLme3RsuN8pAw4CnqR9OatStqiHE5mUiFlZJCGVdjErgnFUbuQT28gTdulBGP4R+H+FbOqmaSQj5QWOM4zWM0Y3sJEXJOQegPt04rZMwnHuZYhTflMAbsbT3zVqGMJLlAdg4IP8J7mg24ViwZlI4cDofenEiIq2M7gFPsa0vczUbFmC2YylwTuZezYLfX1NXbS3M0JA3OvI2sMkmqltLKPkkVi5OQxHBHvWvCJHkXyhuJXPmbjk+3sKykylEpmFl2ReVmPjLO3JIPpxV0QlX2rsU8fMFwRk96vwxJOedwYcY68H/PWrK26qpLRbJBxubnd6VDdy7EAVI2dZfkDkkFQTv9efenR2RIOy4wo6BWOKsywDAVmDMR0zxj6UIuxcMdx9VWmtBNHucIXZtHybeRtH8h2+nNRFZpNUjSJmhdEyzkBsZ4PDVZt1AxuDbi5AJPT059Ov60ump/pzy7g2Tjcx4469OOor6+T1PlYrQLm4ltIZr+W5hWK3DysfKPzKoJxgMMdOo/8ArV45ZQ3V9dTalqF2xuL2QzOY1C5JOc564PH4Cu+8f3bXNpFpMRwlw+ZdxG4xJhiOOcFgvI7qR7Vz0UA8tQrKeAc44OOuPevBx9W9TlWyPVwVO0XMgisWUFRIET0CDn3NQ3FgSnmmSXgZwAFYHPXv2rRHKspYBwQfqPSkXMrvHHuEgB3FhwAOrD88D65rzXJs7krGHdWaTQMVLudwRcndkEjJwePTqO1RwJutFdlwJN0fyJg5DYwAcMQMYHGcc854271Bb2zrGQhb5VO7HHbHX7tUpx896iyyKJE8+OJRu5yFKqAMg7tpxnJLnpgmpT1LRzviKS2TTJJYmjaOAofnb92cNuIwOWBwT0yduK4K/in8x4XeTc0kW0fxBdrZIAHJYtuI6gt3yTXqL6T57W+pXQzLtZ47cHAiz8pBxwW5bJ7EYHrXAzwxwww28jnNs5jnkaIZeLDCHOMHJJHBOQRXRHQls5fRJ5/MS5tmHnwulxGHKllRW2g7m9yDnsMmtG+g87xO0UqymMxqEjh+Z7lcqSvBH8J4JwAFHXFZ/hmzNzcXkUrKkZUN8xADIpAC/icDGRnB5ro73SnmsLfU2a4+1fKsECJiSV3eaNVABICrsZscZGRkVu/iMk9BVuxFfWjT3P2iB3inuJYlKhmAP7pTjhSV645yOxArdiRbW6vbF02NFLJDAkSBIRAy+Yd2R/A7IpPff3OTWX4XeO6ivQrKt3EkctsxKhftAOGk44GzYqoAOR2+atWRLqZXuXk8ye4ht0hQAyS7hy48tuWZlLtj1AAPplLsax11MCTzv7dtFDO1tdS7EzuHyu3lsmckqo3Ljvkc+tdl4YtSiaMtuRsmuMSOVKkwCJRgZ6HMbZ55ABHfPManEwhXU7bCCxuPtETICTgv97GOcYXHvzznjs7sLZ6XZxJGS/nASMMAs3n8A44yASOP72Kyn8Oh1Rim9Dq4owIYeWLtKRGhOd3LE/h93B46NRMg+VUyQB5RyeSTxx2z/jVgMbi9kFpAQIw8KErtIZRk/kGz1x0PrlWtkW1GS0m1QiBV3MTn5j7HAI/ziuewR8yBCI1byx50UTkumceY208n0UcjrnipjbsEt3ZvlkXCqxyHYZGc+2f0qWcQxQNK2VEMRFuuMg7jkE+owOe9RBCsse4sZiShG37h2nLE9OAP5Vm0WgmMrSRbzjUGkUkY2+WRhvlHQcDGeePepHMbLMzz7rfbuLfxSEnIB75PbHYVD5CNNIgfdHt+ZnAbc/YAnnBxn8BTLgyt8sWJnLjfID8rYAyBnGOSfpjnGaTZaXYtSRGSJpFbc85II34CA5BYnjJ4B7Z64piyxTqXtiZIEcRLJL/E5PQL7Z4H86cjq4Zw7yRBnyWwoZjyc9yT2746Yp9xbKzJv8pCMgkLtK7gcn1yemT+lINFuTQMmTsilkKOEkedMBh0bAAz1yAD97sD0pC32iGWYiSUg7FNwQFL5x0XsP7uegOSCKntbcPaGCSLYIly8Lkbd/8AC8jdFwcYHXt702AtNDHcBo5fNQrD5qna2B2UfdXknJx0NWkzPTUSOBvLlSKWRftbhZWwVaXAHygAYCDAG44FFoyG5L2aq4WL91tRm2kdc8AkgYwcf0FW5UlMhtpQsjsV+8pJn9RsOAe2M4HPtTL6aSDHz7UKlkgUYiiA6Engflk1SVhKXQbHNJ+881Jg4YgeXiQRDPyrg8YB5+g5OeKso6L8o3SME3TSrGBk54OO5OOemPTPFUIxNcWcYM6C1Z9o8k+Wztj7uANxwOPfmple1hDL5YhYsuyKEfOBj7zdscZyP7vFO76g0WbgRRWweLc0anEsbMA7L6N7A+lZMGpWpXybJ4Zngbeh42lTxkdzg8c/nnirl06SwyGC4lACbZJ2G3zPYD0wf19cVg6Vo40aRBaPJFHMm7bJGFSZSdxXGMbgeO/UdDQ27lwimtWakzWspMlvlUDeWxkDAZyeB69evrVSeBSW3wHcFIADAlwODx/CQe57VaE7TRHagNwnyoinhzxxj0GceuOe4qfy5Y3aNoyyKu8hupP+c1Nr6opXRj+UVmRoI50iVS2wx5YAkcZ67QeQetVHe5hmDIingksmOhztYnpyetaLzTo8KJJJ90lEDEMwPb6HqBVe3Ec7KkA8udCVBcAo467ee4we3ai9jXpqV51WTbNdbwHZSnlpxgnHGOp6nn0NQTQyy8+bBKMkIxGATnpmteO3YLLJFG0qtIZWUL8qnjLY7Z6cVBqMJid4pkKsHB2lsIFY/wBPWr6XZGl7GHHbpNZmKFEZOR5Q+8Cp5+nWs77NgDEiEyMQr7fmDdcEn8q6V44lMazTtEvmHlQCUPcNjqPU+4rJnaP5tgHmjl8ZCsG6c0k7Cauc5dQxuwRwqddqg/dbPQe1ZN7bBV3bcupxjGT78cfWurubb946gRgZwYsj5SOpz/WsbU7bzIZYbiTO3ByzAFQOhz6D1rROxnJHLzoqsWDBkPRvUe1Qi2QL5YbcoOcf3a1nhMSbAyuwA256c1TEXlyIxX5z3P8AnmtVIycCGzVlYdHkXpnP0wfWt7TNghwY+BnJAPHt9Pf2rIhiWUyIMh0OBjII5zW9p8ivJuRdi5yY+wHTA/GpkxWL67ZCGA2jhQyjgZq/sBhJcEgYJ9T+dM06Axs4DkgsGZSMlK1ns5A0fysqEbTgdee/Tt71BVjEuZlECbnkOWIXaMY/pj3qe1tB5WXALE5JrebTThnjDEqvCEZ49KrNossh3NceUem1efx61Si+o9D1WJmijVugx2bhTz36+9VLaeSK5uA4dS0+2L5QCFznBxxn7x9gOtXJGMCMXXcCu7nqfx781kWLhJIVaQquDvkIJUL95yPQY5r62T3Z8mjlNevopfErWEiotzY26RSkHBaRxvPHsGA/WoNMZEkESghVH97Iya4PX9O1J9bvdd06WR7u9le5lhLBwELcKSOu0bV45GBSeGvFv2jVxa3bhbkEo3B2+/UZGDx75OK+ZrJzk5I9ui+WKiekX0JEStHlmHGF6n6f41WspWMTtsO8ncTlcYHGOtbltD5tsw4xty2Tkj2HtWDMxtL1QMFZl2oM4+YYGB6A5/SuW1nqdEXdWFud0zQoZFiQSpuVeSSWHQ+tZwtWjn8+1VP9EfzYlY8o/IZs9duDtwOeSR0xWhd5hsxNGAzpIhCcDdJz3IwPTNXFjURmCNy4VI2HGzKhSwYZHc5PqM9+KdiuhjTzQPazz2rkJ5R3Bzt8pjncMdufw6jk5ry3xUzJby3VuXNvG0azMTjdIhAAxxl8N0HQHJxkZ7LWLGS9kuGtlV/3W3zYmEayMQBwRySPmG/kHuCBXJ+KTGugmBJrkYmCJAyqQj78Z4G4878nknge1bQ8yXoZmgzxRyRx3yf6NbtFcssPyEqRs5bHbcSAeBj3q6ftF9dXtvIkkdukUUjbNzFhhYyqZztjUuwyOo+UY61X8L6DPd6FfFYf9ImgZYhcMR5jF4lDKcEYyxz/ALuO9bswnDm+dkTFrcwylImDRnymZCS+cMzrkLg4VQQRwBs9zLS5HqtwbLW9I1C0hQS3luYWR1ORcbdoZQMgHdEu0DjIB5ya2ILQT3YLWymfzopJWV9u5irMy9fliDSvkA84JPoKNxCstzpthp+Uu7q5jMLxviSMM0YUs/VRucj1G7IGDgdZ4ajhudUumtfLdjAk6nysROH3eZ5Y6hAWYDdy2OeAKyb0uaqy0MK/0zy/DusbyCkFumwbCpVc7toz2VdoHsPetCCa4l0y0t0nUTL5MpHGF+cOOD3LKSfbHpWl9khNpqFrJHta5szbhOojG3Lndzkk8k9gfpWRaQreTWFs+7zQitIz5BRiAQDgZx8/r/hWXNc7qKvudONRXzCXeKWedgVEYxlmbk/7oPAHpj8eoQfMRsLPDFgSIwKj6D2b/wCtjpXJJbGKN2MREsQ8iIrwA4HBPfPf6+3To9I8xJGS6ZY7dmdssOGKvjcce+ePf6VDRVWCS90hmBaI7iA6DaSFOB0UcenJ49qyINQiuNcTTXaZSC8k7HpGoOevO49PlHOK2LVJZbyeGaMREsGhZSSzAgDH8z+YpDYww3d1fWsjQmQYCkBgxJwVxjOOCfwHTGKxt1JTUdGOjka3QNOoiLOSykjAIJwE9+eowOM1FdJGIXtyQsAG0Y5O5vvKue5wAc4+6SemKL23Wa6FxdsI5lU7ec7QOoPbOeh65HvVdnmUs1vIQzNkNnIztwP89qlsqKvqi9EqRmOeSMqFby/J3nG7nB9wvTPXpnqK0AJHg8oPKfJTc6ocF93XHTBwfXOKoCNrz7MANnloQiRgBsdQOOnbmpoP3oRLaMQvOS1tzk7/AO9gd8HAH19aSJlqPAkS1+x2rqYGJCIRlpT/AHWIGTz1OP6ZsWrNH5zXC77g4Yx7Sfs+OdhJPfjA9evQ4hVJobQxwP5Mm3Y0pc7nIKn5fRsEdP8AHK2kbWoaZ4xHuHnkM4LgEFSzjsTuwByR+JNaK62M29C1DFLIiq4MC3PzTtvIO4f3QOSMDt6dgKcbaJ4WkliFra4ZJIG+9Ng4UN9Tg4HT3pyRx2837hhLPAuBK4yiR9eB+R57jn0JPHbCWK2u5biRJHLIFIfd1y2F6Ek4Ue3aqT0uyE9boZaxS7SsIgtrgrwyIdsXPyqP4eBgkn39qbalCpjQSX8m1VE0gBjAzksCvLE8j04Hbmlezkklt0ujN5RjKi1V8c45ckHn0I/AUpihMMD3e/7CAVjhUbmPIAzj72D/ABH8KevUbl5gEkaUMtwJcDdDEzbiuf4zxz7ZOAOnvAztGlzFPJA6yBXaOfO1DnAbHQEce/4VbnhjKN9tWOJ5CE8oMW3LnCZ44xgDjjtVOSbYhit5YZWjAjeBV+XcPu7WwNx46dOcHrmk9BxdyKK38uJFnvF+0A/LuIzxgjIXkDGevYdulKk85cpcT/JkbJBHhmHXBPYEdzUtsWCRsGuGJPl4eIB4M4/Drnjtn2pk6SxB/OkyHAEcqfdjZSfXnOM+nAHtR00Nb9ytOD5Uyecj3iMSU3bWj5IG3POBVd1imzKsjmdcSj92Uy3frx2P+TVi+Q27M7iP5odn2hQQSQeMjJPf9aq3bQic/asqRgrJCMoQcfOM98c49eKjU1Q+GZHkluYpYxHP+8dWGMhu/tz0HbNJJvCwRyx+a6YXczkBkPUg4zkUREyTiVU3p5YicqpxG3OQR3HBOfpjpShg74miKpIwaHcAxjfuPoeKq+hNkVpUhUypAjblyPJZclhzgH1PpWNrUCw2AukRFjOFlX/nm4HAIHQHBxjrg9K6O8JDxw3syhnTYe5U9jgf07Gsy6to53mRiiTvHuUupwSpOQT/ALQOef51cUhx7swgrO6xyoBI0e8TEDn0z9ao3MZhwZ9+0LgsxGCPQ/Suge08mLyRCTEE2rk8ggnjPfNY2oWq3UYUt5iY3gt/e9KF5g0mzFeANMrHEZGVDAAg81lXNsPNcKw5+XB5wfUdxXQz2SqkkDkbQRtOTgZ/rn9KyrmOWK5KSMkgP3T+FVFvqZuJlSxOkm9JcsSBgjr6j61r6flblAVwXBxx3AyD+dU5gFDYPDjqB+lXNJQG5iUNlAu4KePw9qrcxasdfpUatIqZG8gkjHLHqRz/AJ7Vv2sChyPNQFTguF3fd6DHH/66wBHGqKkrhXX5t55BJ7+oI68UyLW44GKXLfvAcZOSWz0Ynv8Azq4xSDdaHStMsMhZljwjHqpAJ9KgKw8bwgbHIWMkfoaz5dc80OqzqjMwKmZA4QDOBjv6c02LUJdmfPiG7nnP9OKpvsR6nqOrD+znYTgKi53gHK4AJH649q5MtNdadiJ2WW7YwImcHZwXbnoMBRn1Le4Hc/FJraHTfO1CcQ24Rkdo0LPHHtJaQgdl2nGB35wK8Dk+I9pLdm5XzIbZV8u0idf9VEBgA+pPLH1YkntXsYjE+5y9WfP0aXNK/Y7fWNLjsrON0k3R4+6CAWxgHK8MByeCSDj8B82eI7lrXxxNNa79yvkBe59/xr0DxT8SUnt5Ps8QZnGXbON7dN7ds444Arj/AAZ4buNa1pL+7VRCsnmHcMFsdFA7jp+VebFpavY9GMW2fSnh2INpaSHCkEHHJ4PY1keKIPJjjneTC28iSnqpwSBj/PpWrbTNDp1vDGpKY2l2+QAHjIzyeg4qhfwtqGl3DXDMz/Z5PLSHAAKoGwT944bOM4GCRgnBrjlZvQ6Y6O5jSTxDyYVjaS4TBKqc4LADBPr9cDn1qa7tzbzyQToblZkS3GwebHGzyY+YEc5KjBIAHGcDmsrwqTMJREjAB1JGzGcEAKfUgr1JORj0rrb2QM027ypW2GR3JyCcjuc54XPfOarQ0muXQ5bVsyWkn2T7RKpU/JIDGdvclmGNx5HAJz1xxXn/AIoYQWYa68ydbad3byhtS3wp2Y49RHnJJ4OP4q73XYzaWzSJlx5scEcaEGQnzBs+U8PnaeeCMKM9xxWs28k1pPbyOrvdSgElwgRMneuG+7/q1AJP8We+TcHqjN3aL/hm2MOl3rQ3kspihaeAZJURsY+WDbto3YBwf4eh7UfF9jb6fFdfZ/tDQxIZomuZMF/NSOOQhVxuIZXBY5yHX0ro5bS7bUb+2h8myjxNlAu4IuyOTHAwcDcRyBWT4oEMVzqNyJ0e8S2lVVlUbVEqSg7B1Y/e9fujPAFVdtmdupsaYhW90m6uBFbzzRYZY1wsJhb5FbbgAAgE49T7E3tPFyuuJYgOqajJPbqmACkcdw0SYJ7De5yc88U/wjH9r1X7TIscdu81yLVW6LI6iQ5JHACr+IAz0ArQsI83VnMzs09rNcnLPjLh3YIQf9obu/PvUPc1iV/EAjN/ezBpVhht2RAFz5ny4BKr0Bc7R2yB71as7ZrbUrhZmRLqXM0kZIKliRtXsCRkHGPfvTLqL/ifobuIwxGNPMJbe29csWI+g98DrycU+eQxefNaOFdpPMnmb5vlbCqMd8nn2JX3rI7qSbVkbMccckQZGEg3FSi5+YAHDbR0BJOD1x9RixFbRpD5XmhnlAViBuzg5wOuRgsM+2arwQLbwi2SYR2cLpbFwN3mMCC5HsdpA7gYP1tyXX2e7jidcMxEccSAbgv3M55x3JJ55IqZqzB3ew26byYpLl0eRnk2bQeiYwAQMc9Bn8utVgRcJDJIkpSNgp3H52wQWJx68YrXMKLbps2O7BtxU4CBeMD6Yxn8azboBIYFdNqcsdjEs/8AFg+/NZvQUWmVZpZJXjaQbPk81XABBOST+OB16D61WgVpS20AGT5hzuBIGAv1J64q5O0gQ7oQkjg71UYAAyCOCO2B+dQgxeYbcMGfngE4TgZH0GcZ9qzsWia02+Q82CIwVGCeZm3dFHPQY/CrvlYlWzeMuVAMkm4DYpyeT/CcYGMAcj61SsSBJDIsYKAbdsvA2f3hgdCefx9BU8T+RE0T75ZlbGSM7MjIyfYngHPWi4PXQvRlGk3shDI22JiCcnJBIUHgcEHj+dSpJJCWDuLqPftc+bhGzkqXYcM3Ixjgc46VFZDaV+1OCYYyiRBupyfvZxnnjtk1o+bNIn7yMeWioMkZLSAnKgdAcY49+c54uKMJ6MhgQtZCG7QNEHMZUrhXbJ2LknnaB14GeuKWKN7eMqbSEXvzNAUYuBkYDddx689ieOOtMjihaW52p9olDNJ5LksA+B8vsvPI4yeOvSNoGtVmvrvzJJ5URWCYBZi3CgdQo6ZyM9+maq+hL3sXLdBaRgsqK7YE1zOflbC8EHjpycAcdqpWV55MbXMM0k8s5CK4IeRgOAoXvjnJyBxippYP9Jd4rZpR52TK8vmkErzgDr+J46njio1khN3j7M9z58vlwoYiRGoHJ55C5OCRySDgd6oSW+lyG9ujEivMsk8YZmmuLeT50+XjaM4bJ28DgdcdMST2clzEJGs4vMaJdmHwXbBLZx93ngAdfWpXmktmb7G8M0kbFYvKXIhO3LKD0LEZ6c+npTNc811/eDydu0BEjBkb5TwfcYyBzjn6BSejuVFu6toMSC7MjMJ4CRhNyDJjbIz1yduR+RzjGDWdZ3EzXuyKOKSKQsWUvuDoRzgE8EHsK0FtI7uTyYyxQk7jIxTzXBPyknk9846+pziq89ncSGSJriKKMgtagDHl46hWHHPIxj0qXfobRa2kQoRDC1upjd2IIhJOME9scDOPY8d6oOlw4kVBGbt4j/o8UhKFiRkjBPOQSQOf1xpljhfkQ3JURvGchWJAIxk89Og6YxzVeVbZpJIVH2cvny1OdyMGHy54xk9KT8jROzK+EUNcSqLeZVAJUFUlKtjd7H2HvUu0x+dbpPFN5bq4QAM4KnJI74weB9aR1V4jKAMFw7icndgsAQBno2fwpIowJDDMUe4XdtVQSXQ8r154xin5FbjlWNWWOQyK6qYd7nJXHTB7DP41UXaY5PNXEbtktweMYxnnHINXVjlZChZrlFUKxXGVHGNw9sHmi3R4hOvmKC0mwLIMY9GX9T35p6ibtqZvkmK3MEgV/lyrIwICn3rKvRKmoQzfI4dPvR9CQO/p6VsbGW582IomxtjBhvDAjrj0qvdN5quu9MupH3eFPqv1p76CempgXQYRHylBYHJRmPBPfHestz5wPnZCg5Q9B9K2tSkjjtS7IFV227hwckHqMelZl5EufKAXg7hzx9auJDMiUJIAf4lI47k1d8Ow7opboruVjtBJwCF9PzqndgxnKYViACo6knj+ZrZtsW1tHEoClU25zuHvjPvmtIeZjIbeaj5SsHw2fu59e1c9d3zGRzGisS2SCRjP861r3zXIKMRk4AHc+tV5LSRVQFBvboqg8j1NXJpGkYGKsjBzIJo4ZGPzIpGGHoau291IyE7mHPTB4q1JowcLIFQZ5diNwH0NTRacsCBBbhh1zzzU8wclz3Hx3OLfwFrkCyi4nvrNraNHI3wh2VDjjJHz7ueTivFNM8CtNbopaWVQ27Bxgcf56Yr1Px7tNnpUbqPOe5dgu0DAVOTn73Jb6cfhVXR1khiBXcY9vOBXXjZP2zR42DilTuczp3gGytZCTaRgnrkdf6V0UVlDbx/uwq5yAx5C+9a0j7UXB3AcHJ/rUF2FWFQygkH64HfNcMm+51q73Kl9dLttwACGIAXodq9f89Kb5rpp0RUb2ZZIlz3cjIOO4IHQ44HuKyXMk90zqDJCoAMY4z7jt6de4rTmglVFkl8vZFuCYOdm5W+Zj24xj078kYzT1NHFJWMfS4AikxDYse0gkZxgADqcDBzjOeuKty3xllMDQH7Ypz5AUcHkjGSMYJPBIIx06A1ktt1qgPmqskaAk9MYOD7jg1YnEcsH+qXbktGoHLEqcn2OT19q0TFLcrXEKTvE13sYuw2vuO1EGSwHr0GeM8npXF6pGs9+l9IEIk1KIvJPGR5MCsrYJA4P7zLY7LwTggdVcx3NsjusrCHBhdmG7IbO4gjBxx1+bsPY8+kd7MJBGICTfRS43kGOKPZw3y4wPLH4k1pFk2L8ul6cvjuCGZJzI0b3lyPtMmdvlbApO7OePxH5VVltJBZT2f8Ao0lyLaSGeJBlt4k8rhmOdqiXvyeT3rUUvd+IoJ7y5RYJ7t7dwkQQjKpKMn2RX5AU85PvCUhjtr2GQRJ51005lkOX2spjYDuCNiHPfze2Kq5K00F8CyFfCGmyqI18qJAZWbchLoI2cg+wPt7Z4re0tW+26fJbqnlyQ3LqXOcylUCk9xna+O5I9enO+FnNl4NZFDxRCzuINy43Dy5psjHrtx+GcdBXUaI8U969xv8AJsIbkKvQAht2xR6ff6+w645iUtS4RdiK5VbSRZESSSSITxNvUAJvKqvbBxnkAdcipnjjtpwjgPDG5upldvvKNqhcDnHIAGOuT6EUtQlEthBbIx8xpJzs2bNm13QA+3C9+MZovJM3dwxHP7kSMeAuD146YJU9ei5wDUeh3UloaWnsZPJCSiRod8rs+NkZZjyR7gDA9wKvSWySSi6iZvtR2RxOxIIGPmzgfe65/wABVTTdzXUyPGI7yWVABk4CooYZx1wADgcnI6c1asrgBGS3CyywqwldVwoY8Fh24GAPcjnkYUlYuT1ui8qlLYW8LMIUIgAwcyYU7jz13H8se9ZdxeWkE8izvEqwnzJQCMqwPy8+5JIHp69KsrI0dvC+1ZEt4RhE6hm4KjGfmVQSfTnvXIyQy3F3KxtkktS4iDIfmdsHAOTgZOQP6d85BRpKbd2dLAoktW8tt7HaplHBdTgEd8cgc/41XeLy5I7aLMrbhviz1c4+UZ6be59xVmPKWqtM/l+SoEcZ7R5yTj6gYBHX6YplztRBv6TH5FJyQWBLZ9yQDn3HtWbWtieugqlGjibMgaTG6VRt2AdQOeo5xnBHpU9pETvymZJWyoX5Vwf54AyTmnwxbVuAWBw2wsR8pBHLDHUgj9Se9TBSTAjAhnQTeSowFweeg+Ven1pW1C5oxOPPB5VOMRjk7GGDk59RznnpjtUkqbZIliUj7IW2MG6J/E35EYHtVOKJY3LyODHLlFlOAS/YKB26HJ6AdqszTMI1uQzmCM4cvysxHGTgg7en1557VRztajLNJReKqzSL5sYAaReiHuT2bg8n+8SfeTyliFvKrzERSCNFA3ZAP3lB69iWOPr0FGmsh3MspedCYpS/Z+wOMg+uM9uo6Veh2IwRZfPvJsj51DA7T8xxjGMse3OKuCTIlJpmXI27zkjgeVmJlKB8QtluBkdT39uO5FWIhceYFmkMrJIXwsg2ISPlU9+3bvnpmo7iS3kvfJlubqZ4owZbheU4O4jA4J6/nyT0E8CBY/MjtVtTL5mxZo90hYnqxGSBgD68c0JXbHdWKdq6ahplvCxFzI52vHbOxt0deVyT6Agcdc9qneUxK73ZcWo/d+VGWwGB+bAxknkjdnqBUFpDfQPdPDKPmKyNIzhArHO8BP72T6jpz61NbypMI7mGSSazlj5WBfLaRhkAnJyO5zwOpz2p67sNE7LYrRwx21sILiQzWsOVXz2EsoOcj5uy7T04I/DBf5D26xrG0rW6HcrI6sIWC9+/4dOevaordJbKWezWWW3nkxMY9gkZQG+Yq2MAkdsg06xitndmsVAmaTazq+ANv95ScnHU44/KloaJ/cVXgucQyPAkzlj5uTkHI+U4xkH/AHelDhWeK2kniR5YyDCACQ/GO+c+54P51LKPLZ4Z7hIZVKyrI8ZVGOMZJHr/AJ7029t2bOVtolBD4DEgk8biuePUZ7GoszVO7Mq3NpGU8mRmmRcgMAN6KxVly34dPfrip5YPMt4ZbRVd1CLBITuKknIHuDjpVW7Se5jIdAFRV4BzuwOSOmcnJ4zjPTGagV1t4jd3RRkj5Z0Yg8Px09+vA/CpT8jezavcvPHMJvMhcwOu18hAVI5BGc/5/CnBzcPDvZVuUGQpUbuDwwx1yPzpkp2M8B37Q7BTK2VIIGfx6dPWmyx75/s1uAwRtu1gSRgZxn8ePpVNitdale4ZfMeOIf6sCQZBBJJ5H59qryK4jwsu4Z3HaccHoMexp7SzxiQ7meVcEBiMsO35U1bvcsbhVj35BXHIbHSqT7iaMeVWMrM6hWb5nbqOMisqVs3DFYgFwQfm6HPPFbN26NJ8xWKUqWYZ+U5PT+tYt799QgBJ9eM1aMpFCQvJcRrgAh/mfPQVsiNWYKyuWznjGCOnA9ay7KP/AFk2GwGwCPT2rptLty67tj5EYJ2DIB7nHcmtomcUmyna2jG6PmpjCjjPXNX00CW6kUIrM7HgJ146cY6Vs2GmksGZRuGcKW7jr29Bn9a6G10tjb+ZmAjBwjN9/kg9B0GPofalyuTNJyUDjrfTV3hnRFYny1Y4AJ7j0/H/APVTotMlQMJIxuz/AH8fzxXfXGk2MUJWJoiAflLbggXqADwM5yeKxp3hEzBvLYdFZzjcBxkcHg4ocOXciFZSMf42X50tfC6WiSyPGJbi5SK3Z8RuQBI0n3VUEbcH1J7DLtAmaay80EgEZHoarfGTUbg+KpdGs82sEtnHBczsjFpoWy4tlOdu48k4AO1jubGan8OxCDSYbfkbBsIB6YH+OcYrSvJzryPMw8bUVc04wzBH6SHuRnP+NVNau1hkMAYeaYy5wO3QYFWYXYyLhG2bcnHt/wDWrA1tx/wkIgx+9aDchGM7N3Qj06flXNLQ6IK7L2mWzLEgYsrkZIzwD2zWnrkLjSZl3Z3x7dhOce/1P9KZpcU8xcRnyiAV3yoTk+oTIz3HOOx5xirHiC0lbSLpIpt5eM5SRFVRgdEIwc555z098idkW9zAD5so5UKsJEAHy5znqc+nP69+0Mh24BYbBgnjqMnn+dVtNuWl0m3D7g06LIjI3yyqVGAOcZxzj0yfo28hZTI9yzYO5PJQYDk42knrggHPoMjvWiFJa2IphHdAu4Q2qMZG8sblchgU+qj8mPH1qRLK8kkMUanL92zvXJDn8SMZ9u2RVySVFnO7blUPyDAAIGfwA9BnismR/Lsr6VY8NGu9tynDvkYAHpnnr37VdxWZcuLqW1nsSzIC0isx5z5blAXPPTZIBjvyOgpwjYwZKpKDGlnKJMbTIVypGD1LqvXpt4680r+3lneOONn+1S2CT53fNDFlcEHHXI+UDrjsASN+GOB2vLKCLdDbyJMkSDIJ5KjHfv36nNMkxbG1E9hfQs6lYNQm3jeNrb3WU+hJ528Y61u6WZ41+1zPG11mVnIAAEiLjaB67gB9fxqpo+mrBHdafFcedC9tu+0bg2XIQKfqSn1GPamQXJKTrgLdRtjaScbm6gd8sQfoMnrUt6nTR10F0t3mNr9qbdHGp2ouGB3SqxzjHZsE+gNX2Amu57ZtjPcXInncfwnqq5PHAIB+grJ0cTwSErJIJ4pXMZYbgAFbJXHHVwD1yQOmKuxmMzSjB3hd292AUgoAAOw5JJz/APrey0Otqz0H6MrfapZJGZ4jlhGycAseCBx1+XHqRituAj7TbRyrEi5JdkI24UncWI4DE465Hy4JPNYm9LYQyODCJI3k2uxOAMGMAZz1Ix77e3XYijEUluYpFLrGNzSH5YycqWHq45wcZ6mpfwhLVXNGKGeCZ2PyMCUUOGAjdiDjn5dwweD90A56VQu1SylEkEJIT5baMtu3sXI3c4G3scc/L3rRwvzJGuyN0+SOVvnSI4LSN6biDk9eePSmSSSRAXCqxkThXYDCLjgYPHGR+prJswUmtStc4FvGSwkmys0hI5XB4UcZySfy59aSeB2lChElRi29s4BbsoI6EDHPHORVgQmFSXXbCg2xL90n5c7mGc/T6jjvUskBjyZNpVf3iQ5yUU9CMdhzyc1G47kFs8klvGfuRklMjjb/AHmz6jPU1ahj+WXmMLI5jeRudxAwzHPpngdOfWhEVkj3q7CYYCKxQhSDtBOOe5P+FTqiwQtl/MEqqYo9vDbTwcH3H5jPNShNkUrBZDnhjEUjCjKj7wAfH+7zirEkYWZUlU+SIyWjB3ZfHX2Gcdf6U1GFtbXNvbHM6N5gmxn3bbwcknt04zUcG8zOziZHlAmAGMhh0yc8gnouPXPFCFqasRMqws6M0rI+1SD8jYA3t3J/X8OadawK1jAGkkEciM7Sxdz0IJHLEjIwOmcelQrKLOJZogZGYs8se76l8+pJzU1uWCTMrlJVYFkZP9So5IGeAcHGO3Xqa3jY55J9AsYkhSy+V7WFBvS3X78m3+EkYznjggdhUEKylFeV1g5acJIx2onALMwOT3wD0PfjBuISVlKiCG5iYyK5QuNgJ+Y/7R6Y70+7xdqCTajTmTz5WmYfvS3HQ9vfv7GrtdEc2pk28iQzxIlxNN5uPLR8tHKF9eCV6jngnGPrU1LEtm6z6gqX0z+QZbdNoK8Flb6ZwSD7ZzmtXZPgj7Jsl+cIWkO1QAe3px68fXiqSRXMiu4ne4uVUZLKNsh+YlunIA6evesGzZWbuZ8dxNNEj+RfTvLtRvm2p8o/gO0EKeGA5PBODyRLJ+/EpntY2tZJMq9uAGQ45JYZyenf0q3uknKSSxwXLSMoHzDMvqFHATnk4PPPpTfslpawkSQSQqr7VjYZMoOOSvIBGOcHOV9ziviLUkmRKkoWCK9jEdsFbEcoBcKBtByO2eeAetNlMbojT2/kPJArNKozGyqQRk4yBx+vSrVsgthGUZBLEg8oS/vGwDz6jGPp7ZwMwmZo0VElEjbiZc25zFnPGPTPQHk0WKTbZBeLI0rRHyzNA6yIWONqdyPUc4yR3rPmtreOETRRxRvvJ4cMUHVcgHgn17Yq6SxTHmQGaEbpXLrmUZGM57c4+pFQySRxqj/ZJoS+VlDYPBJAI557en+MXN02tiCAoiNE8LpuwVHDKp6E5/h6sKr3Erl5E2FJQQ52sDkhsEr64BzSxndbiTLbZMPHg8LnIIHTOcfnzUMqwCRE8hXRHUuJOqqTliOfSknc0sr3K1wzY8l2D7ZN3AwCD2Pp/SmPM8kDOVZWVj82Adw4GQP60+ZS115kaF45OhU/NzjBz+dU5lxmJUyIj8rsMgcjAb+dNMHqiCdl2MmwxENnpkD3J9+lcxq85SQiJizE7eMAjPXn1rcv7lPMMXIZl3mMt19TWFLbLdarBCSSu8SN7Y9a0ic09DUtbYpZtHhSMZyPTHI//VWv4YvYuIHBUqeQrYJHTgDP1ppRCuQNoye2axLmCeG5W5tM+dG2McDdnr9M1qmZwPS7a+ItSkTpjP8ADgZ/vDrnnk1cXVLox4aZUhAwEx29O3HWuC0vVo72AbpJIXX70YHzA98nv9aW8v8AyceS0p3DaB/U0a7I1lGLR2d/q1vDEDNIidhk9fpmsY65KGY/Z4yGOQZZFjJHbgnOPQ965MXM87EzMCOoYdQB6H6k8itFZFhG0rljycjnNUopbnM79BviLULXVPGHim4t7YapBdyIbS6MpiW0kj+TKqeTwuCOhPtXQae7JZiPOcjAI9e9cnoOnvbxzF3UmW4kkfjGCzEkAdhzjr0xXXwKQihgofBwD3+lRZqTbOeKSgkinq+riwSzDvFDc3EqQK8jkRozNgMSO2cVzcI8/wAUw3Y1ey1HYxsmhhdSWyQWlA/557lGBznvyDV6S8cfEPTY7Kzt9TmsoHkWwmyvnu+F4IBIdd24HB5X8RtrYa1F4s8Owa1b2Fpa21jczRpbhRhi6Bon29WjITuep5ycCuT3Ob9Be05ZqJ1unRhQC42/xKTwM/yqLV5N9uTjCnrjr+Z61elbZu2sWBHJHU8/eI964/xvrCWOmXUqyYnceQm3G7ew6j045rnlrobQ1lcxtII/sTTwY1DCFW2gnhhyOc5z0weuBioF8yK0j2yJOoIAYfKx9TkDB/IenSjS2CWFtGSwVAqA9wc9v1pomw6GMFd25W6EdPlx7nB5+lapDluTTPI/kMEKRmRRt2hmCBsYYLkDrgVUmLvaXKiAbZ0LZmxt+bOCFHUHce/YccZqfcDEYhlSRswpzzk4bv6f5zUFxcBZbWQONsZ8txuyExhgefXJqiSe2ZXgtplVuQwlXeNzFow43HgMcKcjpnAHpWvFMtveXEp2pHIkcu3bhydzgHHU43dvTnPfFsEQj7GqCSNLgg5JG1PnVNv4OQCe5PoKuxSu86IW8uaBWHmYz0yML7cr+K56UPuJIlskW18QXMSgExPOlvvOMFTkoPruJ49/SqV7uhubq5g2L5yeRNIG2+QQwG/PYD7xJwCCc+tarsX1q4jQPGhRpsx4IQMgBAI75RmB9apGGQfaYkVdywok+PvyoM4x68fwkfwkdhUPU6KWjuZ2iIsk99ZyFftEDMwG3huRyT1wcEj2x9KsW7Rzxi6lXOCq8qSWwQvP90FR+OfpiDTgTKFiULL5BWPLA7U3t8mcfe5HzY6ZJyM1eguVhQFBJIkZ8uSLupUMACPYkgfU9RV3R2ttrQk1j/j+CsnMW05ZNyD7xxg9AWDDHTC9sVrwS+XYxLGQQhURxjJ24Xlzng7c43c44/HC1a4jhuHmmLolsFQMEOMABsAdepwMYz+FabRPDB5N2Q0qALsONsYwGxxwTjOSQAeOpxQ9UCXupM2IJYbplKSIyqVXzW6HC/eIOQFyCeOcrnoWFWHcyxxDyspnzIk4XLYwrNnqDknHXjHpWNblY5oiXeKPYC8Z+bgnGD0+Ug8kc89yQa2bC5a5lMjb2l3iQZA2hz0yF9uMDoenBJrFowqQcfQf9ncK7BAJJpmWRhw3mAHgAdFGfqfwpjGGMO2wtEEC5PBduiqvp93Pp+GKmijUh4xIB5gWJmU5wBywU9Mjjn/e59HlmVjJbQiRWLRrH97CgcP6deg/wqGrGSeowBfIjkK4RZgvK7WJYZCr7DkYOeg6Yp7hcuroCTjzXRflijbjGccHgDipLS2dhFHu3SSIYoeRx35GOhJP+eklwGIk8oF35yinCo4xkMPw/DaT3pWDmV7Fc+XCq5UBYXIVtvyMT2AwOmM/Tp0NTx7o0hjiLqwlKiZgfmUH7wHY8gc+gxmopGYXVuyhHkwYtoHKOo7+p9vT61IA6xzxFg8m5oTuPyrnrjpnBPv0pob1JbaASyCGJlgdmZwZGOWAIO73bn6VZdI3YQltgWXz4kjA8xsfxYHBzuxwT/OoLaVZGtoH8yZ3jYee5/1ac5BPvj9cVI0i+RJd28bQpkFpP4k28Ae4PT8evpadjCV27FyPb5O9Q8ruRA0RG7Z3+cH5QQSTn14HIxUF4qWqbbm1gnR0WRWVPmIQbgzZHXOMY6fhmoFnfywsURjUsCZ9uCATwQByQe3fvznl7wMiyRNPMHkJK+Y2GYDnsMAY7cdK1UrrYlQs/eM0S/aI5HZbgEYkmaNgqZ4+Tc2c4GOfxGc0t1eSPbRTGVYQG2NHETJI+PvKR37c89c9Kz72yiuJJ4iUmm38W28cEn7xcnGTyfU5B4qv8qXUklpcXDyFWhUvIQcDhVXuSeO/GKhxb1O6NKL2JppTJcSIpikhRMSZIjI3cYPXacknHrgYFaVs86ZSPKKMKY7l9gCY68dPQ8GsKR3FnJbXFkGuJgG8zys7uhwfUAg8n37cHbsLgXNrcT3OwxyqpQJmNsdNzY+YY9AeO2KjlSKrRcVe2hK8TRuy7SkgUGOaJM7EOBtDEdeSR0NULmwWTUHulnM9t5f2dldsDdngtnkn+hI46VqyKRbB7iTZI5DFEUbfLB2gEcDd09e/Yiqd4Lu3eF7QMWYZUPheCejDGeh46dOB6Elbcwpy7BMoe1R4VETybUIlHK45ycevIx0yayJIXibadwg35XLEZAHr7DjHrWqUghilRoi8bkBu6jAz64wDz64FU3SQOoCDLgoxDZ2qR8u3sCR07/Sk3c3g7GdBB9lSMSBx5bhoTKd52k+vpz0p0ybHQ7OJRhn3cZJ6DPXJxU8rptJyyMG2S5ydwUcKB6471BKpMpjEgCHC7o/m2Y/hB/h4qdC27u7KEqeYiGM7WV+WAGAB1/8A1VjzoCuI4kRSSxKNjecnnFbTQRx4EePLcuybejEnPHoetYdws32h3KotvtwkZB3huc0JDuZlyiLctK6p9o2bQoGBgHp+eDVfQbbzbuWYsQV4BzjJ71NfPK0nGePvvnp7e/StHQIRFCCPlB3NgrknPetEjmqGgIxguQykDa4YZB9M1TuIGjc/IQuNwOep/wA9K0Yw3lkOm0gksc9R6D3qB8FVORJtHORzj61SZmc/dWyvMpjJjlC5DAfkD7GmQ3N0jYuAkhXqemK0bhApYYc5bPXg/wCelUJYjuxtJBGUYfw45GatSBsuWrFxGQFUrnEZGCfwpfM3sxKKDk5zxVS2uCsW/AQrzkNng98j9c9Ka17GWJMgOe5PWqUiOY2dPvY5ofllV1Y5BByOvr71rG8TAZzs7g59Ov4V80QX11FN5NncSxk5LEDp7+1Pm8Sa5ZTtFDqt0VXIXLdiPf8AyK6nh5N6M85YiKWqPpX4X2d9qmr3ut6asEusHzZLSO4iAhIjkWPDMASgO4kMOjKTyF56jxZKll4vHnSRxMlqWWCNMQxvNIXlwwAG/cqghhltwY9TjgPgZqfirTfho2vojXdhHePbqZHEQSMgsZGcKzsglIyOAPmJOM4tfGPVdam8R6bEdQu7W8TTomuZYrLfBF5z/vFjJdtpKoMFSwJXAI7TVpuFNRd9/kRGpz1ro1ta8WWOmwZlffKwUQwRJl5M/d49Dz83T3ryOTW73X9Ue7vGTaoby4FBAjTgnAPOSckn+Q4rY8Y3Vzrd/Pd3JMrYUE4KrsQBE2qegZQGx2zWJaWrK++MCNWyAAchcsSRj26VzRirXO2Mm90dhp8pdER/usMKf5GpPN3KYWdvMXPzEenPA/Gs3Tbki3jbnC4JBxzyR+lTuwM5dQW3ZG7GRng856Z6e1SXc0YJBFPbOC6gEPGB/eBG4H6EL/nNNvF3hkPyW97EGifHEUp3L3P3CCv4DHfNRRsJUjK5FwpGzI28jGFI9DyMcdakEwa2WJ2ZNku+MLkHJJz+IPykdh9aoVi7ZOZoxerCE2qd8bZYq+XLDp2zWkYZDrNuJVDfbEjVug2SOp3kfVduCPT3FYlhG1vcTIylvNCzZEhGMOQRkdQdwzkcE8+ta+ptMBDIjq0tsM72GBgHOT2OBtIPsfSkxkd7LLFLaXe0qZYCkqRkuquQQ0eCOgP14Z8d617qERX0t/FGhaQRO0YY8gnDn8CFBA4Oc1Rvbd54pxCpEcDLNHgfMwYjIx2O7cpJ/hZqs6bdCN4TI2YVIkXYmSAuEeLrngYI7AL0yai5qu5QitIvtcE0bBbje0hbftURkgkqRx68HuTUcMZml+1Fv3s5JRpCA6Ag53EcEcH88itWeJbPUJGjKorK+G6FQudoI7g4wPqO2KtTxiK2jVBkRlUIGD8vB4PbJz79aE7HTTqHNYkNssVwEAJ389+MD8CQTjjoRT13A4hIaSUZVYwTznG3kd/UegPbNX76282SbYoR2YRjYuAXzuK5PHAIIP8As1VtiyGbdlJA3lbtuNvJzz19TxjJP0oR1w1Rp6fDGbmOaQs5iYtjHLkNhQAehOA3PUeuK6CymkdpUJI8sBnkXux4wh7nBAHsSaz7NYU3whMFlYop5wW6ndnjBx17Vo20peOWT5UXAO6NcLt3bQcYxkgdvr6ZJHNW1JzHHcW9w20eS0an92+0kBgD78nB9sfhU8S5fewxvJ+YLgZwcD8yRUygRxzkxhS7iRV7KDkhMdiCB0qQxswkjlAAhHyMTwDtyX9z2A+uag4+axDH8/ATb5hVWlyQVK9gT34AI/Oo5plWJJFypkJt8INrFifvD0AqaRxIDvygZMLEuTvI49sdT+VJdI6s3lxq43EPF02Hb1HZs8ZFJoFvqUWggiLwzRlYV2s0y5PGcbc/59/Wmyq8tlPHKTFJbubhPmwFUtgdOh+nP4VZGFb74NuiICThm34wXx364x2zUjLLJHIAEaI4jiweZADyevQdaaVy3K25BJ5ryiS0Pmo+1Yod3yjgnd9OOD7jvViZ4RcPNFF5oI8sxbNxz0GT7HB5/PvVZ7ZbT7RHaTMWLZ3ct5eTyAep+nHSrAeKKZoUkJ3x+WyL8pLYJxkAZ9MY+tVHexMtdTOnuJBO5nadp7dQkgbIKA5LFQB9714yPXriGz1CxmgW2SGVbfC4dy2WiHA6cnkknt6ccVravbyvDEUhdPK3+bn7wI+pw3Pc8d+K5poZ4LpTIv7l2IQjHy5yOT6A549uOlbbHVRjCrHzJbo2pu4JHhYWZmOyInlnHO9jnOM+/ToMUy6dr0tcWtt8sY8qMgHr/Ftz155JJzVW/kljtIgkqz3DS/KXQncAQFLAklgAPbqM9ataa8U8Id2W1ReGRhjzGHXjJOMnAAOSSPqFzaWN+XkjzdizDPbQiWNLQguAcrh2IGCFH4fzP0F5JHEkrzxSG6dlDKkeSi9lweOnG7Hc4qqkc00rkkSKoDlMgFwQPvSZ/dgDBxjPFWlvGtSVe582YMq7bbMhLAYC88twc54/EHjJp9TlqNN2W5buozDEVClZNylZJJcA5PQnqF5/QegpnmfM4by9xYByGZmYnoCP4eeh74J7VBaqTMyN5O0z5J3hyf8AazjCg8cAcUX4le4KLIsCF8BEP3vc579x06fgVeyM1G7syqYmktVk37Ixu2RY+8Rxz359f8iOKSSa2B8lkiTLNGg6HI+XPvjrWjcOirLKiScfLkD5gBxkDOOeOv8AiazJCYgUbzJEUklVOT7An3+uO1RJWZtF3RUmLyzSgESJjkkEhTwRk9Djpiqkl0j3PkQsjSuhkKLgY4wC2Px/Srs0rNPsYZZfmKgYVT6Hp7etULlo4zKqkmQDOc846ZI6884H4+tRqXcjZwWQM5KqoDlRyT2x7VnasY4nLsGMg7Jng46D86uXciiIsUVJXGNhJJQn+EjPp3qhLAXnQs2/IG04+7j+L3HbPbrWkXYTMxLQzXSjcvHOc9PX8AevuK0reQqzxbCFCfLxwxBx+BqWO1X5hj5WXaABwQOnuB7054Ut1h6vhdgIOTz1A/Gncydr6jICxmfchVCcDPRh6/h1p67nO3bICAdh6Zx2+gBB6UxSWdNrALnjuevII7cj9KmdUmG9UZdjbieoKtxkHsD09qaTM5aGbcZBZI2Vmc4Un7rHBOTjp6VnXDFHOY8AnZxgnbnnnocYBrTvUkJUhUkYEsMcF1+9kZHJ56DrnpWJfqVuTJAbjylBYK7/ADdsgcdeT/Pir2JepM25WUmYMCdxJGAQfXvnIPPt+FZt1ZSzzM8UgI6EYLYPpkVoWLI8QaYOrYGVVhgg4wQccnrj2J44oEcseRblHXqWycZ9uOlVEzueFRbFWWOMbpm5B6beep9qZqsDo0cshJMozuPXI4OfT6dqsW7RQzEbXK7j0HzN3/pkD8aTWrlZpInVJFXqdw6n1Ferd8x5CS5T334JQMfhaZr/AFe90u3guWeOFWb99EXUNNGGbbkEspKj+E5zmrHxOk1G18X2t5rWsXdzqLpbvZWq4hhuoNz+W5MZKhkfe+DnO4Y71wnwn8RWWgeHNVkumRxM7pHYsWQy/u1LMz9gFyBj5tzDHXjqJY3uBpn2yCzgVbFJ1G3fcJuGNjSHJYZTI77XAOcADhr1HJuFjpo00mnf8CsYVMYjcfu3O95AfvMBgj27A/Ss548SRgKOByqgBc+natkJ5jtMY84w0vBw3GR9SAf84qrqMA8wNgunC4x1HYfmRWTZ1KxFYSEpIshTdGwXcUGDzkN/LP1NSQTkLMr8MMhcAkZxnPsPaqkChLmURszKoH3sFtue344P4+1OMpMa7x+/jyXBG75Rjk9OBjP1pMpF1G8qTy5Msjlk75DjHv1x3+ta7RrPbR4CiaRAEdhgbvmJ475w3XGOvXplRStdJ5anBZVYEuD82Bz+QrU0+NrlpYl8xQ/zBFU8scDOO+ce/QDnpRZAPtkBkgjcusjxmIy4GBubO4j0HAI4z0rXt5/t8Mo8vDSQ7ACAAjoWBGOnoQPw+laFRMsrGbCELkM20gjkt3JxyOKdvkR2lj2I0j5TAARmHOMHovBGeoz3PFK7KVmbNod9rYzjzW3RFGMmCxwc/NjqScnGTn5hUEFt5U08EDvuLNJGwIBDDhSvPXHy/gOgNMsplR2tmWTyvME0J5/d5IYqPoRnHpwec1a3u5IjCm5jJmiJBCuMYdV/RsDnk9ehh2ZauTLIJ5oLViI0YGZSoP3SFIIPcDpjt+psqhMcagqjSbQxIGEOT2A6gjI9uKrBopZ4vvmJj9ogZDhxuADkHqPm9fX0IFXYnO1g6phhlG6q5HbpweakpMzljQxxxncqB/tcjseMhePfGMH371FIDOIWCuGMWPl+Xg5x+HHv0wBWjdQ7gsSqo3K75H8bdx9QDj8KiuzI73Luq7BJ5aJglgOCx/PpjpmiLtozspTuQwRh1CEYWOXdIwIwRkAe+SM8gjjA4Na8cpdZIUY+SXCEKSGA9T9NuMnPOMetZMKSxRxRxbN20vJsP3snPPuDtJxirtphElKs24Q8McFgAc5Huccfh+DbKqRT1NnTpUuWlihhdI0dvL55bgDdz2xmrIcqjnb5oXDqrjBYk/yH+eax2u4bO/hikdIpJCu9d2PlwAFUE5yfqPpW2sXzRRuSk2AFYDOEzkhj+NJLTU4qkeX5hCwEkcjh5XbcdwzgKDyO2CBngf8A1qTyGli8mJxukw6yr/Dz0HTtToQXM6hmL7kKgkfLk8r/AC/KklkCzB0ZHWWYfLgbdxAA4HAFLQyW9kOfF5cRyWzsu8lnLDGeMYIPBHX+vu1Y5LmYPZOyZiMaArwhzjcQepPP5DNPCqWj84SAI5LuvzDPt6jnj2qVJFaAvddYnBjliOGQEgZ+vHP1q1ruTL3VoV7iRFlwkrIfNxIm3klegAAx19O3NIqNL5ExiaCbB29Mhv7x4469O/tRe3MSM0byCON222uQVKtjJJIBx0/z0og3P5+8qUZ8SSKCr8e/OcgjnP5dKa1Y1ewM0Qh/f3kkqp+7Ltljkgcso+9n0HQ/U1mzWUlvaotvDhV58wSZbcRnhSRz83cA1qrceWFZzHEUPBChiwxxj3Pr74qA28aJLEtuGwg8ySRiyoSOg6knH07elGhcJODONukJV2e4DLKrbJmkGBxtIUds+mOpq3p7RS2kv2SMrMqjdOUJJA4BXOe/bocd+1jVtNRPmui8UTHZEGK42jn0Oeecfr2qvpVzHDI7zqPKwUjEq4GQpBYHOAMHr3+taQT2PUlUU6d0QRObSwFyxeWR9zrEYvMSQL0LAdOpPPpVi1v76W2iWK3tlILedGiMm4NyTjGe+ORx6YxWXrLKBZebK0NrE21JERVMg6KQ7sMcjp2xnnBBdpoKjyUa7t0Ygs6/MzAc4LHhicgAjbjJ5YAAU6aTIlyyXM1qdJDewSPceXbbSFCBVX5QfQei+/rmrjznyFG+NvkJ3rkknOeT3xnpXJyzTiMzI8sE86lAAmHbcCCT1JJGcDg98ipNPvreYARPulWMea+7CqSMnGRyBkc+9YSi0Q6Ceq2N03JSRAGRo2XhTglyeOcDp7HvVW5+RD5expDw2fXPUn/PSoIXbeA8aqR0Y8bvQHjPpVaacCJUcEo7BGDngM3Uk9zkcD0zmsW7bkcthZ3IkIZJNmcrgjdnjGewB5z17Vn3k7G4LYUAHDBBwf8AZP8AeyMDNWjKsd0AyYYhsKTncvqM8D8eKqqDHKhIKM2fL8tt2fU+vOTz/LFSPQjt4zJJ5zhFbLDcF6fKf1xxUkcJDeW6hTyo2HPy+lWI4QipHg7gcFvQ46ZqtIJY7tZJZFa2J2IMgYckH/I9a0SIchsqoztkkFfm3BtpHTJ/D0rNuriZY1khRiTggBOd2QBgdscHNPvGjlWWeNuSXYkgkkKMDg9R15B54HXiqEzzRxqm3csgbZzySpC4B4JBIY/TNDVtjK5PHI0kjOSoWSUKqr0PA38jn+LPbJ9iat2t0LhIpmHnKiFXj4AK5ClsE8/n16c1lWrPDYxrEJIQCylzhg2FIcFR2HXntx1rS06J5rK2EiB4/LR4gWOEjfcSy+2Cevr9ALjoQ3cgumZLVyHUpE+N4PKP15z1Xgceh5yKo6nDLl7iAY2EEo/IYEY6jpnBGcemRXSC2ZotQDHO852lTuYknIbgjGcccckdKzXQOMZDBF8xQxyw6ZwR19CDnGOtaWJcjBtkLNPcCF1Xg7g+Ac5APTrnHbv+VpIlvVE3lNIxxueLA3HHU5kGT7/SnC38qVVmMZjkIYEnAPpuPOPWnrbPukD+WSGP+tRWPPPBxyvOR9acdCXqfOsU7hpNiRBT68YPqOaddTmQRLsVcf3WyM/0HtVzVUMUJUogctkjGDip/B3hi78UX1zBZyRxJawG4mkkJ4XcqgKB1YsygD35wATXrK0tTxrOOh6D8OrrTtMR7hDKdVhjhltbuKNH+xFWLSfu3O3c2xEBbpvLEHiumvbnULy9uNVuppLq/mIa7HXzGGAGTP3cDAAHArqNR+H134V8NpYWOiFozauk85VZZJm3Z3bAC+/ICgg4XKckMQOZu1tdI16bS7PUP7R0qPy1tbubjcdoymRxuBJXjj5ema82pGXM3Jeh2U5Qb03Bp08oGIMqPlkOBgnuP971FUruRo7eUbvkG2Rt3QZIzn0GR+lajWwQzQqjK6sZFUEYVx9fXr71RdxFctIdwjmQoVYfMoxnbz17jHbj6VmzqRSUqLhGQ7gy/LjjAOOc9j7UX8ckSF4iCiuQ4IwB757LjBPbkUbIyiwMFaJ0Zo3XIGRzgH+8DuIB9TUdxJLZsslyplgIwZMZDZ6hvccDOMY/UGTxybL9Wyzic4BxtA+f5h0zkAnAHpXQWYR5kKHqxG4qBgkDnn8/x9+MAwOVjgZw5OHt5TjBGOVHvx0PXHfFWrWVihV4wJSyqSH3FyBwcjjBPG76E5xgDYzobQSQ3EkaOQVVwhGSwG0kMPoQT9BnjIq1ZCLzmjnBKTfIH2j5Djd26feOD689iKzVzLsmt5dtwqKdwJwwHfp9ePqO1aFtcJe2cqbTDLEVQrkEq4YleMcjBHrwPfAljJrLIaVHkKTAAOx6MQeSO3Od+PfFaq4AhmKsUifaQp5U9OPb3H4cVmJsieK5jQqwG0h8FlIH3ucgjnGfTHpV+GNWKBcglixVTgs2MYI/UevHrzJSZadHRjC21iJN6uEypB6rjHp/XvzT4RL5cbEOzwlwATyzccfgPxpsDRSrAHbELDK7DgYx2PrVq3d95aRh5jOWbP3cZHUDvgilYtOxIqiS9V2YGMqu5M48skEYI/M+5pt6yoksjqGUZAGc5wOntT4otttsBAKrlSfYE4p4VG3EBfmDZDDnccZOO2allQlZmfAfIjZLiUqST8x7DHL/AKYq5Z2AjhVpECyFsAMA6tnBA+nH+cVX8p0uFLiMbyuGbHysTgjnt1rRtVUo8ckm0htucY2vnJbHfPP5ihHTOVloWI7MIzebGJip3hW+bocqcnvVy2cC1jVG3NKGyrZ3ZPJAPp0/KmwH/RYZFdeAwcc5I6g1HC/kyugVGhdNobB4yM9PTt9fWg5JPm3Llq5GGjkUyeV5i8bTkj+oPFRzJCqtHtdWwgyOApJ4yex561FyoJLDDoAjjkrg4GB+v5/hWnvBY27tcPi3gQiR85AJOAfUYyD/APqoXmSotu6LcFyxDhokaRJAjKMjbgcN0OAcDnPf2qyHaWZzLiNJ3wwwWXAAz9On/wCrvmR3EeYwrASRyv8ANjl1HyjHXccnPrg1TW+zb28yweVHD+838/IeScepB79iPxFxXRj9i5bGxcvItuI7l4hdbSQGXEZXdgnPoQOv6darIQzW5mg2xKw8tI2GD0wdpI6Y7DH0744lSX9/KgtICgj2MeGUDduOTzwe+MZI+uvHqTyRAyyLJJMMgoo3Iowdi++McE9+/ONlFMp05QiiWRmU7mZJpSRtU7dsYPGGI53H8h3wM1HaTKwYTKUZSQkEQLb89JDnBHodw9eelZ+pzo+2NBJH5eCEfapdT+PvjPQ5rON8beFjakJIV4lkjLOw6ck9SDnk4JpLRmkcPKS0LmpxJfW2GtYTEflTzV3eaRzzjp6856HsM1l6f58N4FurjF19x2U5EfHGO/fuB1/PUhnt7lmSNCZtgJeWbeyyHGNo5GQeePyrI1HZatNJCkakSL5k8keMsOCNoGcZ9jng9hUydtTpoXV6bNIwCQSJM7SN91QgUbgTgctknAA7fLz0zmmXci+ZMY5EtzFiPaAXCLk8swxlvvA8kDdnjPEMTy/ZXuLuVjJuBCI5Cq5YdPQliDnj6nFQ3lzMt7axokhVZOMJjyuvIHrnv0+YHvWnPdE+zvK1yC7cxljGq7sgIJGLyso98YGR6Ant61RtQTqUu7b5QjXy4kXGD68febGDxxxzjgHRmdW80QJhd/lRxydc5zuPXIODwD2z2OM7VAtvCs6yOs0cpKs3Dt8wBZsgkj1z06ck1nJaHRB3VjXti8l4ThvNHJyflUlflC9y3H4CkeLLKEG5gCSc/dB+8fx96raFLLdNuOUuGYglW3BR67sAenPBP87ku4wnydpkB28jbuJGecfifauZo55rldisI2ll37vLXOcYznHqT1+lP8vYZWQEy4A3NjIBNDO02VY7m3BcgYXGOgqOaWNIEk34QjLgjkgdeOpoRk3Ybcyy/KED+UScuvKgd8e5AOPU8euMzULwqmVmIEjPFGVGcIoyXJ6DofxA9ar6pNJJKiCVlUJvmdHB2rnIx7AfmfqaytQuCUuJ5PKikjAUoGIESAjag6YP3mJPYAZ6CrRlJ2J5b/8A0+CFY4FSImVUXljtCk8E8/f3dDk9aq2MMt4ZZo0EqpJ5MYUMrEgsWYZGcrlcceoqot4t3eTSM6K+7CKxwQmc8H36YHfFdJZXMBFvDbrAtrFtKlyGBwSfTqOST/Fu7EcWkZOQ+1017d5YrdMEQsoCLnczSuScnrnIHf7xHpW3aaahK8eaxgComcGMbTnLAYzk9AD1qob6Kz3XEUrAou15NoJUsPmyP4iRjgADnms+68WRwKsildysVwjBShwTk9881aJ1eiOpClXG3aVaMZUN0crx065AGR7Z7VUlSN0downkhQ+4SA7iM9vwPAwP5V53f+L3eBUSVipVkcjGQDjGMDJ+v1rOuvEt/dSDzy4jyP3aLjIXOO3yjBPP9ea1SfYORo7bUXhK3CghAAduMfL7EYI4I6HnBrIu9XjRomWOcs8auwt0DKDj9DjBI965s3U84EYDBdxYIxI5PU5x1P1yPzxat4blVYG6uY/myBGCoPvVKDK5Ued3tmdQgVkRiASc4yM8k474re+FzwaHql1FqSKo1CLy7eSQEKJAeVZxkqpB5YAnOD2zWVBDrCzP5V1bqzHcAw27z6jgjdWnbW2qpIwOZAwzJEHQ5A54GDg59uvWuhVHB6M85wU90fUng/xLY+JmheO5K+IdKGXh+3MrXACuBG+XHOFLFWBGQGPHNeVeMIYP7R8oadZ6ZH5flTWkRDRRStI7nLKAu4hgcrjaeO1c1o1/fS2k2nS6nOIbhSr2k6bS6nrk9S2ec56Zx1IrTs4WtMxQDzreYbSjZ3cZ/i/ibv8AN1H5VlXre0sgoYf2criJdXFjKVmU4t18tiGyJEPRs9mGPzOBnOAy5gthcrjPlzEMMHCsCRwV7HOM/X2q4FxNbyAb1KbfmbllBGU9hgn8/amm1iZWspwoCMVKNwpU8ZPbI6YHFcz3OxIoXWlwwXB+zDYsjfvIk4H+8B1Deh/Oq9nLJaQtDOubMAK7FT9zoCSMjGR3x3HpWlBGUSIXUpHzbAxOSCOnPsOoPWlvI3trlpJziFgd7EcAEMA5HQDJ5I9efWpKRniJbYTRAf6PgEIV4Q5zgeo5OCO2R6VcSATgGUoYHGAerhsenqCVwff2NRRR+UJYyBE8GVEeMkBeevQ4HI+h74q1aIrsViCNy0m5WOScEsp9evGOo496BkgikiRyZFKSE45GCepwc8Entj09cVoyQSs6XtuD9oRcMpH3043A9hgYPHWqQn2SSFuA4IdeMHocZz0IO72wOOtWLeQzwhBlXi2jB+8o5xntxk+o9aBmhp0ySq7RKSABKigY+YAgoR06D8av221cNGy5CsfmIBYduTzkcD6Cs2RiHMoG2UndwAMhh95QevBJx14PPFX0mJgVmDKyphTGMgdc/UAn9ce9IC8AJYY0QKGb5gueN1WpXxIrYXYU+8pxyQDz9CB07H1NUgBDNvXa0e/zEH5+nY8j8fanCfzLSKNAVzkgDgx8dD7HFJ7WKTNiLzZI9oG6RAVK7Qd6njI/MURZFyxHOMNwOSeBtP4VCjAES7cqTuKueAe4JqceXuyDuZiQhAwSex/L9aloa0GMyNduBHtIG8ewzjH61NA+PLidUHmIFAHqxIbvgdP1PtTAAbjcHDMyBTn2zn9KIrcRSbl4Xc4P8RwTgYx36VJondFsFmnZJNyhlC9DjrwfxOSfwqa1ufMkikBwXBL7uQCTz9OlQj5gWIJ2qzKTyMYGR14NMYP9mlEsSx7gZZFyME+gP1ovYXKmWoQkVuISgjNweSvBAHPPvnJBHtWddzSGMlVJ2YWaKXHblenUnjGKswXkLRgrMX53D5ucjqCP89vasbUW8repiZjncQMfL7j35OKvc1o07yMiHUWtisaSRrBbbsRgYdVY7iVB+g/DnntqC6uFtDPp6OoC7CwTer8jBIPRuTweBxnB6Z+2BfIMMDyLEQU8v5Qc9j+mMcZqVN3mAxyglRtdymGb2x03YA6+n0xrHQ9CVOL6FpJ459tkXSWST5RxuCBc9Prg8HFaFo0Gnx2xlbKNLslUux8xRk5J9cnv/KqVjElvAyR3IeQgHKoSqsT0ZQMDitC+u5IbRAsispwXRRl2OfvZA46cDJ9PStI/zM5qvvPlhsQahaQFZjPGrTIwlJJUlUAO0Kcbs5x04449qognuVLSCVkBTy2ULuU/7uTg+3Yc96sKxvoIRmKOMACUzhQ20E/KPfBP496t2unZXfbxSSFXwd8u0sB13Yz3H6YqJtPYSl7NWbMiy00x3DKT+8KBWji+8oOOGxk85z+FWL77K1nNJBArJkqzRYZk6decnJ+g5Oea12hbMkixSmJmx5cfyqR0ye55z6Z9u9WEeY8jOsJYkYWOTaFQAALnr7/Un8MvUl1nJ8xzkcyi5j+zvLMVc7D5KlI2BGQc9Mc/N1z1yamErvJKzsXDEs0wkOZB3Ck88huRwPr2l1PT4UIFnFFGEbcYjIwEoI53dxnrxz26ViXUgeOYSxeTp2VLBFG/Zk446e2Dk4JqovWx0WVTU05iZ5P3U0sqtJltsbHYpDDZ6nucdODnJ4pNTWSXMfmCHK/MQM7F67ecc5xgnjqQCQKp6ebcXEa3EphljAeJAxBlyOAxPKoc5yeenXpQk7NDI3nrcebg4Vdqx/3y3ZR657DrwM6sLWZRZjY36RgrsYFCqqWLHsoHbqcnnHXkCttZnaKISJvfAK+Ud2Qffp0xk/hWG0bNq9pIroTHgbAdz8g7gT0GOM556YzzW3uLW4AYSHGGGBy358/0rmqaE1pXtciSVvOZpUOFPC9Rjt9DnFY+r6h+8dpR+4iLbFyQWIOMZz+NS6jcP8pkwQyhkx6+30rkZvOvSiqwjijbaMcgE/1Peszlle9x2oauqR43FlGCdo4YgEDPGcdT+I965W7uNV1JY0ii2W6tuXO47+n3s8k9R+NdfZaUnmgMqMsYyDtxljz27/Wta306KORHYN/eLADAPP598/hWiqKOyMnByPO7bQ9Xn8w/bHQseW25wD1/EZ/WopdL1633xx3jvtXBVMDI/D8/evX7a2jaMlvP8t4i6pkMDgfewPx98elWYtKtL+2kmeJUQ/IwOF4UAbs+n1AxW0azfRGfJFHiccl6QqXmo6hGwAHK+YhyevBH59eMVqRaQ08Qe21OKZsgBnjyMZ6kbh1549q9F1HwxbyLuVUJI3Oq9ACeDjJ4PHXHJI6DJ5m98L/Yy0mCiBS37s4A4OMHuPcfhWyqLsUop6JmfJpmoRT/AOjQ6dJgfKsiMpyPU/r6cdazVfUIJw+qQxrC7FTLAPlOe2Dzitu1upoFhiu1LeXyDnJbpgj/AOvVvYJFuI7by5LWQhgCMndnH8+1bKaY3TI4LaBYw8ZlZnxgrAehz0IPfHU46cUwWsgUee9wjnnYvl/KOwILZB9R2rnNbhutOMz6ZczKgcCS33EDJHDKOnbHtXMDxHLEzp9pulYN8wD45/CtYxvsctWsqW504j/5Zy7ZllJKtnJOMEZX17cjmuhsvIXypEUxLxwRnBPXaT9KwrKSOED/AEmKWMYIjPHfOA3VcGt/T5IbgsElhYEYeKQ7Wx6g9Px5FccjNI07i3kkhY7VuCGBCsoBA9VOauwRGSONrV98TYeNud6OCPz5Hf3qrCXUZhZkkhG1kHHHUMnoP0q+U/f+ZGrCGRd0ix8EOOSfYdefXHrWZokSXMaXMMMvlLvOfMjzgZHDce+c1G0STxo0Ep8xAAj7eQwJ4I/z0qe2ZZXu4nyzSYbj++BhiB2B649fpStbvKNykRziX924J2uSuQG+vP5c1Ja0RWCrKgEyqHcESR8kb16MM/eB/WmJCu0W0y42YZCzH/V+gb2Ofz/Ka7VfMIQSRzbC5jcd+hII4564xwe5ps0qTxnzU2XCfvYjj5RkgdMc+n4VJS1M1rR7R1lUMsWQV3DlCOu0nn8OvUdKsx2O0N5QUDbyg/hY9NueO5K/UipLkAxKqIGDHaEBwQc42nvn07HnPWm+eHjLO7bVAzlDlvm/n29QDSGI4S5k/etiVWGc9Hyevtz39iD2pGtWjb94DHJEXBPBIUAdvYY4HBzxyDm0bYyzoY3jVmADF8Ybt16Dtn+mKkhcyFo5iqXKHH8RYkNwc/1pgPtLo3EB8kQmPyxlUGBIM57cH268Y9KtJMkKxlS8iOo2A5wOOmQeOnykfQ+tZ0UY86ONBtTDAYGSuewPUemP0yTUttKwj2nc7RErtHAx1C47gggfhRcDV88gq2wlW3Hf2b2P1GD7ZqxBI2x0DDDLvVsYDDuM+uf0NULVori3Vch4nUDcAdpYckkjoeufxxzzSQTqjnJEfPIY8AZyfqO+RStcVzoFcS2ySDcQeCADhTzzj34qSO4yyLvBSQcoOqvjJ+ncfjWTDOzxRJEG4dhkLj5eTk+o6YqzaO8j+ZI29Wyy552Hj07c8VLLsaNlOViaQoJDgFlPB4HQfyq7sBeCI/KdpLEnjkZFULZNjGNwPlJlYbux7g1bjYICisDyFywyQMUmUh/A2jdIQC2W7f7JB9ePy+tT3KKYo95Z2I2ggdaiti3lRbwAr5Az0z2471ZLqCp8sFFwxUHHI4yBjpz+lSVzW2M+K28p2VBGJACd2B/e7/X+WKhmSJgAAypnIB+U59OOOK0WAMjb2C8BjuA578/hVOaNo8JtJOfmBII55yMdsGqRvTndmObeN59pLCVE2k7gAqn7oHHXH86ei+XEikzy5iGfMOSy+5GOfT0xRKknnRljGYsBFIXB5YY5GeBShy7Nz5ahtrKGALf7WR+A9/xraNrHdq0WYnkSREMbM+7na4bJ9VA5B9ePfipLpJLxFt1C25YhjIQWIPuucA+5/LiqkPBtyLfCDe6sfkVgR0PqAcc4BHX6zGRoSzoHd5TvWFWyqjI4HOQD3zxz07Va0MGrvzE8yW1jhYQwlQhZj/EwPHL9SCfT0wMVuWjgOyzm1CR/Kiw5YDHG4kZCqMAY4x9BzmI1tcwyw3EkciLzkQFtq4wctnr3zxz+FQeY2lSx4jnkjDqkcJO0rkfeAHJbA9uKGuphUhz7aM6YAPFFIsDOFAYBQTgnoCD044H19Kg+xptMhxFG53Lsj5UjIwq/w89/cDPOKljkjm3tK6MqAooR9xUnkDaM7ieDzxjmixk2W4kkfa0zsVDDc5ORghe3THrjqQOTLh3OLmlFNoyNSidFiyzKoffjYrvKQORtAPzEj+fIrmodHUtAcrDHK82fnIdFCjac5HtyTgbjjuD6DcW8YYhEkDdWXAGFPT5mHU5BORwc8nrWckcgwzh7jOCUjBxLyRubd3wf5+tFktzeliHy6HLG1tLbfCZ+ZT5cUwUbwF/iUjs3P1z71WIa6aFG8mYIX807iEZxtAHbOMDPAwcdMc9Hq0TmWOdmV1V9mWbKr7Fjyx+nHHOelUDA0ETI0qWySnzCyofMbJ6knt6EjPfHNTKVjpVRNXvqZESLGIYCyF42AXauDJ0OfUMcE8Y7fWnX++3hdvLEatuiSI8sBjIOc9e5P9KtytFYxi3tisYOSwDZcfLjJ9TgfhjsOmRq0gkWQ7lK4OAp4OOCxHUnJ5xWLdzOUmzDv52mmdV5JywQD5cZ/p15otLJUZSCuzIAbgbmxycev+FTRxKWkVFxkLjA3HH+etatjbFZGjbiOTCylTncCeO2ePXrUPUm19SpDFstzuYKVBBaPlTnPfvn1pFYJHiMAAcAbuh7AECr8vlLMgRiwC/fbhfqAcBRjHFVLvILnYY1Ucbepz3A60JFO2xBBcbXQgIhVcEHoDzng8E8k81s2csTXCySbWVBhkTg56k+47888+lcnqt6liN0qM7P/qo1jzvPcBsYGOevpxmoWvpkEnmTNEg+9tXmPJGNh4y3br044raELmbp32PRGuITjbIGlDHzBuypUDkjJJ555HcnpjgmhhkBESkgsCZMcgDAX8uOvGP189TV76eWJLWMOsJ3vkhmXODtLADAXOAw5YnnNbVlrCO0a7EeWUbJF3BV3c5xxnbjueprXlsRKk4q4ax4diAcQgqynGM8DjJ575zx61y1zbz2OI5CA2CQnOOTnv27iu7+3RzskaFjGoyQ3DZ7HPp3rOvzZXS7WO/cnBXK5zzkkdACWPXv+NXFsmNVx3OI1WVJvOES4ygzluSAcgHHHfB461yEmkWF9I0s7PDIDtIQdfc+/wDhXZ67YpZR+ZCx8lDnkYA56+55Az3wTjiuOSbAZ5UY+YzOrbT8wyf6gj8K7KcmjHERhVRq6NKsc3lJLNAHOVYvkEE4HB4PPHY9K7KzjeSCIzwRSGPIcrySBwW5/oaxJba2u594IjlLYLJg4PQOR0Oe9a2l7kdYJdgkyQqk4R/dW6Y9PY5IrkkzKKNNYVh2zBd8JHL9CoPBUgfXrV5gYIo5Y9xCOu0ocggkDr36022EkaAeUxB5GVz+ftUtsn7yK3QDaSJRluFVTkj656DocH0rJmhLcIbaWK5iXgjL7CBu9cfhWmsCSyyvEUO9d6Ln5ZOFJI9D3qMRLJBJDKAoUhZEwcRt/fHsT9O9Os5Bal4pAuGYlWU5xxj8uP8AIqR2bGzokgyiEIeCHIyjeucdD6VRa1kMLBoc+SfnjJ+dQT1UjgjGDitO6tpJXgliAI5LbztBBBG4fQ4pqMAo8zbBcRkGN2PysP7p/Lp2oLSsZMlvG9w0LB1EzEF5B3wOCMZz79/ccU2OB4fmkOX2cnklh0OfY/pWjIN6p5kLrCWOzDZ8s9cL3xnsaJ2UW6tJtZhlty549SR7Uh2ZTjiCWoeO3kPlBi8auWYburA9CuP5d6ZcKJDGZGIj2gxXKHoCeN3+ySME9setWhCQvmwup3DLLj0/un3HtTUkEKysd0fOWCglATxnHVcj9Rii4WGWqrK8lvcRoSQuS3ynOeGB9c9/zxSoWiuW3FgA20DO0sRxx6HPX3z61Yitw8cP7tuOWHYg/wBCKbGshlkimbMpBTzG4D+x/kR0x9c09wImlVQZYhtORuXbleuc+oPOPbmkmmWWKTdjnAB/utzwfQkZpjQtDIACyoULDJ64HT9OPp3pt5uVZoiyOM/OQ3DcZGSOuOlIVkXlk3OqxuiBuVIGBlshh04HbHbIq7bSskioNgk2gLgdTyMH0+tYaTBefLLFucnrgHG4fhkfgKvR3LO0w2MSmCCOQfYkdP8AP4popI6G2kCxRx53BvmI2jIPQZ9sD9KuZL3CSKD93a2f4T0/Hr1rFt7nB34yCdxUjheRjj0q+0uGR0LHgKcdQPQj1B+lIaLUS5RVRXY7gD04x6frVyAeYZGQfe43sfun0rNhIjPk4AcnLE8ZXtn6GrYZEzkLsdPusST16dKSRRNG4kLKGDAgBnzgKMdM/QE/QUwiF5UEYVXBKkg4wO3J4A/wqQNiBvkHz/Ky/wAWT/jwKlRXELuyvuYbBhv0+lPYadtTGlt2QtIQFGSyhCDnp068ZrPmuPLRRtJkwSSEIUjBx9M5IHXofSujdFyqqMFQUwDgemB+VZV5Zp5Rb5Gbrk5TYPb1wM8U4y1O6jVT+IpFS5UoRCz4O9nypHGAwBB7diDUiuwjZWgikgYthUbaFB/ugnPvkjjNQIRAGwq4A3uYsDaOwxg/pj8Kr3kzvaKW+1zQdWaSEjAweRk5bHqT3PFappo2avIk+3TyLIFmSTywvG7ajDceN3TPbqOufStSK7jvv9HmnjjjUHAjJLL2zkZyc8Z9s+9czDKt7E0bzRPAoRUKuAgLDjJ/vAEdff0rV+RoyI/s7SEGNI4pWXJyB824gnt1yPlpxZNWKJILpxcrJbzXM/mMUii/ukpjKgjA49emepretL1HMsk7eT8/Vu2MdT3OR93genrXNaihgnjWVCHYKhO0srMRgqMdOMn37Yq9pk/2G4jkllnXa5Qlxu3gjgA7QBn2x6dcky5JGFampx5kdSJTHCrcFM4LzbVHOedoHI4x6HjGaieLzZWAZ5OhfJKKfqAfQEYz+XSqNpcxz3dzHHIjzYyV2ljkDtu6kA9zgdMZovoY3SUztL5hGGGBJt74OBx+dTKZwqDT7EU0kZeRlDmVRwY0DMuOoGRheozVCS5maORwhVusko/eNnORnoB0HA9OlTEyPD5cKqkuAN2xSg46KpOMA1QuY1JcyqpAXIAXAXpyAMk8nt/TNZORuomff3B85SsoZBHlj824c9z0x2HArK8k3Em5gSFPJcgluOgOK07uORyUZYYypO48BQcHk49amtbVYreMMX3HgDkE/Qc/59ai9ynoUrSBooV3ggAn5+mT6ZHXHGatyqWBDhR5q4IP3mB6g/hUUDIHkiVsqcSbQDjA7Djp1wO/NWJGV9ip5bSZyS/BAPpx1oSJKk8JgSTDpyBghRtA7cdscce1RxWXlwI2GfuoD9QT3PYc5z/kTzCaWUoio+5dm4jgevy0xWiSSVIFm2kqJAWLAFRwCOB2qlZO423ayOa8Qaf5Nzc3EEksiyMRa25diOgGW5JXAJJAIADZ6cHlre6WW0juJAYVP3QHySynj/gIPT1Ir0W9txKrq2dm3YQGwR74H88ivNPE2mLHfRyWUTqjSFPs7NgbVyC5yc7B8oDcZJOM11R9/VApuKsaaPvg3Mx8pT5qjzeI+TyOMFmyR04AJxnFZlzqRsbqJ0ZwIQDJIcJI2f4UUdBkcMfbJ7UyXVgIbeKJYhJFGSiL8+Rn58dR685wDkD7tYkA+3XN1ehXS2iYmO13ljuUYDlsAnBycdK6Iw6s5ate2i6nYDWL66by4tggY7jKzY2ofmO1TyTxn6e1EN9dTgPJKphPzNKN2Mc5x7jAO30YGsHTJ9xKXEqSSsGHlvlVUHJCAY+X5uPc4zUGpeL7aOJ4G+0rM20TBSOykN2wCMleB0/GtYU0+h5s67jub1zdvcRSRXtxLDE5Xcqn+IrnkA/MMcA/TvyOX13V7R9QYBUUIAgEa/KMcdVIBJOSTySSeTWFqviee9LokYjjydhPLgFcEZ9O4HasaBUKn5yOfSt40bGEsW/snsdgYmBiYFXRiynH3h2+nr9K34oI543TavONyEZDe4H+eKxoo/MJkgf95HyOMHJ7e/vW7apHIR8wQEDc3pyMMCffsK8xu56SRds4UC7I3lCEZA8w7gc+p5x7VpQWiAlETCS/M7KuSzY+/wA85/p9KqQruC78CRCD8v4fMPX1xWtECzjeGDAhiEPcdcH36ms7lEkMD4VyQs6g7j18xfelij326xzx/Ly3l55DHqynuCOadKD8pkUhQd4cHIxn2/KrUbbsZBIUkZA5x2z9OmakpEFpM0UOJlbaDh2HRQeDz2GQDUl0pkTY5BU52kjbg/09xUjwsrFyNxPDKOQ//wBc+4qJDmNGblWOG2/MV7cex4/HNDKQxUWOORMlUwC27kIf7wPpzz7VXkWWNypUnI5kxyOp6dj7VaMoXa8gL7T8xA7Y+9imvD5ajb80UvynLHKikUUY4RzJEmCrjgHOT2IOePp+fNP2Df55ZkDjAb7uMdQef0/GpsMoVn+faSd478dx2+tNIBkYAqAF3EScgr/j6UAkJECzlJDsIG0YGBnGDjjuP89zSvYHuI3xJsuAgG8chvb+Wa0F2eQQFfIGVfdkrihnXzCZdsnA+cevT8egoA5/TzdvG0eoEEru2SE4JIxgZ4/L1GKkI8uQERhkRcjJxj16enp/+utR4AcxZZyp3DeevuT6+/sPrVWVD5mMnYfn3K3X2x1NMXUzWmAlWRAVTbllU9M56Z7HimwTMrozEjPrxv8AUH8KssBGwCKHXO0hsMD6+4A9KpOq+WIosmYE/wAPI6f0HWkVsa0cpSYNvky/+s7gMBgZ9iuBntWtb3A3ypvHl5z14z7n+RrlbW5CuSArqo2nIx9D1z7cds1qQXO5ssGA8ssSScAcHjvnnJ+tHKG50VvcqSVIUB1wu5s7TnqfariSLjzDlnOc5bBB9Pb196w7SfznYyHljtYsucDtx9MjNacN5ASqDKSsN4yMrjpnPrT2GjStwshG9cnqdvG3tz6mpEIJ+/naORzzwB17dfxqgJyCrLnYcP0xwOxqdJCGAT5cdWBz1549alsuxdZgIcNgKePmHT3/AK1DKiNGNqlSMKhJz3p5lDKd6ABiBg88+uajkVgQY95HUjdjB9PepuXDcy7myBRCUUbfmJBxjnpkc889jWdeQlGkO5QxUFAWMjKvccjj9cV0cm2WENnA7DuSOvNZl3ZI5SMxLKrPvO48Afxfj/KrWh10ql9zn9RiMzuTtS2TOUclcsW44wdo6jrjnv0qyhjFtE90rxzRoSBMu3zGBwCXHI9c8HjFNmBfUYQx3qMr5pJCE7emOSegx1PHTgAzXML3SGKPbuDDDh3Lg/xZ3Hk84xkfjVX7G85bI6CzmjICyeUfM+6Qu47e5AXnjGeTV/7IrgIVaNMbjIygH1+8x+UEHHGTXOWFs9sIwoWOZGHms+4NK2DwDzxz09u1bVpdPt4lJXlN7xbpBjvk5x9TntRzJ7nn1YtP3WPit4lj8sXLoBgt5KFsAY6nGDjt6jnvUrfKpMEbxY5Rvu88YLDrx3OO4PHSnRPHcS7HDxnGT5hLZGOowfcZGB1OD0qWdQVDWrHg4KKANowcAnB9epOOlKy6HO5tvUx7p32oHhkd3k+aNOw7Hd/FjGTgdugqG7EcRZQw27dxVjzn8Pf0q59mAd9wClCcbVHQdOCfTPGeO2KrGIBtw3JK/UYLY7jnoSPw9eSKyaZqpIyWcEKW8tcgAKBwg7dwP8/WoJJXV32upY8Y64H1Gc/UD2q/OFLbl3ZIwUxuCn1J7evHSqt1Gq5llQEHJDdQPwqLFXKiSkovzZwdwAbIPTnPf8elLbwN5jM52seWOMA+wH581PJGm0KpBjQ8DBp7uMICdikYxtyCe3HvTE32EZUDheZA/AAGGb2yf/r/AENRfZmjjdjJMSG3RpncnuSSM7ugHbqe1WIVjlfq+1iRvU4OQMnOeh/xqSaBpIkOdiAjDIdxGDg5+npjnrVpE36GXdgyQloyXfcFJC4AHfB71zWuaf58cy3M0oaVWi3OwBjBIOAMdio5rqrp9qhsnk4GBwB9OpzWJqEbTow2lt2SMjgemK1puzG1dHlmnTSR315byQhLpFwoI3hFTkIGBIGODjnqc9MVBaMj2fkhPLMeUMaELgk5I/EHgY49K7TVLWUJJLYqpvhEYoo0TeZnd1A/AfU1w/hwS3d/qcd6pRvs++RHyBvRtgT/AGSMnGcAHGTxXclzK5wVNHZkOrXTJpCAPIJWkZHVlGQTzk98++Bk59K5nYOBiutuLSW7sZYxKDPKu4wyAj7oym3rliO/HX0PHJA8A12Ubcp4+ITjOzGGIHrgVLbwLsP1pDipoQdpxgDNaGB7HAisGIG1uST3HvWtYhkChsfu+cHpz29qyNOZkBH30yQD3H+yf8a24FDPkAB8YJPI9q8Vn0CNKMojRurN5TAqpY8ofT/PrWkrKpCPhABuT+9Hjpn1HIHvVKAea0eQdrHDFeQ3196vRqm7CEyL1Lg/MP8AaHoRUMZdtzJ5OAGYKCWjHGfcelPiLCRGiYAHheOo9DVe3O3btfac4R0HX29/p2qxlpGTdGAW6gYCt7j0NSykSI2SJUIVSCropAwf9nPQVXlCRTA84Y7lYAk89V+nvVr77PlCx9cnK/XFRvE5bypHLfxKrc8d8Gky00Qyf65gzZJJDMpGVz0bHoaJVBYo2C+MhcY+uMipGhwyLuf5Pub+oHp+VMKEfvYsvGTltwzuP9KWwx0MbJIqCThSCPcUACOQIT8mw/xA9+OvAxUUjMEyw356Z4INL/rFMbhZGHQdCBTQxCip5mA4Zm+becg9Op/wo+zhGf5hsc4UK2VzTQjiVGiZSy5BznB4wOtKqYPltJj5d3Pr9PzoAi8veWyRvjGGUdGHvVaZIi+3Lrgggj+H/OBz/hV7aqhVDGNSd23b09GHvmobjC5LIcucOB156Y/GgCjPEDnbhQQVKhcsexz9ayrghZCGZmbIUFVIIIHXOeD2xWu8RCkhGcH0GTkf/WqjKjm7OzcUYZVtxBUnv+famhPQx3kEZJZS0edo2nBx1xz3yBz7fhVqGQf8tSEL/MrYBDZznnnv/nIp06NLIQx+ZQQ2TwvYjGPWqU22MM0fynBBwT1xgg+2AaYjbtboRD5tyBjjBYfMM9z0OMda0ra4cyFXb5flD88DI4+g9/WuTWZo0aVRIWOQcYIB56D09KjvNRlVhFIXx93ZGOOny/MOf896VrmsFzOx3ySLJJGUwCp5AHX/AGavwygkOYzhCQSrcL+NchpupvHvjkUmRQOAwxkk9SDz06mt2C4RkG8A7OOBjbnqBUtNFyTjob9vKka4LYYj+M5JpskyshAGWHCnPesyO6UFNpGSxy5/iB9T3qeG4JGUBTaQPmOcfSkiUy/EPlIlUA/xICMZ/wA4pbtBMPKOeMHgcf5FV4n5zlzlvlHXuKuQyho8GQZJyT1Of6Uy+azujJ+wbfkjRpZMfKoxhWA6nP489eetTRRyRRLveMTRpgyEBmZjx07DB46/WrrOH6H5uT8qZ2d85z149KjXyyGERVJCRkOAc46dOvB9OOaEnYp1W9yZ9piCwhoYmGMKQWb/AL4GOajlgSaMxOhQ5B3yNgkDBwwxnjAOPf06AumbIDIu3H8JZunBAzzzxjOeahknViTAZA6sACq/Ko79SOT7jtT0MuZospM8duFdF8sxrnyy6oO2ck85yOeowc9amkg8mMxRneinKg8bs4JbryOR069PWs1ZWTLB5HjI/wCWjKj56np/EAM8dBzxVt51VGKsZWdifl6A45Izyc5PQHODzzTM5b6CXD+TbGaGFhGEB2qCx6DIPGOpx7Y54zVM7zEwkLbycgRqQMY6/N1Azjsc+taQuG2EkrhAgVYlzhuMAA9evHcelR+SojcyMwjbPy4JOO+FIH47jkY6DpS5QUrbmZJawJLIPLIkDYILAgkAfNn/AOt+FU443aZMrEIcAAofY5AyOMY/HNbcoOGO7YMrvwMDnuOxB6/QcZGKpz7dyurkdsMwwPRiR05yPepcbFxncpgNt8sbUDDIBkHO09P1/HNZt2pffEu8YPJYcZ/+t/Stfyy7tJKzsvYHOByRyT36fn270NQiuHYPGuVQhnJTlQD0x37evIzUmkdWNsExEqO7BTkc8hjzk/hwfxq5cKFUec2xwMfdPy/4nr0zSWzjzSyxlZNo2AHleeATnjnJx1B9qfLFG7BEchSSSMAbSAM9eCOSM88n6VUV2F1M25Uyj5vMBTBw33fwPWqOoKsabQ+I8cHqAT1Hvn1rUDLGCGliQjBG75flPQEZOD/9btzVWZEkQEh9rHgNkZPbBI44qrWLtc5qeFUlEmGUK4GF4PB7e9cx4o8Pzfav7Q0sQp5gMdyHfBdWwM4zjjnpjrn6d1c2vmcKQGDY4OO46npVO9gxbKQvyMecgjJ/ka6KU2mYVaakjzTUYGtBEiJMswiUqqSk+XtJ6Me+F6HgZBz2rjr6NI72ZI8sm4sueoB5wfUivSvE8bMFCHMgYsAAAT1x6Ywf0rgtfiZL4nzA7YVGcH7zAEfd4I6V6GHlfQ8XHQ5WjKIFTQn5T9aiPTB4/GpoBlDn1roPPPaLZGD/ALzDBvl6c59MVr2caxpsJUDAKyAZx+FZ9uVLHcC3Jz/j/ntWlbjY0TAAJu3Kw5wfevDPoTWVAEBYZAwA68df5H+Yq3AoDbZCu/PyuPl3Hp+tVYNyxkySEpncSv8ACf8ACr0SHzQhUOcZbIwV9CPXtSYAwKnzgpGSNwX+Y7e1WQ0RQFkDKxy0incPYj69KjWUMm5WcNj5kYZCe1DIuV8sxgMu7CnkcdP/AK1SxokQbJCcK6np8/YjpmnM2XwVCxqM4Y4x+NV3kV0w+0SA5Vl6H8O1OWRo4mY4kQnOQd3Pf8qCiUSOzMjNtj3DD9xnpg96h83y4nbmTa3zAnBx9KSMg8BsDByh4Bz3FPV1Ows23A5z/FSKQbginGH5ztHJ/AGmT4li3xIzqoA47euf8Ke8f7r5Mbo+FYng9PxpoYxxBkOM8A56eoNMskZ1YjlmQLgDHUYpo8sFDIMheQSc0JIgYKh2kD7p5z7UKVyZACoPJDLxj0FIQ4OI+RnLHbk4IYf0phTdGoccMcBlOajlxFmUjK5+Ynt7VG25WJXacc4zj60AQNwc/KQfvYPOScDiop48kYIXgKUI6/jViSTG0OxIA257/jUZSMsoJPl4++p6eppkvUoSo7MXYh8YHzHGcdh7+9UfJS4jUEKwOeW+cj6+/GK2HjVxztZWXC/w9O1RT2yOxOVjUjvkfXmmI5yeBokQhmKyR7juJGD6A9Pw/lVV2XK7gCDwpII/E+lbpto5C/mgHnjA7etUru22fu4nYoW+UMuePWmtBrQoxhwxmtZDAw5wwyAPTnr2rYsNRkwiSRrvJYhgx+6fUEcHr7VkzRbGMiF+Bgso59/pTN7rlXIEYI3fLk/h2zj3p2uae1ezOytr2J40RSVI6DH61ciu9qjcSecDAyCfWuHkvZ4wbiFUlCt8yRMAykjsuee3H5c8VatNT3KrPIyj7pV0IK+2DRyMnnWx3C34CvtdlZcgkdjU63mF5IDSAHaMDdj1NcnDfMpiVGDuvVguGjOcEdckDI9M9KsrcqqEFAS4LbV5wPUjtQ4gpI6ZbhJACp5HTdHgnvVo3KRocI4T+JQ2NrHuPzz+Ncwb4KQwYADoqkZOPfv+nWp2vPkK4Ei8EMjqQM56nqcc0uVibubjXXmxOvmM6KPmU5YDtyB9TwaiaV8xLJJnYeCvPBPXklT9PTisZp3kOQcbu5AA6YyefSpI23qREyDI3KFIOQO5wePxpW7hzWNNWiiYJ5akMcB9pGM9uvHQcfj7VZt5j50BLExqdqqpwg4IzkHA49c9axTcKpXZ8oOGwi5b8T6dPzpDeApvLFlHybznHXgD+nqOaVh3ubvnxEOUWBUTLKodVJXuAw78Yxjnr7h5ufngQqrqD8uwhQpPUgEc55xnHPfkVhpcMMhVDs6/KG5PTr+nfnjNXILghN4eWNOC3I445JAxnLY59hRsTY1Ic7cgsVJ/vfxt0JGeWx3yfX1qG5jWdF3zErnPlyKfm5wRhSDwfX2qK1uJFDlUd2UchBt28jd2Oc89D1GcVYa5i86OKPy3lQ7hh8qpHcdjgEevt2Adk1dk3aBbaIwrH5ZLRjYrbCFIPG0Dpzntzz14wa1zakCOKMdFCDZnHsR2z/MkirCXSzSFSqkYBJkUueM7l4PbnGTwD05qNo2OXdRt3bVBjJdsDp/eGc5CgZ55xxhcqaLjKz1KuBBIq7Nmzlo2AO4dscZJ64z/AIUjKFz5+0MzEKcjIOOmfz57YOeM1bCFHaFNgSGNVbf92LdlgBj7zHPyhckHcAB1qosonkkkkjYDd5fy4VdozkhegwN3cjkZySRT5LFqaZVdB5zSoY5IwzeXn5mZR16jIUrn+eQadeJ+6aP5jcDkFlXhe+TnjHTj2IzmrqiN5C6qEtm9SGk4zjcc8ntjrxwc4xBOiMwbygoZd0IZwfw+nHr09aqxXPfQyrxY4TBBJ5i+cx27VLDPYE+p6cevtWDqykyb1RjuzhhyAc9Rntk9+/FdRqEaY2zYDLh0kCheD/F+f8PXgGuZvpRc3EsccgQs4Xy2+UYyCMn1LHp2wDx0ppMmUrnK+JyIUYrJk4KqNvBJ6tnpxx05zx0zXnfidxJNaHI3rEytgkD77YAB6cEf/XrvdfmaONy0TsImZcsc53eg7YwOeh5yPXzvxAQdQYh1ZSoZTuDEhuzHuR055GMV6GFXU8bHSvYzMc1JD9049aiJGalg+4eD1rrPOPcbQsAQCc9xj/P1rWtAGOIyoPULjge9ZMEexjsbKqSQcevatW3ZXw/AI6YrwmfRGlasqlynEncdj7kVbh2ZUjczAEg+mO/qPTHvVOJsujklWzjoOR3xV4gSLu3Ajrgj9eO9GgiaKcBDIVK85ZOcH6etNLqrh1jOGGPlAx7cGiJWZD5p3K3zKV74/UGporYqwUszSnJGDnj3NSykV5SNzMjkAglS444HP61Awz8oDDIzkcE/T1rQjAY9UDKCArcfXrVZ7YFSpePLjqewHepKRXC7XUwOCQPmX1/Dv+FSwybid7bWxhsdvfHf0qPycSssqF2wCXPHA78U5oTmQoeARuKnkU7lE6P5g4xv4J28Z9/r7Zpcs28EJlWHynI/H3qtE/OSquMFCynp/Pmpt8ki7t2ZEOORyKQDmkYSjA2qeAzdSKVnAAbBAb769AD60hkVncbyCDu/3TS9SyyYKEbtw9aBjXKORgsx6kD+I1Gylgh5JB289VX39RT2BUO65AztJ9fpTZGMhPHXHAPJppgRyFXZfLYjJGc9B71CEUviRQFz8uD96rEyBiHZAiEkFhjgjtTJQFjJTeNwG5c8g+n0p3YloRjqCPvYKkZzio5t0hiKngdQP6e9TL5kfMYfj5cYzx7f41Hw0hzgkNhiDww9qBXKLrwVRRgnAGMEc9ailidgzI+Cp6gj8vxrW8vLCOQseSNvQe1DWwYD5NpJ4btkdqaEY/2VXVTI8oXac7Nv5kd+e4qnJpylflJxuyArD88/4/jmumWMAKpJz1IGB9Fzmqk8Su5EgYuPuggsMe7VakT1MSKwZEmEYiLKdx/egYBHIBY8kD+719+lI8XkxkiaOT5lJCc5HPOWUjHtwD0961J0DgMpjWT7gd+G4+p/pVQDlvM8p1PG3+E/l3quYVilKEacbFODwx3Bfm9RtAIHoOx9qlS5gQYS53Rk7TlM847g+vQHkjrUzKqMAsjgjnYR8vbjv/L86rSxjILsS2DwVwPpxwfyFNMLFpbt4oUbOwNwwTcSf9ok8k9RU0V2ApDvul2FS2dpA56ALk8VmFlhbMqqq9DyAPpyP1oikcYYKHwTgZ3HPtg09Auasd0p4kYYKHh8E4PfP4dOtQC4T/WEGNuoYlcD17Dt71WWZVJOFY7flHoT/L60qSxGNgAEz90Bunqf/r0WQmy4l0AXVgGkzkbHCkY79eBUk90wSME/Kedj4G36/wB76/15rP8ANwgGC3UKRwc92GO9VjcHdvVYmB+XIP0+nNPlRPO0bq3aNbhG2qQcuecfX6VftrlA2wjB6uqn5MDtj07ZHP8AXlUuDtG1uQ2QrD5lb1A54/HuKcdWIiRrh3VFzkuRuBGPY+nPU0eyuCqHXxS7jvch485IDZOBz69OnTFT21wTIm0ISG4JQsM9uuSe/B7VyttqSuAS25eQu1CBu9T6H+lXZLzIZJI9rjOSQS+O2eufy/lWbptFqaOmW6j2bsCXptB4A9/TOeCMcj1qZZEmKM8m8spAJkbdJtP3TuOM9eR+BGMVzcN3jy8SqidcA53MfVcjP19+1WTNHI/73cXB3Nlid+BgAg+gx69Ki1jRWZfnyXRiJGBJPmEMFXOcD5COeCABt/h5qWG7V5pFhjDgx+WgnfO5VXHToCQTz0HoazDfxK0bpISxyS0bHcq85GOwPPB49fSqjXsgdInf6h8BUX6cADnr27DtVDumdA9w8TqA4nd8kMFK8dSSen0755zUDXCXL7Nz7sFn3scqBjgk9sdu/c96xoLsNMjqfnYbgFGCoHrn/PerKTxJbLGGEQXOPmJXd3Ppkf4/iWBySHaxKDCyKgEZXOVXIJIwOPyyT9a5qcNbebksZ3b5wWyRxwc9jknjtirlxdtIWKMoTGDlcKDwPl9+/P8AhXP6reOs6xRIsjuwUxoeVZTk5PYY5NaRjd2RnKrZHPazcJDHKDJGPLPmO46ggEjbxgZ4AyeOB2rzq7uHuriSeUku7EnJ/StXXtUW6X7NGwlQOJHlYcluenYcH0rEJx0r06MOSJ4eIqc8gGalhHynnvURP0qWH7p6da0MD3a0KnOBhj144atCFQApUnge3WsqIncS5G3PI9a1bYsCnzDJAJJHQ14bPoS/azBH2MTvzyMcD1rQt3HmABgCehIAzzWYi+crKuAy5Gw8cZ6+9WoAokjUtnjIOO/qfSpGjUikP3JQuCSVKDBBH9KkUMqKEw+MHcT+XHXPbrUUSgyMc7sYYEDp69+fpV0QscO23B65+XPpxSY9BFAkAMg+dlGA3TH19aiuIkEoXy2VR1GNwHHT6VMwRFLB2AB2jcuMdR0/rRmaHCMRKM4Ubuh7ipauMz54DhTGFxkFXLEc+n0qIAq5XaqlcthhyR0OD+Fa5O5mUQndnDIRnH5VTmjDklA+1W4PB+bjIPqKWw0yoyKjHbuAJ+YYP+NLEYlc7myu772c44qdcxuHUbkHEi56e9Dxg58ojBzhV/i9xRcdyIqHkDEEy5wGK9vekjQrhMMF3fKrHrTo5fLiBEZIH8OfmNSMhaIGMEjqv+NO47kZVNpwFC55ye5qEptcFwFbof8AZ9OasBMx/I0ZI455A+tKqEqrGP7p45z9f8mgL2K6xAqUKkt6E9cd6coKFSV5K4JPercSkLtkxgHHA5+lRyxhSTuzkYyaZJF5SmMDI4IAJbFIIFZQUVOMnk8E1Ose4EkNtxtHYVIY1jb0AGMk5A+lMbKUsaiHazoofAG4nk9xjHNPIKqAFIJByPQ+xqy8JSM42EkZOOc/nURQr+8+YoOHQ9qYirJHhOhwOeOTmmP5siFWUDcMgFsYHrVplOwhCFU8+gx71DIN8RGVLPgLjk49qYihNCyAtknoCQMkj0/+vUEsIZGZCqgHGD932wfX8K0mQwqdxxGOMZ5/CqAjZWO0kAj+EZH4jHJpoT1KpicbgQyt3cdR7VXYSNGpYBh0Ycjd9DWg2UBC5OB/rBxj2IqKdWD7gNvQHg8n2qhGe6Foh5SqVGQ3y449/Wq8gKthhxj7ytj8qvPvckooUrwVbjIqtKqz4wueeccMPbHWqQtjNkuoIzhplVv4cAuQAeen/wBeh760VwUkZkI7bW/oDUradbb2wrsWOcZI5/TFLBawRqy2yAK2TtC4LN9DxVqxTcbCxXVpIVUl1JHygq3A9cZwKeJomB2Hd6EoMkH+X4UkcZC4IHljjOeD7YprvkfexIvO3A5psybGyQJJGAp3Lt2jcxG32HqO9VJogqlRL5e1gQAcHj16DnnjmrpmjzkghGGA49ffjj6Gq8ksRQb8OehRBnIH+farjdEMpyyp8jeVgg7wyLgE9z93n86ZBrgW7fz0VV52gjJPoPQdzzjrwQaZfzQRorM0ahuOf5Yx07f0qqbO8ntjOLJ47UHBkbKL+A6n8q6aac9LHPUkoa3N+318BV3NuUZGGHU49D3wf/19avNfKGUnneo2K5U8Z457ZGfeucj0S3dcyGbe5zuTCgjHT1xVm20YQktFK+DkFUJ6dvxGeDW7y9y12OdZgo+ZsxXxKiISmXc5LkN0PPGB6ccenWm+cGiYSSkKjBnXHUHtntz3rKs7CWGERxzySKowVzgtycDPUcntVa6bUIYXEVqGXBJJkJII6Y6Hd82c9MZ5zgVnLLprYtZjBnSxXgRupLf3efu//r/maiuNQKu0bMBFjeVyOSOPm9OfTrmuQfUJWsBOkMbyhRgHOMrtx+grlLrxLqhclAlrkEYRMnH1bPv+dQ8G47lfXovY77VteSCMNJMkS7N4MhJ3jj7o6nOGH4da8+1nXnvC8VkZ0tyoBeVsyMMYYHHAB64FY0kjyuXmdnc8ZY5wPQelNPH06VrCkobHLVxEqgmfpTSMDrS9/pR9RWhgNqaDlT9aiPfNTQfcP1oGe424wu5jgbsc9frWlEjbfLYNsPIOeVHvWZASWJUrjtjr9K1LRiUKjy+MYweAK8Nn0JoICSu/JA6O3atK1Yb2WUbT1BYZJ+tZ6DhSzDA5yTxWhEpKoGDbn+UkcgjtipYFiIFAzRZ2k8r0BPqKswuoffks/PB/hA74qOE4G0DdHjAz2PSrDxbY8YGMDcOeOO3vUN2HdFh9zOd6NJhcYBHH/wBY5qBflV1iEfl/x5Izx09+aq7Qsm7gOOVfdnj0A7VaBkmbIjXfkYx0I+vY07oom2rwZVkST0J6e/FMkJB+bkngOrcDPT/69SK7KCQ8hUDGCOufbtTEQnKREM/Vo2OD74A4qdwRWcRqPMTI6JuI6++f0qNGZH3ElNp+6Oh9T9auGM4O05O3JBHT6VVaEPzk7DwxPYjpQkMhlAcO0XG0g5bqKYpXzFcNlT028YHcU6RSN33TMvVd2cikuISjAxLkEbyvrSKHAgyBQxO8cHHH0p0QKkkknIJJFQRSZUbFCupwAx+YH2q35kRIcFVByufT/wCvmmiWKyblIw4JGFOeAKXyl+YMDwOh7e9RbgM7wTu+VlPb/ap29JAcktxtAz1p2EWURVgO8MyqcKTxge9RrGiR4DgqxyOetGUCb0YhM4xnoacrZKljvB56c5ppCuJMyiPKgYPdjycelRu0bZZTznLLnmluCRhSSQTyM/rUDEqu1OSeVyOPzppBcdjLDaA2D8uCMH61XYRqjdevysTj64/GnIBmRPlJX+EcAE96il2uuVO/BxhSAQR2ApiuNkZeBIrYPAx/Oo3I3dlxywOeabPKhU7FQqeAMkFT61UlmUIVkHy42ZfnB9RTSuLmQS7TKCc49DjLflVYTRiYglMt1DdR+NRyy70UMVJx8v19apT3ETjL54PPHIPvWkYkuRcZ18uMlcOD9/qCP8+tVpiHl+VQDjqx4NUJrpF43rtxnO7mqUmpxqTt2k9DuatYwbIlM05HcY2hR6gdKjE7E/K+A3LknqPy5qrp1rqGtuyafaJJgZLSnansO5612WkfDa6vZI31LUXiiXG5bdAv4bmIwc8cDp710Qws57I55YmnHdnH3M0e9mLDjOfRvfHrVMXYmPl2yee4IJWJTJj6Y57Y6HrXuHhj4WeGzCGvLX7YwPD3Ds549OQMfhXYvp2n6fGlvptnb2isAu2FQi7RyOB7muqGCu7M5pY7+VHzjp/hzxFqEkYh0823nfMGumCkcZyRyfz5rXt/AEy65aWusahuSYkMlsgX7v8AtcnkZ7CvUbfbLr99HGS4hARiPuhuvB71n60sp12xfT9rzI+07/u8jkZ9a7oYKnG1zkqYypNb2K2neDNH0mNjb2kJmHWR13tj0yc1nazZpIhR1O0kjGOp+ld00EjW/wC8Ta+3kZzj8axrjSftCvKZFiiU4LNyc/7NdkIRgtDklKUt2eWWmkuJ54EkjV4hvVHO0uM9jU0+nXVqf30LwuAHwO6/hVvxj4cvEmj1HSb17mSE5e3cY3J6D3qayvZpbdWjmcBxhoyfzB9xQ0iWYTJtnDDCkjA96uOgYOZY+cDlR1q5dwQ3Fu2+L96BnenBA7cVFpchZWiZPNbpmmogcZe2R0+9baimCXqAOQazdX8P/wBqQKybUZcgYrvdd0hriEvCu2RTuHPWsbT48Jh1KE87SeazdNPRlczWx5FqGmXOnSlbhCADgMBwaqYyOxFe13dhHdRkSKrDH3W561nx+F7JgIRCqrLweK5pYV9DRVLnkRx+FNIrS8QaY+k6nNavkqDlG9RWdk46VyNNOzNUNPJ69Klh5U/WoT7VNATsODxmkUe4RcucHqeOOlaESEryTkcHJ6D2rJtim4gkE5PTrWnbMigI3JHOfWvCaPoUakDEbNzMCpwSw+974rTtWKDAB2AZxnr9P8KybbIIBIK43HfzzWlbsHOD8w6tgcZ9qTQWNJfukghx6Z6GlgckLtclMk477qghyHCom4suD6EDofY1OQSy4+Ve2PWpKWiJZEC7QdmVON3rnuaVW8vaqE7RnLldpNOCsGUgKrgZwRnI9DS/vJQrEAqcll9fpRYWpIkuf3cikAf8tB0I/wAaY6sZMtIViAxGAPu/U0zcoRlByBxtbuKdGyuAjgcdIyO31zSZSXUc+WYF4wqqSMAnp3OaWUD7vyleo56Uh8yLAjj8xD1XPqKbIGCZEZYN1GOQP60tSkMdRLgAqSpOG6E1Acs2XPU/Lz29B7VLKPmLwMCeAQRx+NQybdvCBZAT05oBjLiOPIkC4JGTioJFCudzMGXk8c/QVNkhgGQbC33j2FNnVAwyGD9R7mgQiOTKQvJJy2egqwCQwRELZ4zjge9VV5Z8c89Ov502UkIqNyvXI7fWmS9S5E4R2Dktzxg7efpSM2Bt2uAfl3s2OaqGcB83ByOgdcnHoMUNP8gQC4Ut8qg8j3qiS2jMJGQEgDjJGefUU25bYGILKF7kcE1T8z98kUjbhngA9Md80x5MbDJIGXJ3Kx6U7ASAZLKMseoYd6iecK7Fo8EDBAOKrPdNEyBRmMnAAbmqbu4WTL8k5L5zx6CrUWJk9zO4YomMn5gcZx7EVlyXbsHJKnLZINR3VzvUtJtYDgMaybu8SNcqST/CcjkevvWkY30IbLdzfIoztZWTsRwT9azjdy3V0sFtFNPcOCwhjUs5x3x6e9Y95qnmzpCpV2P8RUZFej/BjWY7DWLmxuliWS7GYpTwxPdfTn0612YegpzUZO1zlrVXCLkit4d8A6hrFp9u1CYWtgBuaK3wXUDruzx+VYPiKxsrWTZo6x+Sj7C+NzP7ljXtOox/8Is8qX1xjS7iNzDJtJMTH+Fvx7V4Da6g89/eJM2JZSzqSu3PORgdh7fWveWEo04+7r5nj/WKlR+8z134OQ7fDs1wyoxMpG4D5gAOleiSMd6woPnkGOOlc78PNPGneE7KEZV3HmyfjzXS6WhubppWB2KxVcH8zSSSA6CwRILcIP4U7/zrBupl893z3znsK1pZWjtpgOH27QT35rEkQkseAW7diKUFq2DKpmIu7iT5WcbQpA6DHbHHWstf+Q9ZoTjLlgT6454q/GyCa5ijA83cG2jjtVYRbvElowQZVXJ5zz7VvYxbublw4CFR19qy9QX9zDED8oXLY7kmtOc5JwACRg1VvYyki5B5QYBHtVIW5yd/AdnGBz1rj5VNpeyM2Njn5gO/ocdq9IvLXcm7HSuS13S/tMUhQASgcGm7MRjkEN82GB7qaq2ibb2TaACPm3DjioLW4YL5TZ8yI4bPGR6Vez/pcUwzsYYYDtSEXHiEhdQSFHHNYMNqDqs6AYOzOM11KlJthZMHuQO1ZWpweTfLKMITlMnpihjKMcSrKAF+9wR1IqxcQqkMTgbSDjirsOnz+RC0EUkzOfnckKP1pb+AbI0A+YnoOaGhJnmvxD0sXmntdRjMsHzcDkr3ryvnOa9+1GAGN0blWBU5FeJ6/p7adqMsRUqh+ZM9wa4MTDXmR0UpdDNJ9qmt/uHr1qA9qlg+6frXIbHtVuWCh2AIA4x1rTt3BVQpwO/+FZNs7rtYt8pPJJ/zxWlEuHyDgdevWvDZ70Ua9oQmGIzg4GPXtWhA+8hmOCozkHv9Ky4GHmK24qcdOv1q/E6rl/lDLyuO3vUlmgspAO1SHGOCOMev1qygUoSgOCvJznB9qoeaSqg4JJ7HrUsWcsAXQfwHHapGWYmIcjLhm6sf5VaUgN8rAEHAz0qokwYHrubsPX1FOyWCrKRgcHPUf40XGWZTyq7cNkgjHb2qLhWVCAHYcM2ee2KVZ8o0TDfEh+8x5H1Panq7yZiaTBHzZYdj0NKw7gF2v+6YpkYAPIJqKaaaOVWQDKkKUB4/+tmhxINow7IPflfXHtTI5VEh3gu3K7cfe980ikySaRlfHl+UT1UNkL9TULOzOSxBbGDgc4qUN5Z5XMYH3R6+lVvncHy+VJxv6H6UMNxN4bYSwHouOn1qTJfDDPC/X8qjYbypCqpB+YKeo9aIyBgsfnGce/pQtQYSKwQNtHynk98+ozUSKQ7BThmPAPerbB5ACSx9j2/Cq1xFIzN8oI7HPOParRmMJ+8APLYLgEd/rTXlERbGd4UBRnj3xUMsgRt+dvGCPWq0z7jkPkngK3f6U7CZYnkOxY1Uea/ynnt7YrPmniUsVYBsgGOQdaGmOwhdhB4JBK4qtdXEiJt8/cm3hS2f51okTcSeVipYRRhunD/+O9P0qnPdli2QiEDC+WeBjrioLm68uXcZCpI4G7JB9Qc1g398JQ6IN38PyngHtWsY3M5SLGpX6FGEZbJ5ORkZrnZmdlKkkoOQcYxVhYXlZYxhnzjGelOnRolK5JwMNW2kFZGWsmUrWEy6iqjGVBIPvXSRK4iWVG8llwysGxtYd/rWRoMAlmdur57+ldAbWW4a3tIIy8txMsSIOM5Pr/WkuZzSQ5W5XfY9avfFFnf/AAqjvvEVldyeanlu0Q+aF/urP7pnHNeH+HLP+1PE1o0cUiRhtv7zgvz1P517f4ojWy8LXlra28tnaW4WAQynOOm4A9x/9evLPgx5uoeIdRvJyHht5jHFz1wOg/Svppvkik+p4atJtnvUEgihCQgbhiNAOnSuh0uIRWbAEAqM8Vzfh2MzSvJIoKW/3d3989q6lcRwbO+PmxWT2AuRPEZXhlACyoFB64btWFeQtazvHLjI6N2Yeo9u1Wr6UM5YMF5yDn2qpdySNbE4EjheMdWFOEdRNmUH8vVHcINssQTPqRTYQD4lRsjCxNyOxJxVXVp1j+x3EByqyjdj+LPFWbNc+IJgchBGq5HHOf8A9Vb+pk9DWbcQcgEZ6jvUmoKWe2kzwyY/KiZtiEmPkc9e3rTSwe1Lli2D19vUUra3EUrlMDavQ1ialAwcjygTjGc9K3ifMQsDhAevrVeeMvEVO3JHOfSqWgWvqeTeJLMQXv2iPAVuGPYe9VEkLxLuHC8MR6+td5rVgJQYmHytnAx0rgoMwTy20+QUJALfp+lDQjf06YvEkq85+UgHjinaxEfJ8xCuN3XHOfWs7RpBFLJATtXOQev5VrXsm63wO4I2+vvTESQ2r3Nsxk1HZOSCm9Mqo78CqurKEkRI3DYPDgYBHrVu3VU0+3W3VgqqC288u1Vrg7rsbgGypBHpRIFsYs8e8FXPzMMg+ted/EjTCdPS6UZeFsE+xr0+6tgAfmBQjgHt9K5fxlayXOgXiOOfL3AeuKyqQ5lY0i9Tw8+9SwZ2nkdaizxmpIQNp+teSdSPbLbk7y3Tg55+mKtw4C7XUgdM1VVlV2BAycjpzVuAjaNjAhs4PUfjXhM95GlERIFUfeHTb3FWkdgUOflB424J+prPXOQeF9sd+9WkBjKqG5OO+c0iy/GU4dcq2DyTk/h/9erAn2qN+1lAC4zzVAyB+QuC3yjsMg+uamjlBkG7kj+HtUlI0FmVVUxjexOBk9RUsjO6hnAB64A7jqKpqwSQhNpGNrccCnpON0at1Ofn6/8A6qBEySLJkSDpzz1//UKsxnedsTHPJG4Zx7H8KpSKrN+8Oxs5Vh0+pp7OQ3Jw3Yj+RpDNDcrxEMAGI5BOB19c1VltmACoN6HkD09RSLKpDbwAONwx/KmtkvmLOV6Z7UxrQj3FDtQncexHegOrYJYIM7gfU1I+1yQcLxknHAqCRTGQM71JwCOGA9KllXJPn6sCCOh7GjfldpCluoPQf/rpVZgzlTyPl4HAHekb5uuPc564ppCuOwxxyMKOTnoaheTIGFKMOppzSKibsEj7oGfSqc8hJIKMjfw88kehqjNsdOyyKcGLD8k5rNniIUlTuOOMdqlnmYsQ8SHnPGciqk11kN5SlU/iXOMVcRMhuPPUhpCVU8ff61mXM82GEWFkIwG28L+dWLq6GCBnOMkgc1j3s7S7lD4boVI6VrFGbbKdxO8oczMz7vQ4ziqYgLOvHI9OgqdY2aQ7cEdyeg/GrCRiKMFXY45LHkfhWt7IztcjjhNvFhcb5OjH+nvWdeEttTJy5wPatO5bhyOmcjtis+yhM8zyNzn5QDU3uWlY19FtfKDkkk4xnHUV0WkPZ2E/22+R5JoHQwqrlQOeWP061nW8awwAdCeMCrJyYyWOC+BwKqjU5Jqdrk1I88XE7/4m3Zt9BBbP2G4aOaGckvvUjkk9Bya5D4a2Mem2k0sa4Ds8544yQAP6VkeIPFr6X4Y/sLVmaTSZW3xvtLtGw5CD/Z6V1Pw8tw8Wm25LFZR5xz1K5yM+nbivofbxrxUkeLOk6baZ61okH2LSrZZDjcN7/wC0auGUuBlWLkEj2FU7mVRdRWyZ5Tc1TxNiAn5S44GfStDMjmk5wATk8H6VFIxDKFIJ9uKGJDcjOAOnHWmqp3lguWyFGaogyNStRJr2jwRKVidpJnUDghatwkf25Lgje0SkDvjNSyPnxI8AAP2ezGW/3m/+tXO63erpXi7QbkkrBOZrZ/QfJuXr75rVe8zN6HbTMPs3PJ285rFkmEcaohIDDaAvQ81Yt70XcLbVwDkVl3RAjdTnMeG4qoxtoS2alu+ImB+aoJZQW5IIA554ogYfY/MJ+XrgdR9aqpF5zsS3ynquOtDQ72IrxGm+csgbGFGetcD4rsjDeQ3QBAI8tzXpM1vH910UZ4yD0rn/ABJpf2ixZc7XOWU+hpXA4iE+XNDLggAY5H8PrWldv+4bk4Bzj0JqqsYa0t42QB1JGOxqzfACznjAzkbs+mKBGrpwY2kRIHTioJxi+BPHy5wO9aunzslnBgKGEY6LzUF1KbnUHaUKXEeN2KYWsZjRncHZScDIFZWrwLLBLGTuRht+mc1tzx942DA8YFZt2g5IBz02jkVLQ1ofNV3EYLmaNhgpIykemDRAQFI960fF8C23ibUYkxtEpIA6c1mwgbT06+lePNWk0di1R7e6quMADDHFTx/eC/w+lFFeEz3UaEChlO7n6mrcQ42/wjoPSiikzQvwopCKRww5HrT4VUxOpHC8D2ooqARZWNDH93sDUTAeeoxwwwR60UUFEkahECKPlLEEHnjFT28amAIQdp7ZNFFIBjsVOATjrTbkAKCOp60UUIZNbIs1rmUbiZCpye1MUZEinON2MZoopoCIEx3WxCQu7GM1GwClcd896KKaExT/AK5B2YZI9az5FGR15znmiimStylKMSIBkDB71TnRcRnHJ680UVpEmW5l3f3QOcFwD9M1RnQK2VGDk85oorRGTJIlCeUi5CtESwz1Oae4y6g9AOlFFDGjI1IAKSM/McnnrWrYRoBCoUAbRwKKKXQpGw6jYhxz0qTy1wvHeiiktwOK+Jyj7JYjHHmD+le1/DeNS6ttGRbKAfT5qKK9fBnm4rc7OQlteYk5KxYFaqqDGQRwUyaKK9JHAyBQPIJxzmpbQZwD9aKKsRQsgG13XZGGXDQpn225x+tcp8SIkKaNIV+dLwhT6ZGDRRW1P4kYVPhOwtIkjtUCKAAO1Ys6K166kcHHFFFMkuXKiKW2EY2iVSzgfxEVa8tMp8vXBNFFKRaEnRS4BHfNZmoopLDHHPFFFSBwLgLfyIPurJwPSrLRq0WCoIEZooqkI3dPjRYIwFGNg/lVWYAXbkDnbRRR1BkskEW1BsGGODXPwsz3F4rElVlKr7CiipBnhvxHiT/hL7z5eu0n8hXOxRrtPHf1ooryqvxs64bH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After making lemonade during an outdoor excursion trip, this 38-year-old female presented with erythematous linear and angulated patches and crusts on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34182=[""].join("\n");
var outline_f33_24_34182=null;
var title_f33_24_34183="Perindopril and indapamide: Drug information";
var content_f33_24_34183=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Perindopril and indapamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/49/39701?source=see_link\">",
"    see \"Perindopril and indapamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5176506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Coversyl&reg; Plus;",
"     </li>",
"     <li>",
"      Coversyl&reg; Plus HD;",
"     </li>",
"     <li>",
"      Coversyl&reg; Plus LD",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5176509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide-Related",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5181169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note: Coversyl&reg; Plus and Coversyl&reg; Plus HD are not indicated for initial treatment of hypertension. Titration of individual components to an appropriate clinical response is required prior to converting to an equivalent dose of Coversyl&reg; Plus or Coversyl&reg; Plus HD.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypertension: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: Perindopril 2 mg/indapamide 0.625 mg once daily; may increase as necessary to perindopril 4 mg/indapamide 1.25 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose: Perindopril 2-8 mg/indapamide 0.625-2.5 mg once daily.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5181170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Dosage adjustments may be necessary; however, specific recommendations are not provided in the approved labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5181171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: No specific dosing guidelines for the combination product are provided with the approved labeling; use lower doses with caution due to perindopril component. Dosing of perindopril 8 mg/indapamide 2.5 mg is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5181172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosing recommendations are provided with the approved labeling. Use is contraindicated in patients with severe hepatic impairment or hepatic encephalopathy.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Coversyl&reg; Plus: Perindopril erbumine 4 mg and indapamide 1.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Coversyl&reg; Plus HD: Perindopril erbumine 8 mg and indapamide 2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Coversyl&reg; Plus LD: Perindopril erbumine 2 mg and indapamide 0.625 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11236684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5181174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer early in the day to avoid nocturia. Food may decrease the bioavailability of perindoprilat (active metabolite of perindopril). Administer prior to a meal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5176510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Coversyl&reg; Plus LD may be used as initial treatment; Coversyl&reg; Plus and Coversyl&reg; Plus HD are not indicated for initial treatment of hypertension.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5180972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Observed with perindopril/indapamide; also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (2% to 7%), hyperkalemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (2%), vomiting (2%), dyspepsia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: BUN increased (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (3% to 5%), upper respiratory infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to significant or life-threatening): Agranulocytosis, angina, angioedema, arrhythmias, colitis, creatinine increased, CVA, dermatitis, depression, ECG abnormal, edema, eosinophilic pneumonia, epidermal necrolysis, epistaxis, erythema multiforme, erythroderma purpura, fever, flushing, gout, hemoglobin decreased, hepatitis, hyperbilirubinemia, hyper-/hypotension, hypersensitivity, hyponatremia, impotence, interstitial nephritis, metabolic alkalosis, neutropenia, oliguria, optic neuritis, orthostatic hypotension, palpitation, pancreatitis, photosensitivity, pruritus, rash, renal impairment, respiratory insufficiency, rhabdomyolysis, Stevens-Johnson syndrome, syncope, tachycardia, tetany, thrombocytopenia, tinnitus, torsade de pointes, transaminases increased, uric acid increased, ventricular arrhythmia, visual disturbance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5176514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to perindopril, indapamide, any other component of the formulation, or sulfonamide-derived drugs; hereditary/idiopathic angioedema or history of angioedema related to previous treatment with an ACE inhibitor; hypokalemia; severe hepatic impairment; hepatic encephalopathy; second and third trimesters of pregnancy; breast-feeding; concomitant therapy with non-antiarrhythmic agents causing torsade de pointes; severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute);",
"     <b>",
"      Note:",
"     </b>",
"     Coversyl&reg; Plus HD is also contraindicated in moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5180939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose), angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs. Consider discontinuing therapy if symptoms of hepatic dysfunction (eg, fever, malaise, muscle pain, rash) present within the first weeks to months of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Severe reactions (eg, Stevens-Johnson syndrome, erythema multiforme) rarely have been observed with indapamide use in postmarketing studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Indapamide may cause hypokalemia, hypochloremic alkalosis, and hyponatremia. Measure potassium levels during the first week of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement if needed may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use perindopril with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity. Indapamide can cause systemic lupus erythematosus (SLE) exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use indapamide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: Hyperuricemia has been observed with indapamide use. In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by indapamide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use is not recommended in patients with heart failure due to lack of evidence supporting safety and efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with prior hepatic dysfunction. Prior to initiation of therapy obtain baseline transaminase and bilirubin levels. In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy. Contraindicated in patients with severe hepatic impairment or hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with indapamide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use perindopril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in  pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Patients with renal impairment may be at increased risk for hematologic toxicity. Use of Coversyl&reg; Plus HD is contraindicated with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute. Use of Coversyl&reg; Plus and Coversyl&reg; Plus LD are contraindicated with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angiotensin receptor blockers: Concurrent use of angiotensin receptor blockers may increase the risk of clinically-significant adverse events (eg, renal dysfunction, hyperkalemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Indapamide may prolong QT interval. Concurrent use with other non-antiarrhythmic drugs known to prolong QT interval and possibly induce torsade de pointes is contraindicated. Use caution in patients at risk for QT prolongation, including patients with pre-existing QT interval prolongation; patients taking antiarrhythmic medications or other medications that lead to QT prolongation or other potassium-wasting medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [Canadian Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Use is not recommended during the first trimester and is contraindicated during the second and third trimesters.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Formulation contains lactose; avoid use in patients with Lapp lactose deficiency, glucose-galactose malabsorption, or hereditary problems of galactose intolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5181159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5181162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Bioavailability of perindoprilat (active metabolite of perindopril) is reduced ~35% by food.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5176511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [Canadian Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Use is contraindicated during the second and third trimesters of pregnancy. Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12765766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in breast-feeding women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5181173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take without food.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5181176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; BUN, serum creatinine, uric acid (as appropriate), glucose (as appropriate), and electrolytes; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acertil Plus (HK, KP, TW);",
"     </li>",
"     <li>",
"      Bioprexum Plus (ID);",
"     </li>",
"     <li>",
"      Biprel (CL);",
"     </li>",
"     <li>",
"      BiPreterax (AR, BB, BM, BS, BZ, CO, CR, DE, DO, FR, GT, GY, HN, IE, JM, NI, NL, PA, PE, PH, PK, PR, SR, SV, TT, VE);",
"     </li>",
"     <li>",
"      Coversum Combi (DE);",
"     </li>",
"     <li>",
"      Coversyl Comp (DK, FI, SE);",
"     </li>",
"     <li>",
"      Coversyl Plus (AU, BE, BR, GB, IN, MY, PH, SG, TH, UY);",
"     </li>",
"     <li>",
"      Coversyl Plus LD (AU);",
"     </li>",
"     <li>",
"      Noliprel (BG, CZ, EE, PL, RU);",
"     </li>",
"     <li>",
"      Perindo Combi (AU);",
"     </li>",
"     <li>",
"      Predonium (HK, NZ);",
"     </li>",
"     <li>",
"      Predonium DS (NZ);",
"     </li>",
"     <li>",
"      Prestarium (EE);",
"     </li>",
"     <li>",
"      Preterax (AR, AT, BB, BM, BS, BZ, CH, CO, CR, DO, FR, GR, GT, GY, HN, IT, JM, MX, NI, NL, PA, PE, PH, PK, PR, PY, SG, SR, SV, TR, TT, TW, VE);",
"     </li>",
"     <li>",
"      Preterax Forte (CH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5181199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5181165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34183/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lapostolle F, Borron SW, Bekka R, et al, &ldquo;Lingual Angioedema After Perindopril Use,&rdquo;",
"      <i>",
"       Am J Cardio",
"      </i>",
"      , 1998, 81(4): 523.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34183/abstract-text/9485152/pubmed\" id=\"9485152\" target=\"_blank\">",
"        9485152",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34183/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mourad JJ, Waeber B, Zannad F, et al, \"Comparison of Different Therapeutic Strategies in Hypertension: A Low-Dose Combination of Perindopril/Indapamide Versus a Sequential Monotherapy or a Stepped-Care Approach,\"",
"      <i>",
"       J Hypertens",
"      </i>",
"      , 2004, 22(12):2379-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34183/abstract-text/15614033/pubmed\" id=\"15614033\" target=\"_blank\">",
"        15614033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myers MG, Asmar R, Leenen FH, et al, &ldquo;Fixed Low-Dose Combination Therapy in Hypertension &minus; A Dose Response Study of Perindopril and Indapamide,&rdquo;",
"      <i>",
"       J Hypertens",
"      </i>",
"      , 2000, 18(3):317-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34183/abstract-text/10726719/pubmed\" id=\"10726719\" target=\"_blank\">",
"        10726719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34183/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9449 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34183=[""].join("\n");
var outline_f33_24_34183=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5176506\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5176509\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181169\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181170\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181171\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181172\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076335\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11236684\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181174\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5176510\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5180972\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5176514\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5180939\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299855\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181159\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181162\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5176511\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12765766\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181173\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181176\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539800\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181199\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5181165\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9449\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9449|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/49/39701?source=related_link\">",
"      Perindopril and indapamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_24_34184="Ultrasonography of pregnancy of unknown location";
var content_f33_24_34184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ultrasonography of pregnancy of unknown location",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/24/34184/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/24/34184/contributors\">",
"     Tejas S Mehta, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/24/34184/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/24/34184/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/24/34184/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/24/34184/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/24/34184/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/24/34184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic pain or vaginal bleeding during the first trimester of pregnancy is a common presentation to clinicians in the office or emergency department. Determining the location of the pregnancy is the first priority in the evaluation of these women, with the exception of hemodynamic stability. Whether the pregnancy is intrauterine or ectopic (and the precise extrauterine location) guides the remainder of the evaluation and management. Early diagnosis of ectopic pregnancy is important to avoid adverse sequelae of this potentially life-threatening condition. Pelvic ultrasonography is the most useful imaging modality for these patients.",
"   </p>",
"   <p>",
"    Sonography of women with pregnancy of unknown location will be reviewed here. General principles of the diagnosis and management of ectopic pregnancy and of obstetric ultrasound are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36824?source=see_link\">",
"     \"Ultrasound examination in obstetrics and gynecology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ULTRASOUND VERSUS OTHER IMAGING MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography (US) is the",
"    <span class=\"nowrap\">",
"     pelvic/abdominal",
"    </span>",
"    imaging modality of choice for pregnant women. It does not require the use of potentially harmful ionizing radiation, is readily available, and allows real-time imaging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnetic resonance imaging is useful if US is not able to elucidate the location of a pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/1\">",
"     1",
"    </a>",
"    ]. Examples of this include differentiating an intrauterine pregnancy (IUP) from a cervical or interstitial pregnancy or elucidating the anatomic relationships of an abdominal pregnancy.",
"   </p>",
"   <p>",
"    Computed tomography generally has no role in the evaluation of pregnancy of unknown location, due both to its limited resolution of tissue planes and use of radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ULTRASOUND TECHNIQUE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transabdominal versus transvaginal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transvaginal ultrasound (TVUS) is the principle approach used for sonographic evaluation of pregnancy of unknown location. TVUS allows for earlier and more reliable detection of an intrauterine or ectopic pregnancy (abdominal pregnancies are an exception) and for more reliable detection of a fetal heartbeat compared with transabdominal ultrasound (TAUS) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56290 \" href=\"mobipreview.htm?8/55/9087\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65128 \" href=\"mobipreview.htm?34/26/35233\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/2\">",
"     2",
"    </a>",
"    ]. For the remainder of this review, the term US refers to TVUS if not otherwise specified.",
"   </p>",
"   <p>",
"    TAUS is useful as an initial study since it allows for a larger field of view than transvaginal scanning. We start with a TAUS to get a general overview of the pelvic anatomy and also scan the upper abdomen. A low frequency transducer (typically 2 to 5 MHz) is used, which allows penetration through the anterior soft tissues. Imaging of the upper abdomen is used primarily to check for free fluid.",
"   </p>",
"   <p>",
"    The next step is a TVUS, performed with a higher frequency transducer (typically 5 to 12 MHz). Since the area of interest is closer to the probe, less penetration is needed.",
"   </p>",
"   <p>",
"    Principles of ultrasound transducers and probes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36824?source=see_link&amp;anchor=H6#H6\">",
"     \"Ultrasound examination in obstetrics and gynecology\", section on 'Transducers and probes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Doppler ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler color flow ultrasound is of limited value in the diagnosis of ectopic pregnancy. Trophoblastic tissue has high velocity systolic flow and low impedance diastolic flow, characteristics that are highlighted with Doppler. However, the absence of a finding of color flow Doppler in a complex adnexal mass does not exclude an ectopic pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, color flow Doppler does not differentiate a tubal pregnancy from a corpus luteum, since a \"ring of fire\" appearance can be seen for either entity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68980 \" href=\"mobipreview.htm?1/49/1811\">",
"     image 3",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H21\">",
"     'Fallopian tubes'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The primary contribution of Doppler in women with pregnancy of unknown location is that it occasionally identifies an adnexal mass that was not detected on grey scale US (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57420 \" href=\"mobipreview.htm?5/48/5890\">",
"     image 4",
"    </a>",
"    ). In addition, Doppler ultrasound may aid in determining placental patterns of blood flow at ectopic sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Three-dimensional ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional US is typically not needed for diagnosis of ectopic pregnancy. However, it may be useful if the precise location of a pregnancy is unclear, such as in interstitial pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ABSENCE OF FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a pregnant patient with pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding has an US, particularly a TAUS, that has no findings (ie, no IUP, adnexal mass, or echogenic fluid), the differential diagnosis is normal early IUP, nonviable IUP, or ectopic pregnancy. Approximately 15 to 26 percent of women with ectopic pregnancy will have a \"normal\" initial US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a hemodynamically stable patient, an US with no findings should be repeated when the human chorionic gonadotropin (hCG) reaches the discriminatory zone for endometrial findings or in three to four days, since the gestational sac of an IUP grows approximately 1 mm per day and is visible on US when it reaches 3 mm or greater. In 11 to 16 percent of cases with an indeterminate initial scan, ectopic pregnancy is evident on follow-up US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     hCG discriminatory zone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of pregnancy is made by measuring the serum or urine hCG. The hCG is often positive before US can detect a pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44808?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of early pregnancy\", section on 'Detection of hCG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discriminatory zone for hCG is the serum level above which a gestational sac should be visualized by ultrasound examination if an IUP is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/10\">",
"     10",
"    </a>",
"    ]. At most institutions, the hCG discriminatory zone for TVUS is 1500 to 2000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    (this is using the second standard international units; the discriminatory zone was lower with the first standard international units) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/14\">",
"     14",
"    </a>",
"    ]. The level is higher (6500",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    with TAUS. This is a general threshold and may vary across women and with multiple gestation. In one study, there was a 95 percent probability of visualizing a yolk sac with a serum hCG of 7832",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    or higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, if an IUP is not seen at this level and the patient is stable and has a desired pregnancy, hCG testing and US should be repeated within 48 hours. Since factors such as the margin of error of hCG measurement, multiple gestation, or recent pregnancy may elevate the hCG, and the quality of US is variable, there is no established maximum hCG at which a patient with no IUP on US should be treated for ectopic pregnancy without further evaluation. As an example, in a retrospective series of 51 women with an hCG greater than 2000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    and no IUP on US, 15 were treated for ectopic pregnancy and 35 were managed expectantly. Of those who were managed expectantly, all had an IUP at follow-up US (viable IUP: 16; spontaneous abortion: 19) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical pattern of hCG concentration in early pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\", section on 'HCG below the discriminatory zone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EARLY ENDOMETRIAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the first three to five weeks of pregnancy (conceptus phase), the endometrium has a \"trilaminar\" appearance. The first sonographic finding of either a normal or abnormal pregnancy is an endometrial fluid collection. As a pregnancy progresses, a yolk sac and embryo should eventually be visualized, which confirm the location of the pregnancy (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Endometrial findings diagnostic of intrauterine pregnancy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Sonographic measurement of endometrial thickness has also been studied as a diagnostic test for ectopic pregnancy, but most investigators have not found it to be clinically useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many women develop pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding during early gestation, thus, it is important to identify characteristics of endometrial fluid collections associated with either IUP or ectopic pregnancy. Depending upon patient symptoms and hemodynamic status, management decisions often must be based upon this early information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intrauterine pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings consistent with a gestational sac are suggestive, but not diagnostic, of an IUP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gestational sac",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gestational sac of an early pregnancy is distinguished from other intrauterine fluid collections (including an endometrial pseudosac) by the presence of the intradecidual sign and the double decidual sign. The presence of a gestational sac without a yolk sac",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    embryo at specific sac size thresholds is diagnostic of a missed abortion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77246 \" href=\"mobipreview.htm?20/50/21281\">",
"     image 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=see_link&amp;anchor=H33#H33\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intradecidual sign &mdash; The intradecidual sign is the earliest US finding associated with an IUP. On TVUS, this sign can be seen at approximately 4.5 weeks of gestation, when the hCG is equal or greater than 1500",
"      <span class=\"nowrap\">",
"       IU/L,",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      when the mean sac diameter (ie, the average measurement of the sac obtained in three planes) is 3 mm or greater [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intradecidual sign is a small round fluid collection surrounded by an echogenic rim (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52770 \" href=\"mobipreview.htm?10/2/10278\">",
"     image 6",
"    </a>",
"    ). It is eccentrically located within the endometrial cavity and should deviate the endometrial lining. This structure and its echogenic rim represent the chorionic cavity, implanting chorionic villi, and associated decidual tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=see_link&amp;anchor=H9#H9\">",
"     \"Prenatal assessment of gestational age\", section on 'Gestational sac'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detection of the intradecidual sign in a woman with first trimester bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain is only partially reassuring, since its sensitivity for detecting an IUP is 48 to 68 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Further evaluation is needed to ensure an IUP and appropriate growth of the pregnancy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Double decidual sac sign &mdash; The double decidual sign is visible at 4 to 6 weeks of gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/21\">",
"       21",
"      </a>",
"      ] until up to 9 weeks of gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/22\">",
"       22",
"      </a>",
"      ]. It is most helpful prior to 6 to 6.5 weeks of gestation, as an embryo is typically seen after that time. It consists of two concentric echogenic rings of tissue surrounding an intrauterine gestational sac (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56970 \" href=\"mobipreview.htm?17/28/17859\">",
"       image 7",
"      </a>",
"      ). This sign is mostly useful for identifying an IUP using TAUS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/22\">",
"       22",
"      </a>",
"      ]. When the double decidual sac sign is seen on TAUS, a yolk sac can typically already be seen using TVUS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ectopic pregnancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pseudosac",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pseudosac can be seen in up to 20 percent of women with an ectopic pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/23\">",
"     23",
"    </a>",
"    ]. A pseudosac is a small fluid collection that is centrally located within the endometrial cavity and is surrounded by a thick decidual reaction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69791 \" href=\"mobipreview.htm?14/46/15073\">",
"     image 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/24\">",
"     24",
"    </a>",
"    ]. Differentiation factors between a pseudosac and the intradecidual signs are that a pseudosac:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      does not have an echogenic rim",
"     </li>",
"     <li>",
"      tends to be located in the middle of the uterine cavity rather than embedded in the decidua",
"     </li>",
"     <li>",
"      can change in shape during the scan",
"     </li>",
"     <li>",
"      may appear to be complex since it contains blood",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonspecific findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Decidual cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decidual cysts are small cysts within the endometrium that can be seen in either intrauterine or ectopic pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/25\">",
"     25",
"    </a>",
"    ]. Factors that differentiate these cysts from a gestational sac include that decidual cysts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64175 \" href=\"mobipreview.htm?15/26/15777\">",
"     image 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      tend to have a thinner wall",
"     </li>",
"     <li>",
"      do not abut the endometrial canal",
"     </li>",
"     <li>",
"      are generally located in the peripheral endometrium at the myometrial junction",
"     </li>",
"     <li>",
"      can be multiple",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ENDOMETRIAL FINDINGS DIAGNOSTIC OF INTRAUTERINE PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Yolk sac",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a yolk sac within the gestational sac is diagnostic of an IUP, but does not confirm viability. On TVUS, the yolk sac is typically seen by approximately 5.5 weeks of gestation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when the mean gestational sac diameter is &ge;8 mm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65128 \" href=\"mobipreview.htm?34/26/35233\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/27\">",
"     27",
"    </a>",
"    ]. If a yolk sac is not seen, a clinician should suspect that the pregnancy is abnormal, and possibly ectopic. However, the gestational age and sac diameter thresholds are not absolute. If the patient is clinically stable and the pregnancy is desired, definitive treatment should not be given until a follow-up ultrasound is performed.",
"   </p>",
"   <p>",
"    The yolk sac is a round fluid structure seen within the gestational sac [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/28\">",
"     28",
"    </a>",
"    ]. On TVUS, a yolk sac should always be visible before the embryo is visible. Thus, when a yolk sac is not seen and an embryo is identified, an abnormal intrauterine pregnancy is present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=see_link&amp;anchor=H33#H33\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Embryo",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an embryo also confirms an IUP. An embryo is typically seen at approximately 6 to 6.5 weeks of gestation. A commonly used discriminatory criterion for visualization of an embryo on TVUS is a mean gestational sac diameter of 18 mm.",
"   </p>",
"   <p>",
"    Cardiac activity confirms viability of a pregnancy. It is generally detected by the time the embryonic crown-rump length is 4 mm in size; if the crown-rump length is greater than 5 mm in size, without cardiac activity, it is a non-viable pregnancy.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=see_link&amp;anchor=H33#H33\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADNEXAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An extraovarian adnexal mass, seen in 89 to 100 percent of women with ectopic pregnancy, is the most common US finding in tubal pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/11,26,29\">",
"     11,26,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ovaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a woman with a pregnancy of unknown location, US of the ovaries is performed to differentiate the normal corpus luteum of pregnancy from a tubal or ovarian pregnancy. This distinction is simple when the corpus luteum has a thin, almost imperceptible wall and is clearly located within the ovary. However, when the corpus luteum is hemorrhagic with a thick wall or is exophytic, it can mimic the appearance of an ectopic pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In challenging cases, the degree of echogenicity of an adnexal mass may help distinguish the tubal ring of an ectopic pregnancy from a corpus luteum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72660 \" href=\"mobipreview.htm?38/63/39926\">",
"     image 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/31\">",
"     31",
"    </a>",
"    ]. The corpus luteum is usually equal to or less echogenic than the ovary, while the tubal ring of an ectopic pregnancy is usually more echogenic than ovarian parenchyma.",
"   </p>",
"   <p>",
"    A bimanual scanning technique can be used to determine whether the mass is separate from the ovary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/32\">",
"     32",
"    </a>",
"    ]. To perform this technique, one hand is on the TVUS probe and the other hand applies gentle suprapubic pressure to move the uterus and adnexae. Pressure should be gentle to avoid rupturing an ectopic pregnancy.",
"   </p>",
"   <p>",
"    In a stable patient, repeating the US can also help to differentiate an ectopic pregnancy from a corpus luteum. Ovarian cysts rapidly change in appearance and such change may clarify the findings.",
"   </p>",
"   <p>",
"    It should be noted that the laterality of the corpus luteum has no significance regarding the potential side of tubal pregnancy. Implantation occurs contralateral from ovulation in up to one-third of pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Fallopian tubes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fallopian tube is the site of 98 percent of all ectopic gestations; 75 to 80 percent of implantations occurring in the ampullary tubal segment (",
"    <a class=\"graphic graphic_figure graphicRef55921 \" href=\"mobipreview.htm?10/35/10804\">",
"     figure 1",
"    </a>",
"    ). Therefore, imaging will visualize most ectopic pregnancies between the uterus and ovary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21752?source=see_link\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A range of sonographic adnexal findings can be seen in a tubal ectopic pregnancy. US confirmation of a tubal pregnancy is made when an extrauterine sac with a yolk sac",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    embryo is visualized. The embryo may or may not have cardiac activity, depending upon its gestational age and viability (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52672 \" href=\"mobipreview.htm?35/50/36642\">",
"     image 11",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61837 \" href=\"mobipreview.htm?16/12/16581\">",
"     image 12",
"    </a>",
"    ). The finding of an embryo with cardiac activity is 100 percent specific for a tubal pregnancy, but has low sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An adnexal finding that is suggestive, but not diagnostic, of a tubal pregnancy is a \"tubal ring.\" This is an early finding, no yolk sac is seen. The fluid center represents the sac and the echogenic ring represents the trophoblastic tissue (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50089 \" href=\"mobipreview.htm?33/20/34113\">",
"     image 13",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Commonly, a noncystic, extraovarian mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53149 \" href=\"mobipreview.htm?31/56/32646\">",
"     image 14",
"    </a>",
"    ) is visualized. This is a nonspecific finding, and may represent either an ectopic pregnancy or another type of adnexal mass. A meta-analysis of 565 women in 10 studies reported that using a sonographic finding of an adnexal mass other than a simple cyst or an intraovarian lesion for the diagnosis of a tubal pregnancy had a sensitivity of 84 percent and specificity of 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since some types of adnexal masses are long standing, an US with a nonspecific adnexal mass may be compared with prior studies to assess whether the mass was visualized previously and whether it has changed in appearance. In a woman without evidence of an IUP, any type of new adnexal mass should be further evaluated until the location and status of the pregnancy have been confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PERITONEAL FREE FLUID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echogenic peritoneal free fluid in a woman with a pregnancy of unknown location is associated with ectopic pregnancy.",
"   </p>",
"   <p>",
"    A small amount of clear free fluid in the pelvis is a normal sonographic finding. There is no established threshold for the volume of fluid that is physiologic and the volume is difficult to measure sonographically. However, fluid that is anechoic and isolated to the pelvic cul-de-sac and adjacent recesses is likely physiologic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/35\">",
"     35",
"    </a>",
"    ]. Larger quantities of simple fluid are typically reflective of pathology, even if due to a ruptured simple ovarian cyst.",
"   </p>",
"   <p>",
"    Echogenic or complex fluid is never physiologic, even when present in small quantities, and almost always represents hemoperitoneum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61836 \" href=\"mobipreview.htm?11/40/11910\">",
"     image 15",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Alternatively, echogenic fluid may also be purulent. For example, patients with ruptured appendicitis with secondary abscess formation or tuboovarian abscess, can have focal, \"walled-off\" areas of echogenic complex fluid. This fluid appears more contained (rather than free intraperitoneal, as in the case of hemoperitoneum) and the clinical presentations of these patients are different from those with positive pregnancy test presenting for assessment for ectopic pregnancy. When echogenic fluid is seen in the pelvis, it is important to scan the upper abdomen around the liver, kidneys, and spleen, to assess for additional fluid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81382 \" href=\"mobipreview.htm?17/51/18230\">",
"     image 16",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36823?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31370?source=see_link\">",
"     \"Acute appendicitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echogenic fluid in a pregnant woman with no evidence of an IUP is worrisome for ectopic pregnancy. In a prospective study, the finding of echogenic fluid in pregnant women with a pregnancy of unknown location had a sensitivity of 56 percent and specificity of 96 percent for predicting an ectopic pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/9\">",
"     9",
"    </a>",
"    ]. The main differential diagnosis for this finding is a ruptured hemorrhagic corpus luteal cyst. The presence of an adnexal mass with characteristics consistent with an ectopic gestation helps to clarify the diagnosis (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Fallopian tubes'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The presence or absence of peritoneal free fluid is not a reliable indicator of whether an ectopic pregnancy has ruptured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. This was illustrated in a retrospective study of 132 women with tubal pregnancy who underwent TVUS prior to surgery. Among women found to have tubal rupture at time of surgery, 21 percent had no fluid or trace peritoneal fluid on US. On the other hand, 37 percent of patients with large amounts of free fluid (defined as fluid present in the upper abdomen) on US had intact fallopian tubes at time of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe bleeding from either an ectopic pregnancy or a ruptured corpus luteal cyst requires immediate evaluation and treatment. If there is a large volume of echogenic fluid (&gt;300 mL), the patient should be assessed for ongoing bleeding and hemodynamic instability. An unstable patient needs immediate surgical intervention. If the patient is hemodynamically stable, follow-up with serial hCG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    US may be performed until the evaluation for ectopic pregnancy is complete. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/53/5976?source=see_link\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9863?source=see_link\">",
"     \"Evaluation and management of ruptured ovarian cyst\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RARE ECTOPIC PREGNANCY LOCATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Interstitial pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An interstitial pregnancy is implanted in the interstitial portion of the fallopian tube, which is the proximal tubal segment embodied within the muscular wall of the uterus. Interstitial pregnancies may be misdiagnosed as intrauterine because they are partially implanted in the endometrium and also may be discovered at an advanced gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21752?source=see_link&amp;anchor=H23#H23\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\", section on 'Interstitial or cornual pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21752?source=see_link&amp;anchor=H24#H24\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\", section on 'Angular pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sonographic signs used to diagnose interstitial pregnancy are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      eccentric location of the gestational sac proximal to the uterine cornua",
"     </li>",
"     <li>",
"      gestational sac is surrounded by thin (&lt;5 mm) myometrium and close to the uterine serosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      \"interstitial line,\" defined as an echogenic line that extends from the most superior and lateral aspect of the endometrium to the midportion of the interstitial mass or sac (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73714 \" href=\"mobipreview.htm?20/56/21377\">",
"       image 17",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interstitial line likely represents either the endometrial canal or the interstitial portion of the fallopian tube, depending on the size of the gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the signs used to diagnose interstitial pregnancy, data from small series suggest that the interstitial line is more useful than eccentric sac location or myometrial thinning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term interstitial pregnancy is often used interchangeably with cornual pregnancy, however, a cornual pregnancy specifically refers to a pregnancy in the horn of a bicornuate uterus.",
"   </p>",
"   <p>",
"    The term angular pregnancy is seldom used. This refers to a pregnancy that extends beyond the interstitium into the lateral \"angle\" of the uterine cavity. This distinction is important since angular pregnancies, unlike interstitial pregnancies, are more likely to miscarry than rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ovarian pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sonographic diagnosis of an ovarian pregnancy is difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. An ovarian ectopic pregnancy can be mistaken for a corpus luteum, unless the gestational sac of an embryo is visualized surrounded by ovarian tissue. Laparoscopy and pathologic analysis are often necessary to make the diagnosis. Ovarian pregnancies can be confused for hemorrhagic cysts even at laparoscopy. Pathologic criteria developed by Spiegelberg to distinguish primary ovarian pregnancies from other ectopic pregnancies with secondary involvement of the ovary are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/24/34184/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;(1) The fallopian tube on the involved side is intact and separate from the ovary.",
"   </p>",
"   <p>",
"    &nbsp;(2) The gestational sac is in the normal position of the ovary.",
"   </p>",
"   <p>",
"    &nbsp;(3) The ovary with the gestational sac is connected to the uterus by the ovarian ligament.",
"   </p>",
"   <p>",
"    &nbsp;(4) The specimen has ovarian tissue attached to, and in, the wall of the gestation sac.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Heterotopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who undergo in vitro fertilization (IVF) are at increased risk of heterotopic pregnancy compared with other pregnant women. Thus, even when US identifies an IUP in an IVF pregnancy, it is important to carefully survey potential ectopic gestation sites (eg, tube, ovary, cervix).",
"   </p>",
"   <p>",
"    Sonographic signs suggestive of heterotopic pregnancy are the same as for any ectopic pregnancies (eg, complex adnexal mass, peritoneal free fluid).",
"   </p>",
"   <p>",
"    The diagnosis and management of heterotopic pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other locations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potential ectopic pregnancy sites are cervical, hysterotomy scar, and abdominal. Their sonographic diagnoses are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11062?source=see_link\">",
"     \"Cervical pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic ultrasonography is the most useful imaging modality for women with pregnancy of unknown location. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ultrasound versus other imaging modalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 15 to 26 percent of women with ectopic pregnancy will have an initial US with no findings. The serum human chorionic gonadotropin above which a singleton gestational sac should be visualized on ultrasound examination is 1500 to 2000",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      with transvaginal ultrasound. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Absence of findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sonographic identification of an intrauterine gestational sac is suggestive, but not diagnostic, of an intrauterine pregnancy. An endometrial pseudosac can be seen in up to 20 percent of women with an ectopic pregnancy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Early endometrial findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of a yolk sac or an embryo within the endometrium is diagnostic of an intrauterine pregnancy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Endometrial findings diagnostic of intrauterine pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adnexal findings that are suggestive, but not diagnostic, of a tubal pregnancy are a \"tubal ring\" or a noncystic adnexal mass. Sonographic confirmation of a tubal pregnancy is made when an extrauterine sac with a yolk sac",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      embryo is visualized. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adnexal findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echogenic peritoneal free fluid almost always represents hemoperitoneum. The presence or absence of peritoneal free fluid is not a reliable indicator of whether an ectopic pregnancy has ruptured. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Peritoneal free fluid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/1\">",
"      Tamai K, Koyama T, Togashi K. MR features of ectopic pregnancy. Eur Radiol 2007; 17:3236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/2\">",
"      Nyberg DA, Mack LA, Jeffrey RB Jr, Laing FC. Endovaginal sonographic evaluation of ectopic pregnancy: a prospective study. AJR Am J Roentgenol 1987; 149:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/3\">",
"      Kurjak A, Zalud I, Schulman H. Ectopic pregnancy: transvaginal color Doppler of trophoblastic flow in questionable adnexa. J Ultrasound Med 1991; 10:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/4\">",
"      Cheng PJ, Chueh HY, Qiu JT. Heterotopic pregnancy in a natural conception cycle presenting as hematometra. Obstet Gynecol 2004; 104:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/5\">",
"      Seow KM, Hwang JL, Tsai YL, et al. Transvaginal colour Doppler diagnosis and assessment of a heterotopic cervical pregnancy terminated by forceps evacuation following in vitro fertilisation and embryo transfer. BJOG 2002; 109:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/6\">",
"      Araujo J&uacute;nior E, Zanforlin Filho SM, Pires CR, et al. Three-dimensional transvaginal sonographic diagnosis of early and asymptomatic interstitial pregnancy. Arch Gynecol Obstet 2007; 275:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/7\">",
"      Chou MM, Tseng JJ, Yi YC, et al. Diagnosis of an interstitial pregnancy with 4-dimensional volume contrast imaging. Am J Obstet Gynecol 2005; 193:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/8\">",
"      Izquierdo LA, Nicholas MC. Three-dimensional transvaginal sonography of interstitial pregnancy. J Clin Ultrasound 2003; 31:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/9\">",
"      Nyberg DA, Hughes MP, Mack LA, Wang KY. Extrauterine findings of ectopic pregnancy of transvaginal US: importance of echogenic fluid. Radiology 1991; 178:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/10\">",
"      Braffman BH, Coleman BG, Ramchandani P, et al. Emergency department screening for ectopic pregnancy: a prospective US study. Radiology 1994; 190:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/11\">",
"      Dogra V, Paspulati RM, Bhatt S. First trimester bleeding evaluation. Ultrasound Q 2005; 21:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/12\">",
"      Sickler GK, Chen PC, Dubinsky TJ, Maklad N. Free echogenic pelvic fluid: correlation with hemoperitoneum. J Ultrasound Med 1998; 17:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/13\">",
"      Chen PC, Sickler GK, Dubinsky TJ, et al. Sonographic detection of echogenic fluid and correlation with culdocentesis in the evaluation of ectopic pregnancy. AJR Am J Roentgenol 1998; 170:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/14\">",
"      Barnhart K, Mennuti MT, Benjamin I, et al. Prompt diagnosis of ectopic pregnancy in an emergency department setting. Obstet Gynecol 1994; 84:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/15\">",
"      Connolly A, Ryan DH, Stuebe AM, Wolfe HM. Reevaluation of discriminatory and threshold levels for serum &beta;-hCG in early pregnancy. Obstet Gynecol 2013; 121:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/16\">",
"      Mehta TS, Levine D, Beckwith B. Treatment of ectopic pregnancy: is a human chorionic gonadotropin level of 2,000 mIU/mL a reasonable threshold? Radiology 1997; 205:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/17\">",
"      Mol BW, Hajenius PJ, Engelsbel S, et al. Are gestational age and endometrial thickness alternatives for serum human chorionic gonadotropin as criteria for the diagnosis of ectopic pregnancy? Fertil Steril 1999; 72:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/18\">",
"      Hammoud AO, Hammoud I, Bujold E, et al. The role of sonographic endometrial patterns and endometrial thickness in the differential diagnosis of ectopic pregnancy. Am J Obstet Gynecol 2005; 192:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/19\">",
"      Dart RG, Dart L, Mitchell P, Berty C. The predictive value of endometrial stripe thickness in patients with suspected ectopic pregnancy who have an empty uterus at ultrasonography. Acad Emerg Med 1999; 6:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/20\">",
"      Chiang G, Levine D, Swire M, et al. The intradecidual sign: is it reliable for diagnosis of early intrauterine pregnancy? AJR Am J Roentgenol 2004; 183:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/21\">",
"      Laing FC, Brown DL, Price JF, et al. Intradecidual sign: is it effective in diagnosis of an early intrauterine pregnancy? Radiology 1997; 204:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/22\">",
"      Bradley WG, Fiske CE, Filly RA. The double sac sign of early intrauterine pregnancy: use in exclusion of ectopic pregnancy. Radiology 1982; 143:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/23\">",
"      Filly RA. Ectopic pregnancy: the role of sonography. Radiology 1987; 162:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/24\">",
"      Bhatt S, Ghazale H, Dogra VS. Sonographic evaluation of ectopic pregnancy. Radiol Clin North Am 2007; 45:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/25\">",
"      Ackerman TE, Levi CS, Lyons EA, et al. Decidual cyst: endovaginal sonographic sign of ectopic pregnancy. Radiology 1993; 189:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/26\">",
"      Atri M, Leduc C, Gillett P, et al. Role of endovaginal sonography in the diagnosis and management of ectopic pregnancy. Radiographics 1996; 16:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/27\">",
"      Levi CS, Lyons EA, Lindsay DJ. Early diagnosis of nonviable pregnancy with endovaginal US. Radiology 1988; 167:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/28\">",
"      Bree RL, Edwards M, B&ouml;hm-V&eacute;lez M, et al. Transvaginal sonography in the evaluation of normal early pregnancy: correlation with HCG level. AJR Am J Roentgenol 1989; 153:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/29\">",
"      Dialani V, Levine D. Ectopic pregnancy: a review. Ultrasound Q 2004; 20:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/30\">",
"      Hertzberg BS, Kliewer MA, Bowie JD. Adnexal ring sign and hemoperitoneum caused by hemorrhagic ovarian cyst: pitfall in the sonographic diagnosis of ectopic pregnancy. AJR Am J Roentgenol 1999; 173:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/31\">",
"      Frates MC, Visweswaran A, Laing FC. Comparison of tubal ring and corpus luteum echogenicities: a useful differentiating characteristic. J Ultrasound Med 2001; 20:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/32\">",
"      Webb EM, Green GE, Scoutt LM. Adnexal mass with pelvic pain. Radiol Clin North Am 2004; 42:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/33\">",
"      Berry SM, Coulam CB, Hill LM, Breckle R. Evidence of contralateral ovulation in ectopic pregnancy. J Ultrasound Med 1985; 4:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/34\">",
"      Brown DL, Doubilet PM. Transvaginal sonography for diagnosing ectopic pregnancy: positivity criteria and performance characteristics. J Ultrasound Med 1994; 13:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/35\">",
"      Sirlin CB, Casola G, Brown MA, et al. Us of blunt abdominal trauma: importance of free pelvic fluid in women of reproductive age. Radiology 2001; 219:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/36\">",
"      Atri M, de Stempel J, Bret PM. Accuracy of transvaginal ultrasonography for detection of hematosalpinx in ectopic pregnancy. J Clin Ultrasound 1992; 20:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/37\">",
"      Frates MC, Brown DL, Doubilet PM, Hornstein MD. Tubal rupture in patients with ectopic pregnancy: diagnosis with transvaginal US. Radiology 1994; 191:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/38\">",
"      Jurkovic D, Mavrelos D. Catch me if you scan: ultrasound diagnosis of ectopic pregnancy. Ultrasound Obstet Gynecol 2007; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/39\">",
"      Lau S, Tulandi T. Conservative medical and surgical management of interstitial ectopic pregnancy. Fertil Steril 1999; 72:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/40\">",
"      Jansen RP, Elliott PM. Angular intrauterine pregnancy. Obstet Gynecol 1981; 58:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/41\">",
"      Fleischer AC, Pennell RG, McKee MS, et al. Ectopic pregnancy: features at transvaginal sonography. Radiology 1990; 174:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/42\">",
"      Ackerman TE, Levi CS, Dashefsky SM, et al. Interstitial line: sonographic finding in interstitial (cornual) ectopic pregnancy. Radiology 1993; 189:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/43\">",
"      Auslender R, Arodi J, Pascal B, Abramovici H. Interstitial pregnancy: early diagnosis by ultrasonography. Am J Obstet Gynecol 1983; 146:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/44\">",
"      Tal J, Haddad S, Gordon N, Timor-Tritsch I. Heterotopic pregnancy after ovulation induction and assisted reproductive technologies: a literature review from 1971 to 1993. Fertil Steril 1996; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/45\">",
"      Odejinmi F, Rizzuto MI, Macrae R, et al. Diagnosis and laparoscopic management of 12 consecutive cases of ovarian pregnancy and review of literature. J Minim Invasive Gynecol 2009; 16:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/46\">",
"      Sergent F, Mauger-Tinlot F, Gravier A, et al. [Ovarian pregnancies: revaluation of diagnostic criteria]. J Gynecol Obstet Biol Reprod (Paris) 2002; 31:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/24/34184/abstract/47\">",
"      Spiegelberg, O. Zur kasuistik der ovarialschwangerschaft. Arch Gyneakol 1878; 13:73.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5410 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34184=[""].join("\n");
var outline_f33_24_34184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ULTRASOUND VERSUS OTHER IMAGING MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ULTRASOUND TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transabdominal versus transvaginal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Doppler ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Three-dimensional ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ABSENCE OF FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      hCG discriminatory zone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EARLY ENDOMETRIAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intrauterine pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gestational sac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pseudosac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonspecific findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Decidual cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ENDOMETRIAL FINDINGS DIAGNOSTIC OF INTRAUTERINE PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Yolk sac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Embryo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADNEXAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ovaries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Fallopian tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PERITONEAL FREE FLUID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RARE ECTOPIC PREGNANCY LOCATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Interstitial pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ovarian pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other locations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5410\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5410|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/55/9087\" title=\"diagnostic image 1\">",
"      Gestational sac TAUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/26/35233\" title=\"diagnostic image 2\">",
"      Yolk sac 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/49/1811\" title=\"diagnostic image 3\">",
"      Corpus luteum Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/48/5890\" title=\"diagnostic image 4\">",
"      Ectop preg hemoperit Doppl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/50/21281\" title=\"diagnostic image 5\">",
"      Gestational sac empty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/2/10278\" title=\"diagnostic image 6\">",
"      Intradecidual sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/28/17859\" title=\"diagnostic image 7\">",
"      Double decidual sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/46/15073\" title=\"diagnostic image 8\">",
"      Pseudosac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/26/15777\" title=\"diagnostic image 9\">",
"      Decidual cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/63/39926\" title=\"diagnostic image 10\">",
"      Tubal preg vs corpus luteum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/50/36642\" title=\"diagnostic image 11\">",
"      Tubal preg yolk sac embryo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/12/16581\" title=\"diagnostic image 12\">",
"      Tubal preg heartbeat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/20/34113\" title=\"diagnostic image 13\">",
"      Tubal ring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/56/32646\" title=\"diagnostic image 14\">",
"      Tubal pregnancy adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/40/11910\" title=\"diagnostic image 15\">",
"      Hemoperitoneum pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/51/18230\" title=\"diagnostic image 16\">",
"      Hemoperitoneum abdomen pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/56/21377\" title=\"diagnostic image 17\">",
"      Interstitial pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5410|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/35/10804\" title=\"figure 1\">",
"      Normal female anat detail",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31370?source=related_link\">",
"      Acute appendicitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11062?source=related_link\">",
"      Cervical pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36823?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9863?source=related_link\">",
"      Evaluation and management of ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21752?source=related_link\">",
"      Incidence, risk factors, and pathology of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/53/5976?source=related_link\">",
"      Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36824?source=related_link\">",
"      Ultrasound examination in obstetrics and gynecology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_24_34185="Olanzapine: Pediatric drug information";
var content_f33_24_34185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Olanzapine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"    see \"Olanzapine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/16/28934?source=see_link\">",
"    see \"Olanzapine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ZyPREXA&reg;;",
"     </li>",
"     <li>",
"      ZyPREXA&reg; IntraMuscular;",
"     </li>",
"     <li>",
"      ZyPREXA&reg; Relprevv&trade;;",
"     </li>",
"     <li>",
"      ZyPREXA&reg; Zydis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F203157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Olanzapine ODT&reg;;",
"     </li>",
"     <li>",
"      Apo-Olanzapine&reg;;",
"     </li>",
"     <li>",
"      Ava-Olanzapine;",
"     </li>",
"     <li>",
"      CO Olanzapine;",
"     </li>",
"     <li>",
"      CO Olanzapine ODT;",
"     </li>",
"     <li>",
"      Mylan-Olanzapine;",
"     </li>",
"     <li>",
"      Olanzapine ODT;",
"     </li>",
"     <li>",
"      PHL-Olanzapine;",
"     </li>",
"     <li>",
"      PHL-Olanzapine ODT;",
"     </li>",
"     <li>",
"      PMS-Olanzapine;",
"     </li>",
"     <li>",
"      PMS-Olanzapine ODT;",
"     </li>",
"     <li>",
"      Riva-Olanzapine;",
"     </li>",
"     <li>",
"      Riva-Olanzapine ODT;",
"     </li>",
"     <li>",
"      Sandoz-Olanzapine;",
"     </li>",
"     <li>",
"      Sandoz-Olanzapine ODT;",
"     </li>",
"     <li>",
"      Teva-Olanzapine;",
"     </li>",
"     <li>",
"      Teva-Olanzapine OD;",
"     </li>",
"     <li>",
"      Zyprexa&reg;;",
"     </li>",
"     <li>",
"      Zyprexa&reg; Intramuscular;",
"     </li>",
"     <li>",
"      Zyprexa&reg; Zydis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1028249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Atypical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1028285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"      see \"Olanzapine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Bipolar I disorder",
"     </b>",
"     (acute manic or mixed episodes):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children 4 to &lt;6 years: Limited data available: Initial: 1.25 mg once daily; increase at weekly intervals according to response and tolerability to target dose: 10 mg/day.  Dosing based on an open-label trial in 15 children (mean age: 5 &plusmn; 0.8 years; mean weight: 20.8 kg; mean required dose: 6.3 &plusmn; 2.3 mg/day) that showed significant improvement in manic symptoms (Biederman, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children 6-12 years: Limited data available: Initial: 2.5 mg once daily; increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day (Frazier, 2001; Kowatch, 2006; Wozniak, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents:  Initial: 2.5-5 mg once daily;  increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day. In adolescent flexible-dosing (2.5-20 mg/day) clinical trials, the mean modal dose was 10.7 mg/day (mean dose: 8.9 mg/day) (Kowatch, 2006; Tohen, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Children &ge;8 years (Limited data available) and Adolescents: Initial: 2.5-5 mg once daily; increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Doses up to 30 mg/day were used in one study of adolescents who were treatment refractory; however, some patients did not tolerate doses &gt; 20 mg/day (Kumra, 2008); safety and efficacy of doses &gt;20 mg/day have not been fully evaluated. In adolescent flexible-dosing (2.5-20 mg/day) clinical trials, the mean modal dose was 12.5 mg/day (mean dose: 11.1 mg/day). Dosing in children is based on two double-blind comparison studies which included both children and adolescents [n=35, age: 8-19 years with seven children; n=13, age: 7-16 years (mean age: 12.8 + 2.4 years)] (Shaw, 2006; Sikich, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Anorexia nervosa:",
"     </b>",
"     Children &ge;9 years and Adolescents: Limited data available: 1.25-2.5 mg once daily has been shown in one small trial and several case reports to improve BMI and other disease-related symptoms (eg, eating attitudes, anxiety); another case series used initial doses of 2.5 mg once daily and final doses of 5 mg to 10 mg once daily; reported range: 1.25-12.5 mg/day; however, it has been suggested that higher doses (&gt;2.5 mg once daily) may not be associated with greater efficacy. Further studies are needed (Boachie, 2003; Dunican, 2007; Legerro, 2010; Mehler, 2001; Mehler-Wex, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Tourette syndrome, tic disorder:",
"     </b>",
"     Children &ge;7 years and Adolescents: Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient weight &le;40 kg: Initial: 2.5 mg every other day for 3 days, increase to 2.5 mg every day for remainder of week; increase to 5 mg/day by second week if needed; then increase in 5 mg increments at weekly intervals as tolerated; maximum dose: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient weight &gt;40 kg: Initial: 2.5 mg every day for 3 days; increase to 5 mg every day for remainder of week if needed, then increase in 5 mg increments at weekly intervals as tolerated; maximum dose: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     An open-label study of 10 pediatric patients (7-13 years of age) reported significant reductions in tic severity [Yale Global Tic Severity Scale (YGTSS)] from baseline at a mean final dose of 14.5 mg/day after 8 weeks of treatment (Stephens, 2004). An open-label trial of 12 children and adolescents (7-14 years of age) reported a significant reduction (30%) in total tic severity (YGTSS) at a final mean dose of 11.3 mg/day (range: 2.5-20 mg/day) (McCracken, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Acute mania associated with bipolar disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Monotherapy: Initial: 10-15 mg once daily; increase by 5 mg/day at intervals of not less than 24 hours. Maintenance: 5-20 mg/day; recommended maximum dose: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Combination therapy (with lithium or valproate): Initial: 10 mg once daily; dosing range: 5-20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Initial: 5-10 mg once daily (increase to 10 mg once daily within 5-7 days); thereafter, adjust by 5 mg/day at 1-week intervals, up to a recommended maximum of 20 mg/day. Maintenance: 10-20 mg once daily. Doses of 30-50 mg/day have been used; however, doses &gt;10 mg/day have not demonstrated better efficacy, and safety and efficacy of doses &gt;20 mg/day have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M. (short-acting):",
"     <b>",
"      Agitation",
"     </b>",
"     (acute, associated with bipolar disorder or schizophrenia):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pediatric patients: Limited data available: Children: 5 mg; Adolescents: 10 mg. Dosing based on a retrospective report of I.M. olanzapine use in an inpatient psychiatric setting which included 50 pediatric patients [children (n=15; mean age: 11 years); adolescents (n=35; mean age: 15 years)] and evaluated 163 doses administered; results showed a 90.2% response rate (Khan, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Initial dose: 10 mg (a lower dose of 5-7.5 mg may be considered when clinical factors warrant); additional doses (up to 10 mg) may be considered; however, 2-4 hours should be allowed between doses to evaluate response (maximum total daily dose: 30 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M. (extended release): Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Establish tolerance to oral olanzapine prior to changing to extended release I.M. injection. It may take up to 3 months to re-establish steady-state when switching from oral olanzapine to long-acting I.M. injection. Maximum dose: 300 mg/2 weeks or 405 mg/4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients established on oral olanzapine 10 mg/day: Initial dose: 210 mg every 2 weeks for 4 doses or 405 mg every 4 weeks for 2 doses; Maintenance dose: 150 mg every 2 weeks or 300 mg every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients established on oral olanzapine 15 mg/day: Initial dose: 300 mg every 2 weeks for 4 doses; Maintenance dose: 210 mg every 2 weeks or 405 mg every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients established on oral olanzapine 20 mg/day: Initial and maintenance dose: 300 mg every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients who are debilitated, predisposed to hypotensive reactions, exhibit multiple factors that may result in slower metabolism, or may be more sensitive to olanzapine: Initial dose: 150 mg every 4 weeks; increase dose with caution and only if clinically needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Use with caution. Dosage adjustment may be necessary; however, no specific recommendations exist. Monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyPREXA&reg; IntraMuscular: 10 mg [contains lactose 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for suspension, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyPREXA&reg; Relprevv&trade;: 210 mg, 300 mg, 405 mg [contains polysorbate 80 (in diluent); supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyPREXA&reg;: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 5 mg, 10 mg, 15 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyPREXA&reg; Zydis&reg;: 5 mg [contains phenylalanine 0.34 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyPREXA&reg; Zydis&reg;: 10 mg [contains phenylalanine 0.45 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyPREXA&reg; Zydis&reg;: 15 mg [contains phenylalanine 0.67 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyPREXA&reg; Zydis&reg;: 20 mg [contains phenylalanine 0.9 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes Injection (powder for suspension, extended release)",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11238295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, only prescribers, healthcare facilities, and pharmacies registered with the Zyprexa&reg; Relprevv&trade; Patient Care Program are able to prescribe, distribute, or dispense Zyprexa&reg; Relprevv&trade; for patients who are enrolled in and meet all conditions of the program. Zyprexa&reg; Relprevv&trade; must be administered at a registered healthcare facility. Prescribers will need to be recertified every 3 years. Contact the Zyprexa&reg; Relprevv&trade; Patient Care Program at 1-877-772-9390.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zyprexa&reg; and Zyprexa&reg; Zydis:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM134700.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM134700.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zyprexa&reg; Relprevv&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM194579.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM194579.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1028292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (short-acting): For I.M. administration only; do not administer I.V. or subcutaneously; inject slowly, deep into muscle mass. Reconstitute 10 mg vial with 2.1 mL SWI; resulting solution is ~5 mg/mL with a clear and yellow appearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (extended release): Adults:",
"     <b>",
"      For deep I.M. gluteal administration only",
"     </b>",
"     ; do not administer injection intravenously. Add appropriate amount of provided diluent to proper vial size (see package labeling) and agitate vigorously to suspend drug. Do not use other diluents. If foam develops, let vial stand to allow foam to dissipate. If suspended drug is not used right away, agitate vial again vigorously to resuspend drug prior to withdrawal from vial. Once drug is withdrawn into syringe, use immediately. After needle insertion into muscle, aspirate to verify that no blood appears; inject slowly, deep into muscle. Do not massage injection site. Solution may be irritating to the skin; use of gloves recommended during preparation; flush skin with water if drug comes into contact with skin. Use diluent, syringes, and needles provided in convenience kit; obtain a new kit if aspiration of blood occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: May be administered with or without food. Orally disintegrating tablet: Remove from foil blister by peeling back foil (do not push tablet through the foil); place tablet in mouth immediately upon removal; tablet dissolves rapidly in saliva and may be swallowed with or without liquid. No faster onset compared to oral solid.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1028270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, extended release: Store at room temperature, not to exceed 30&deg;C (86&deg;F). Once suspension prepared, stable for 24 hours at room temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, short-acting: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Protect from light. Use immediately (within 1 hour) following reconstitution. Discard any unused portion. Incompatible with diazepam, lorazepam, or haloperidol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet and orally disintegrating tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1028250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of schizophrenia (FDA approved in ages &ge;13 years and adults); acute and maintenance treatment of manic or mixed episodes of bipolar I disorder (FDA approved in ages &ge;13 years and adults); adjunctive therapy (to lithium or valproate) for treatment of manic or mixed episodes of bipolar I disorder (FDA approved in adults); in combination with fluoxetine for treatment-resistant depression or depressive episodes associated with bipolar I disorder (FDA approved in adults). Has also been used for anorexia nervosa, autism spectrum disorders, Tourette syndrome, and tic disorders. Therapy should only be initiated in pediatric patients after a thorough diagnostic evaluation and an assessment of potential long-term risks; adolescent patients experience a higher incidence of weight gain, and greater increases in total cholesterol, triglycerides, LDL, prolactin, and hepatic transaminase concentrations than adult patients; other agents with fewer risks may be preferred as first-line treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M. extended release (Zyprexa&reg; Relprevv&trade;): Treatment of schizophrenia (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M. short-acting (Zyprexa&reg; IntraMuscular): Treatment of acute agitation associated with schizophrenia and bipolar I mania (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F203206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       OLANZapine may be confused with olsalazine, QUEtiapine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyPREXA&reg; may be confused with CeleXA&reg;, Reprexain&trade;, Zestril&reg;, ZyrTEC&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyPREXA&reg; Zydis&reg; may be confused with Zelapar&reg;, zolpidem",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyPREXA&reg; Relprevv&trade; may be confused with ZyPREXA&reg; IntraMuscular",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F203203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"     Unless otherwise noted, adverse events are reported for placebo-controlled trials in adult patients on monotherapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypertension, orthostatic hypotension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system:  Dizziness, fatigue, fever, extrapyramidal symptoms, headache (adolescents), insomnia, personality changes, restlessness (adolescents), somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast-related events ([adolescents] discharge, enlargement, galactorrhea, gynecomastia, lactation disorder); menstrual-related events (amenorrhea, hypomenorrhea, menstruation delayed, oligomenorrhea); prolactin increased; sexual function-related events (anorgasmia, ejaculation delayed, erectile dysfunction, changes in libido, abnormal orgasm, sexual dysfunction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (adolescents), appetite increased, constipation, diarrhea (adolescents), dyspepsia, flatulence, nausea (dose dependent), vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Incontinence, UTI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased &ge;3x ULN, hepatic enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, akathisia, articulation impairment, back pain, falling, hypertonia, joint/extremity pain, muscle stiffness (adolescents), tremor (dose dependent), weakness (dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, epistaxis (adolescents), pharyngitis, respiratory tract infection (adolescents), rhinitis, sinusitis (adolescents)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Accidental injury",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acidosis, agranulocytosis, anaphylactoid reaction, angioedema, apnea, atelectasis, atrial fibrillation, cerebrovascular accident, congestive heart failure, deafness, diabetes mellitus, diabetic ketoacidosis, diabetic coma, dystonia, encephalopathy, facial paralysis, glaucoma, heart arrest, heart failure, hemorrhage (eye, rectal, subarachnoid, vaginal), hepatitis, hypercholesterolemia, hyper-/hypoglycemia, hyper-/hypokalemia, hyperlipemia, hyper-/hyponatremia, hypertriglyceridemia, hyperuricemia, hyper-/hypoventilation, hypoproteinemia, hypoxia, jaundice, ileus, ketosis, leukocytosis (eosinophilia), leukopenia, liver damage (cholestatic or mixed), liver fatty deposit, lung edema, lymphadenopathy, myasthenia, myopathy, neuralgia, neuroleptic malignant syndrome, neutropenia, pancreatitis, paralysis, pulmonary embolus, rash, rhabdomyolysis, seizure, sudden death, suicide attempt, syncope, tardive dyskinesia, thrombocythemia, thrombocytopenia, transient ischemic attack, venous thrombotic events",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"     Unless otherwise noted, adverse events are reported for placebo-controlled trials in adult patients on extended-release I.M. injection (Zyprexa&reg; Relprevv&trade;). Also refer to adverse reactions noted with oral therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Hypertension, hypotension (short-acting), orthostatic hypotension (short-acting), QT prolongation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, abnormal thinking, auditory hallucination, dizziness, dysarthria, extrapyramidal symptoms, fatigue, fever, headache, pain, restlessness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Acne",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite increased, diarrhea, flatulence, nausea, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Vaginal discharge",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, muscle spasms, stiffness, tremor, weakness (short-acting)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Otic: Ear pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, nasal congestion, nasopharyngitis, pharyngolaryngeal pain, sneezing, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Toothache, tooth infection, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: CPK increased, post-injection delirium/sedation syndrome, syncope (short-acting)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1028254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to olanzapine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5137962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment, signs and symptoms of hepatic impairment, or being treated with potentially hepatotoxic drugs; olanzapine may increase transaminases (primarily ALT); greater increases in hepatic transaminases were observed in adolescent patients compared to adults in clinical trials; dosage adjustment may be necessary.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with breast cancer, history of breast cancer, or other prolactin-dependent tumors; olanzapine increases prolactin concentrations; a higher incidence of hyperprolactinemia has been observed in adolescent patients treated with olanzapine than adults (47% vs 30%), high concentrations of prolactin may reduce pituitary gonadotropin secretion; galactorrhea, amenorrhea, gynecomastia, impotence, decreased bone density may occur. Use with caution in children and adolescents as adverse effects due to elevated serum prolactin concentrations have been observed; long-term effects on growth or sexual maturation have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Olanzapine may cause increases in serum lipid concentration and weight gain (higher than normal) in adolescent and adult patients. Very high triglyceride concentrations (&gt;500 mg/dL) have been observed along with modest increases in total cholesterol. In adolescent patients, increases in fasting total cholesterol, LDL cholesterol, and triglycerides were generally greater than in adult patients; measure fasting serum lipids at the beginning of therapy and periodically during therapy in these patients. Compared to adult patients, adolescent patients had both greater magnitude of weight gain and proportion of patients who had clinically significant weight gain (incidence: 29% to 40% vs 6%). With long-term olanzapine exposure (&ge;24 weeks), 89% of adolescents gained at least 7% of their baseline body weight, 55% gained at least 15% of their baseline body weight, and 29% gained at least 25% of their baseline body weight; discontinuation due to weight gain occurred in 2.2%. Monitor growth (including weight, height, BMI, and waist circumference) in pediatric and adolescent patients receiving olanzapine; compare weight gain to standard growth curves.",
"     <b>",
"      Note:",
"     </b>",
"     A prospective, nonrandomized, cohort study followed 338 antipsychotic naive pediatric patients (age: 4-19 years) for a median of 10.8 weeks (range: 10.5-11.2 weeks) and showed that olanzapine was associated with greater increases in weight, fat mass, BMI, and waist circumference than other atypical antipsychotics evaluated (ie, quetiapine, risperidone, and aripiprazole). The following significant mean increases in weight in kg (and % change from baseline) were reported: Olanzapine: 8.5 kg (15.2%), quetiapine: 6.1 kg (10.4%), risperidone: 5.3 kg (10.4%), and aripiprazole: 4.4 kg (8.1%) compared to the control cohort: 0.2 kg (0.65%). Also, compared to the other atypical antipsychotics evaluated, olanzapine showed higher increases in metabolic indices (eg, serum glucose, total cholesterol and LDL-C). Biannual monitoring of cardiometabolic indices after the first 3 months of therapy is suggested (Correll, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with seizure disorder or conditions that lower seizure threshold (seizures have been rarely reported); in suicidal patients; in patients with concomitant systemic illnesses, unstable heart disease, or a recent history of MI (these patients not adequately studied); and in patients at risk of aspiration pneumonia (esophageal dysmotility and aspiration have been associated with antipsychotic agents). May cause orthostatic hypotension with resultant dizziness, tachycardia, or syncope (especially during initial dose titration); use with caution in patients with history of cardiovascular disease, cerebrovascular disease, conditions predisposed to hypotension (eg, dehydration, hypovolemia) or concurrent drug therapy that can induce hypotension, bradycardia, respiratory or central nervous system depression. May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Moderate to highly sedating; a higher frequency of sedation-related adverse events (defined as hypersomnia, lethargy, sedation, and somnolence) have been observed in adolescents compared to adults. Use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause anticholinergic effects; relative to other neuroleptics, olanzapine has a moderate potency of cholinergic blockade; use with caution in patients with decreased gastrointestinal motility, history of paralytic ileus or related condition, urinary retention, BPH, xerostomia, glaucoma, or myasthenia gravis. Olanzapine concentrations may be lower in patients who smoke, dosing adjustment not recommended by manufacturer but may be considered. Use with caution in patients exposed to temperature extremes; may cause alteration of temperature regulation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Orally disintegrating tablets contain phenylalanine which must be used with caution in patients with phenylketonuria.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     I.M. administration: Two different I.M. formulations are available (short-acting and extended release preparations) and are not interchangeable. Patients should remain recumbent if drowsy/dizzy until hypotension, bradycardia, and/or hypoventilation have been ruled out. Concurrent use of I.M./I.V. benzodiazepines is not recommended due to potential for excessive sedation and cardiorespiratory depression (fatalities have been reported, though causality not determined). Extended release product (Zyprexa&reg; Relprevv&trade;) may cause local skin irritation, use gloves during preparation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1028255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     May cause neuroleptic malignant syndrome; symptoms include hyperpyrexia, altered mental status, muscle rigidity, autonomic instability, acute renal failure, rhabdomyolysis, and increased CPK. May cause extrapyramidal reactions, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of these reactions is dose-dependent. To decrease risk of tardive dyskinesia: Use smallest dose and shortest duration possible and evaluate continued need periodically. Risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause hyperglycemia, which may be severe and include potentially fatal ketoacidosis or hyperosmolar coma; there is a stronger association of hyperglycemia with olanzapine than other atypical antipsychotics. In clinical trials of adolescents, 14.3% of patients at 12 weeks of olanzapine exposure and 23.1% of patients at &ge;24 weeks exposure had an increase in their fasting blood glucose concentration from the borderline category (100 mg/dL to &lt;126 mg/dL) to high ( &ge;126 mg/dL). Use with caution and monitor for symptoms of hyperglycemia in all patients treated with olanzapine; monitor glucose closely in patients with diabetes mellitus (or with risk factors such as family history or obesity) or with borderline increased blood glucose (fasting: 100-126 mg/dL or nonfasting: 140-200 mg/dL); measure fasting blood glucose at the beginning of therapy, periodically during therapy, and in any patient who develops signs or symptoms of hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasia or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Pediatric  psychiatric disorders are frequently serious mental disorders which present with variable symptoms that do not always match adult diagnostic criteria. Conduct a thorough diagnostic evaluation and carefully consider risks of psychotropic medication before initiation in pediatric patients. Medication therapy for pediatric patients with bipolar disorder and schizophrenia is indicated as part of a total treatment program that frequently includes educational, psychological, and social interventions. The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature. An increased incidence of cerebrovascular adverse events (eg, transient ischemic attack, stroke), including fatalities, has been reported with the use of olanzapine in elderly patients with dementia-related psychosis. Olanzapine is not approved for the treatment of patients with dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Extended release I.M. injection (Zyprexa&reg; Relprevv&trade;): A postinjection delirium sedation syndrome, characterized by severe sedation (including coma) and/or delirium (including agitation, anxiety, confusion, disorientation, and other cognitive impairment), has been observed",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; other symptoms including ataxia, aggression, convulsion, dizziness, dysarthria, extrapyramidal symptoms, hypertension, slurred speech, and weakness have been noted; in some patients, clinical signs and symptoms were associated with an inadvertent rapid rise in olanzapine serum concentrations; exact mechanism for introduction of drug into the bloodstream is unknown. Administer at a registered healthcare facility where patients are continuously monitored (&ge;3 hours) for symptoms of olanzapine overdose; symptom development is highest in first hour but may occur within or after 3 hours; risk of syndrome is cumulative with each injection; recovery expected by 72 hours. Upon determining alert status, patient should be escorted to their destination and not drive or operate heavy machinery for the remainder of the day. Diluent contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F203191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: OLANZapine may enhance the adverse/toxic effect of Benzodiazepines.  Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May decrease the metabolism of OLANZapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May enhance the sedative effect of OLANZapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11397411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rate or extent of absorption is not affected by food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2839122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No evidence of teratogenicity reported in animal studies. However, fetal toxicity and prolonged gestation have been observed. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. There are no adequate and well-controlled studies in pregnant women. Healthcare providers are encouraged to enroll women 18-45 years of age exposed to olanzapine during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1028296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; CBC with differential, fasting lipid profile, and fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment, at 3 months, then annually or as symptoms warrant); periodic assessment of hepatic transaminases; weight, BMI, waist circumference; personal/family history of diabetes or obesity; orthostatic blood pressure; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS). Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider switching to a different antipsychotic agent for a weight gain &ge;5% of the initial weight. Monitor patient periodically for symptom resolution. Following I.M. administration, if dizziness and/or drowsiness are noted, patient should remain recumbent until resolved. Extended release I.M. injection (Zyprexa&reg; Relprevv&trade;): Monitor patients continuously for 3 hours after injection for symptoms of postinjection sedation syndrome and olanzapine overdose; once patient is alert, escort patient to their destination; patient should not drive or operate heavy machinery for the remainder of the day.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1028273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atypical antipsychotic (thienobenzodiazepine class); highly potent antagonist of serotonin 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     , dopamine D",
"     <sub>",
"      1-4",
"     </sub>",
"     , histamine H",
"     <sub>",
"      1",
"     </sub>",
"     - and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors. Olanzapine shows moderate antagonism of 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     and muscarinic M",
"     <sub>",
"      1-5",
"     </sub>",
"     receptors, and weak binding to GABA-A, BZD, and beta-adrenergic receptors. Although the precise mechanism of action in schizophrenia and bipolar disorder is not known, the efficacy of olanzapine is thought to be mediated through combined antagonism of dopamine and serotonin type 2 receptor sites. Antagonism at other receptors may explain additional observed olanzapine effects: Anticholinergic-like effects due to muscarinic M",
"     <sub>",
"      1-5",
"     </sub>",
"     receptor antagonism, somnolence due to H",
"     <sub>",
"      1",
"     </sub>",
"     receptor antagonism, and orthostatic hypotension due to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5140659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Within 1-2 weeks for control of aggression, agitation, insomnia; 3-6 weeks for control of mania and positive psychotic symptoms. Adequate trial: Typically 6 weeks at maximum tolerated doses",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1028275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (short-acting): Rapidly absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Well absorbed; not affected by food; tablets and orally disintegrating tablets are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive throughout body; V",
"     <sub>",
"      d",
"     </sub>",
"     : 1000 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93% primarily to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Highly metabolized via direct glucuronidation and cytochrome P450 mediated oxidation (CYP1A2, CYP2D6); 40% removed via first pass metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral and I.M. (short-acting):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients (10-18 years; n=8): 37.2 &plusmn; 5.1 hours (Grothe, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 30 hours [21-54 hours (5th to 95th percentile)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (extended release): 30 days (effective half-life)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Maximum plasma concentrations after I.M. (short-acting product) administration are 5 times higher than maximum plasma concentrations produced by an oral dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (short-acting): 15-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (extended release): ~7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients (10-18 years; n=8): 4.7 &plusmn; 3.7 hours (Grothe, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (57%; 7% as unchanged drug); feces (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients (10-18 years; n=8): Apparent: 9.6 &plusmn; 2.4 L/hour (Grothe, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adult: Apparent: 25 L/hour [12-47 L/hour (5th to 95th percentile)]; 40% increase in olanzapine clearance in smokers; 30% decrease in females",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by dialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1028300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/16/28934?source=see_link\">",
"      see \"Olanzapine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each new prescription and refill of olanzapine. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; may cause postural hypotension, especially during initial dose titration (use caution when changing position from lying or sitting to standing). Report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; avoid alcohol. Report persistent CNS effects (eg, trembling fingers, altered gait or balance, excessive sedation, seizures, unusual muscle or skeletal movements), rapid heartbeat, severe dizziness, vision changes, skin rash, weight gain or loss, or worsening of condition to your physician. If you have diabetes, monitor blood glucose concentrations closely at beginning of therapy and periodically thereafter (may cause hyperglycemia). Patients may be more vulnerable to overheating and dehydration while taking this medication; maintain adequate hydration unless advised by prescriber to restrict fluids. May rarely cause photosensitivity reactions; avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); use sunscreen; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F11408495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term usefulness of olanzapine should be periodically re-evaluated in patients receiving the drug for extended periods of time.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional detailed olanzapine dosing information for Children and Adolescents: Oral:",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Autism spectrum disorders:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Limited information exists in the literature; dose not established; efficacy results have been variable; further studies are needed. A double-blind, placebo-controlled study (n=11, 6-14 years of age, study duration: 8 weeks) reported a response in only 3 of 6 treatment arm patients using an initial dose of: 2.5 mg every other day (patient weight: &lt;40 kg) or 2.5 mg every day (patient weight: &ge;40 kg); dose increased at weekly intervals in 2.5-5 mg increments as tolerated (maximum dose allowed: 20 mg/day); final dosage range: 7.5-12.5 mg/day; mean: 10 mg/day (Hollander, 2006). An open-label, 6-week, comparative study with haloperidol in 12 children (4.8-11.8 years of age) used a similar dosing regimen and reported responses in 5 of 6 patients in the olanzapine treatment arm; final dosage range: 5-10 mg/day (mean: 7.9 &plusmn; 2.5 mg/day) (Malone, 2001). However, an open-label, 12-week study in 25 pediatric patients (6-16 years) reported a response in only three patients, final dosage range: 2.5-20 mg/day (mean: 10.7 mg/day) (Kemner, 2002).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, &ldquo;Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(2):596-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/14747245/pubmed\" id=\"14747245\" target=\"_blank\">",
"        14747245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biederman J, Mick E, Hammerness P, et al, \"Open-Label, 8-Week Trial of Olanzapine and Risperidone for the Treatment of Bipolar Disorder in Preschool-Age Children,\"",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 2005, 58(7):589-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/16239162/pubmed\" id=\"16239162\" target=\"_blank\">",
"        16239162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boachie A, Goldfield GS, and Spettigue W, \"Olanzapine Use as an Adjunctive Treatment for Hospitalized Children With Anorexia Nervosa: Case Reports,\"",
"      <i>",
"       Int J Eat Disord",
"      </i>",
"      , 2003, 33(1):98-103.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/12474205/pubmed\" id=\"12474205\" target=\"_blank\">",
"        12474205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carrillo JA, Herraiz AG, Ramos SI, et al, \"Role of the Smoking-Induced Cytochrome P450 (CYP)1A2 and Polymorphic CYP2D6 in Steady-State Concentration of Olanzapine,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2003, 23(2):119-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/12640212/pubmed\" id=\"12640212\" target=\"_blank\">",
"        12640212",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chavez B, Chavez-Brown M, Sopko MA Jr, et al, \"Atypical Antipsychotics in Children With Pervasive Developmental Disorders,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2007, 9(4):249-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/17705564/pubmed\" id=\"17705564\" target=\"_blank\">",
"        17705564",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Correll CU, Manu P, Olshanskiy V, et al, \"Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(16):1765-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/19861668/pubmed\" id=\"19861668\" target=\"_blank\">",
"        19861668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunican KC and DelDotto D, \"The Role of Olanzapine in the Treatment of Anorexia Nervosa,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2007, 41(1):111-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/17190846/pubmed\" id=\"17190846\" target=\"_blank\">",
"        17190846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farwell WR, Stump TE, Wang J, et al, \"Weight Gain and New Onset Diabetes Associated With Olanzapine and Risperidone,\"",
"      <i>",
"       J Gen Intern Med",
"      </i>",
"      , 2004, 19(12):1200-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/15610330/pubmed\" id=\"15610330\" target=\"_blank\">",
"        15610330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frazier JA, Biederman J, Tohen M, et al, \" A Prospective Open-Label Treatment Trial of Olanzapine Monotherapy in Children and Adolescents With Bipolar Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2001, 11(3):239-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/11642474/pubmed\" id=\"11642474\" target=\"_blank\">",
"        11642474",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grothe DR, Calis KA, Jacobsen L, et al, \"Olanzapine Pharmacokinetics in Pediatric and Adolescent Inpatients With Childhood-Onset Schizophrenia,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2000, 20(2):220-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/10770461/pubmed\" id=\"10770461\" target=\"_blank\">",
"        10770461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollander E, Wasserman S, Swanson EN, et al, \"A Double-Blind Placebo-Controlled Pilot Study of Olanzapine in Childhood/Adolescent Pervasive Developmental Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(5):541-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/17069543/pubmed\" id=\"17069543\" target=\"_blank\">",
"        17069543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kemner C, Willemsen-Swinkels SH, de Jonge M, et al, \"Open-Label Study of Olanzapine in Children With Pervasive Developmental Disorder,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2002, 22(5):455-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/12352267/pubmed\" id=\"12352267\" target=\"_blank\">",
"        12352267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khan SS and Mican LM, \"A Naturalistic Evaluation of Intramuscular Ziprasidone Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Children and Adolescents,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(6):671-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/17201611/pubmed\" id=\"17201611\" target=\"_blank\">",
"        17201611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kowatch RA, Fristad M, Birmaher B, et al, \"Treatment Guidelines for Children and Adolescents With Bipolar Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2005, 44(3):213-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/15725966/pubmed\" id=\"15725966\" target=\"_blank\">",
"        15725966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kryzhanovskaya L, Schulz SC, McDougle C, et al, &ldquo;Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatr",
"      </i>",
"      y, 2009, 48(1):60-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/19057413/pubmed\" id=\"19057413\" target=\"_blank\">",
"        19057413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumra S, Kranzler H, Gerbino-Rosen G, et al, \"Clozapine and 'HighDose'  Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison,\"",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 2008, 63(5):524-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leggero C, Masi G, Brunori E, et al, \"Low-Dose Olanzapine Monotherapy in Girls With Anorexia Nervosa, Restricting Subtype: Focus on Hyperactivity,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2010, 20(2):127-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/20415608/pubmed\" id=\"20415608\" target=\"_blank\">",
"        20415608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone RP, Cater J, Sheikh RM, et al, \"Olanzapine Versus Haloperidol in Children With Autistic Disorder: An Open Pilot Study,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2001, 40(8):887-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/11501687/pubmed\" id=\"11501687\" target=\"_blank\">",
"        11501687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCracken JT, Suddath R, Chang S, et al, \"Effectiveness and Tolerability of Open Label Olanzapine in Children and Adolescents With Tourette Syndrome,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2008, 18(5):501-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/18928414/pubmed\" id=\"18928414\" target=\"_blank\">",
"        18928414",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mehler C, Wewetzer C, Schulze U, et al, \"Olanzapine in Children and Adolescents With Chronic Anorexia Nervosa. A Study of Five Cases,\"",
"      <i>",
"       Eur Child Adolesc Psychiatry",
"      </i>",
"      , 2001, 10(2):151-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/11469288/pubmed\" id=\"11469288\" target=\"_blank\">",
"        11469288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mehler-Wex C, Romanos M, Kirchheiner J, et al, \"Atypical Antipsychotics in Severe Anorexia Nervosa in Children and Adolescents - Review and Case Reports,\"",
"      <i>",
"       Eur Eat Disord Rev",
"      </i>",
"      , 2008, 16(2):100-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/18000964/pubmed\" id=\"18000964\" target=\"_blank\">",
"        18000964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw P, Sporn A, Gogtay N, et al, \"Childhood-Onset Schizophrenia: A Double-Blind, Randomized, Clozapine-Olanzapine Comparison,\"",
"      <i>",
"       Arch Gen Psych",
"      </i>",
"      , 2006, 63(7):721-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/16818861/pubmed\" id=\"16818861\" target=\"_blank\">",
"        16818861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sikich L, Frazier JA, McClellan J, et al, \"Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2008, 165(11):1420-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/18794207/pubmed\" id=\"18794207\" target=\"_blank\">",
"        18794207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stachnik JM and Nunn-Thompson C, \"Use of Atypical Antipsychotics in the Treatment of Autistic Disorder,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2007, 41(4):626-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/17389666/pubmed\" id=\"17389666\" target=\"_blank\">",
"        17389666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stephens RJ, Bassel C, and Sandor P, \"Olanzapine in the Treatment of Aggression and Tics in Children With Tourette's Syndrome - A Pilot Study,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2004, 14(2):255-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/15319022/pubmed\" id=\"15319022\" target=\"_blank\">",
"        15319022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tohen M, Kryzhanovskaya L, Carlson G, et al, \"Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(10):1547-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/17898346/pubmed\" id=\"17898346\" target=\"_blank\">",
"        17898346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wozniak J, Mick E, Waxmonsky J, et al, \"Comparison of Open-Label, 8-Week Trials of Olanzapine Monotherapy and Topiramate Augmentation of Olanzapine for the Treatment of Pediatric Bipolar Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2009, 19(5):539-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/24/34185/abstract-text/19877978/pubmed\" id=\"19877978\" target=\"_blank\">",
"        19877978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16033 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-49CB555465-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34185=[""].join("\n");
var outline_f33_24_34185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709177\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203156\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203157\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028249\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028285\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203131\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203116\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11238295\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874938\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028292\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028270\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028250\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203206\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203203\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028254\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5137962\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028255\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203191\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203125\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11397411\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203127\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2839122\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028296\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028273\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5140659\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028275\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028300\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11408495\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=related_link\">",
"      Olanzapine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/16/28934?source=related_link\">",
"      Olanzapine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_24_34186="Toxic epidermal necrolysis - abdomen";
var content_f33_24_34186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59418%7EDERM%2F68458%7EDERM%2F82150%7EALLRG%2F66134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59418%7EDERM%2F68458%7EDERM%2F82150%7EALLRG%2F66134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple bullae and large areas of desquamation are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse erythema and large areas of desquamation are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple bullae overlying diffuse erythema are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Usually caused by drugs, toxic epidermal necrolysis demonstrates widespread erythema and confluent vesiculation, leading to sloughing of the skin. Affected patients are at risk for hypernatremic dehydration and sepsis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34186=[""].join("\n");
var outline_f33_24_34186=null;
var title_f33_24_34187="IH features morbidity";
var content_f33_24_34187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of infantile hemangiomas with highest risk for morbidity according to anatomic location and/or morphology of the hemangioma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Anatomic location/morphology",
"      </td>",
"      <td class=\"subtitle1\">",
"       Associated risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Facial, large segmental",
"      </td>",
"      <td>",
"       PHACES syndrome (posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects, eye abnormalities, sternal clefting)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nasal tip, ear, large facial (especially with prominent dermal component)",
"      </td>",
"      <td>",
"       Permanent scarring, disfigurement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Periorbital and retrobulbar",
"      </td>",
"      <td>",
"       Ocular axis occlusion, astigmatism, amblyopia, tear-duct occlusion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Segmental \"beard area,\" central neck",
"      </td>",
"      <td>",
"       Airway hemangioma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Perioral",
"      </td>",
"      <td>",
"       Ulceration, disfigurement, feeding difficulties",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Segmental overlying lumbosacral spine",
"      </td>",
"      <td>",
"       Tethered spinal cord, genitourinary anomalies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Perineal, axilla, neck, perioral",
"      </td>",
"      <td>",
"       Ulceration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multiple hemangiomas",
"      </td>",
"      <td>",
"       Visceral involvement (especially liver, gastrointestinal tract)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Change LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: Implications for management. Pediatrics 2008; 122:360. Copyright &copy; 2008 American Academy of Pediatrics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34187=[""].join("\n");
var outline_f33_24_34187=null;
var title_f33_24_34188="Pulm drug complication I";
var content_f33_24_34188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pulmonary complications of cardiovascular drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential mechanism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procainamide",
"       </td>",
"       <td>",
"        SLE-like syndrome",
"       </td>",
"       <td>",
"        50 to 90 percent of patients have positive ANA test; 10",
"to 20 percent become symptomatic; pleuritis, pleural effusion, and",
"parenchymal infiltrates are common",
"       </td>",
"       <td>",
"        Autoantibodies against histone H2A-H2B complex,",
"potentially induced by interaction of drug",
"metabolites with DNA, or drug-induced alteration in T-cell DNA",
"methylation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinidine",
"       </td>",
"       <td>",
"        SLE-like syndrome",
"       </td>",
"       <td>",
"        Rare; pleuritis and pleural effusions are most common",
"pulmonary signs; parenchymal infiltrates uncommon",
"       </td>",
"       <td>",
"        Autoantibodies against histone H2A-H2B complex,",
"potentially induced by interaction of drug",
"metabolites with DNA, or drug-induced alteration in T-cell DNA",
"methylation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tocainide",
"       </td>",
"       <td>",
"        Pneumonitis/fibrosis",
"       </td>",
"       <td>",
"        Incidence is about 0.3 percent",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flecainide",
"       </td>",
"       <td>",
"        Pneumonitis/fibrosis",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mexiletine",
"       </td>",
"       <td>",
"        Pneumonitis/fibrosis",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Unknown; interferes with theophylline metabolism and",
"can cause toxic elevations",
"in theophylline levels in serum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        ACE inhibitors",
"       </td>",
"       <td>",
"        Cough",
"       </td>",
"       <td>",
"        Incidence is 5 to 15 percent; occurs with all ACE",
"inhibitors; whether these agents precipitate bronchospasm in patients",
"with asthma is controversial",
"       </td>",
"       <td>",
"        Decreased degradation of irritant and",
"bronchoconstrictive mediators (bradykinin and",
"substance P); direct increase in sensitivity to irritant-induced",
"cough; genetic predisposition (based on differences in ACE gene).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angioneurotic edema",
"       </td>",
"       <td>",
"        Rare; can lead to respiratory failure",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sotalol",
"       </td>",
"       <td>",
"        Bronchospasm",
"       </td>",
"       <td>",
"        Occurs in 2 percent of patients",
"       </td>",
"       <td>",
"        Direct blockage of &beta;2-receptors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenosine",
"       </td>",
"       <td>",
"        Bronchospasm",
"       </td>",
"       <td>",
"        Occurs with rapid infusion in 5 to 10 percent of",
"patients; may trigger acute bronchospasm in patients with asthma or",
"COPD. Reversible with aminophylline",
"       </td>",
"       <td>",
"        Induction of mast cell mediator release",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Zitnik, RJ, J Respir Dis 1996; 17:254; and Zitnik, RJ, J Respir Dis 1996; 17:293.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34188=[""].join("\n");
var outline_f33_24_34188=null;
var title_f33_24_34189="Sotalol after MI";
var content_f33_24_34189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Decreased survival with sotalol in the SWORD trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 308px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results from the Survival With Oral d-Sotalol (SWORD) trial. The administration of d-sotalol to patients with an ejection fraction &le;40 percent after either recent myocardial infarction (MI) or after symptomatic heart failure with a remote (&gt;42 days) MI was associated with increased mortality compared to placebo (5 versus 3.1 percent). The excess number of deaths was presumed to be primarily due to arrhythmias.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Waldo AL, Camm AJ, DeRuyter H, et al. Lancet 1996; 348:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34189=[""].join("\n");
var outline_f33_24_34189=null;
var title_f33_24_34190="Foodborne illnesses in the United States";
var content_f33_24_34190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimates of domestically acquired foodborne illnesses in the United States*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated number of cases per year (mean)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Foodborne (percent)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Travel-related (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hospitalization rate (percent)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Death rate (percent)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacillus cereus, foodborne",
"       </td>",
"       <td>",
"        63,400",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brucella spp",
"       </td>",
"       <td>",
"        839",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Campylobacter spp",
"       </td>",
"       <td>",
"        845,024",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        17.1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clostridium botulinum, foodborne",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        82.6",
"       </td>",
"       <td>",
"        17.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clostridium perfringens, foodborne",
"       </td>",
"       <td>",
"        965,958",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        &lt;0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        STEC O157",
"       </td>",
"       <td>",
"        63,153",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        46.2",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        STEC non-O157",
"       </td>",
"       <td>",
"        112,752",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ETEC, foodborne",
"       </td>",
"       <td>",
"        17,894",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diarrheagenic Escherichia coli other than STEC and ETEC",
"       </td>",
"       <td>",
"        11,982",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Listeria monocytogenes",
"       </td>",
"       <td>",
"        1591",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        15.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycobacterium bovis",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        4.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Salmonella spp, nontyphoidal",
"       </td>",
"       <td>",
"        1,027,561",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        27.2",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Salmonella enterica serotype typhi",
"       </td>",
"       <td>",
"        1821",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        75.7",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shigella spp",
"       </td>",
"       <td>",
"        131,254",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        20.2",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus aureus, foodborne",
"       </td>",
"       <td>",
"        241,148",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        &lt;0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus spp group A, foodborne",
"       </td>",
"       <td>",
"        11,217",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibrio cholerae, toxigenic",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        43.1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibrio vulnificus",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        91.3",
"       </td>",
"       <td>",
"        34.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibrio parahaemolyticus",
"       </td>",
"       <td>",
"        34,664",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        22.5",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibrio spp, other",
"       </td>",
"       <td>",
"        17,564",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        37.1",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yersinia enterocolitica",
"       </td>",
"       <td>",
"        97,656",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        34.4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         Subtotal",
"        </em>",
"       </td>",
"       <td>",
"        3,645,773",
"       </td>",
"       <td colspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryptosporidium spp",
"       </td>",
"       <td>",
"        57,616",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclospora cayetanensis",
"       </td>",
"       <td>",
"        11,407",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giardia intestinalis",
"       </td>",
"       <td>",
"        76,840",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        8.8",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasma gondii",
"       </td>",
"       <td>",
"        86,686",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trichinella spp",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        24.3",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         Subtotal",
"        </em>",
"       </td>",
"       <td>",
"        232,705",
"       </td>",
"       <td colspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Astrovirus",
"       </td>",
"       <td>",
"        15,433",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        &lt;0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis A virus",
"       </td>",
"       <td>",
"        1566",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        31.5",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Norovirus",
"       </td>",
"       <td>",
"        5,461,731",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        &lt;0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rotavirus",
"       </td>",
"       <td>",
"        15,433",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"       <td>",
"        &lt;0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sapovirus",
"       </td>",
"       <td>",
"        15,433",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        &lt;0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         Subtotal",
"        </em>",
"       </td>",
"       <td>",
"        5,509,597",
"       </td>",
"       <td colspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9,388,075",
"        </strong>",
"       </td>",
"       <td colspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ETEC: enterotoxigenic Escherichia coli; STEC: Shiga toxin-producing Escherichia coli.",
"     <br>",
"      * All estimates based on United States population in 2006.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Percentage foodborne among domestically acquired illness.",
"       <br>",
"        &Delta; For laboratory-confirmed illnesses. Unadjusted hospitalization and death rates are presented here. These rates were doubled to adjust for underdiagnosis before being applied to the number of laboratory-confirmed cases to estimate the total number of hospitalizations and deaths. The hospitalization and death rates for atrovirus, norovirus, rotavirus, and sapovirus presented here are the percentage of total estimated illness and were not subject to further adjustment.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States&mdash;major pathogens. Emerg Infect Dis 2011; 17:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34190=[""].join("\n");
var outline_f33_24_34190=null;
var title_f33_24_34191="Improper twisting carrying load";
var content_f33_24_34191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    IMPROPER mechanics: Twisting at the waist while carrying a load",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 268px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sharon Alzner, MPT.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_24_34191=[""].join("\n");
var outline_f33_24_34191=null;
